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ABSTRACT 
 
Annexin-A1 (AnxA1) is an endogenous anti-inflammatory protein that has been 
shown to exert a protective role against the lethal effects induced by the Toll-like 
receptor (TLR) 4 agonist lipopolysaccharide (LPS). The aim of this PhD 
studentship was to expand these observations and investigate the possible cross-
talk between AnxA1 and other TLR signalling pathways in macrophages. To this 
aim, we compared the response in vitro of AnxA1-/- to AnxA1+/+ bone marrow-
derived macrophages (BMDMs) after stimulation with TLR2, 3, 5, 7 and 9 ligands. 
AnxA1-/- BMDMs exhibited higher expression of the activation markers MHC II and 
co-stimulatory molecules CD40, CD80, CD86 at the basal level, but a similar 
upregulation after stimulation with different TLR agonists. Stimulation of AnxA1-/- 
BMDMs with MyD88-dependent TLR agonists caused an increased production of 
TNF- and IL-6 compared to AnxA1+/+. Conversely, stimulation with the TRIF-
dependent ligand poly (I:C) caused a decreased production of IL-6, but not     
TNF-, by these cells. Interestingly, comparison of MyD88 and TRIF-dependent 
downstream signalling pathways in AnxA1+/+ and AnxA1-/- BMDMs showed 
different kinetics of NF-B DNA-binding activity, IB- degradation and ERK1/2 
phosphorylation. Consistent with this, measurement of MyD88-dependent or TRIF-
regulated genes in AnxA1+/+ and AnxA1-/- BMDMs indicated a different time course 
of expression following stimulation with TLR3 (TRIF-dependent), TLR9 (MyD88-
dependent) and TLR4 (TRIF and MyD88-dependent) ligands. Finally, AnxA1-/- 
mice showed an increased survival after challenge with poly (I:C), in contrast to 
increased lethality after injection of LPS, compared to AnxA1+/+ mice. These 
results suggest that endogenous AnxA1 influences mainly the MyD88-dependent 
pathway and to a lesser extent the TRIF-dependent pathway both in vitro and in 
vivo. In addition, this study provides future venues for the investigation of 
molecular mechanisms by which endogenous AnxA1 preferentially interferes with 
specific TLR signalling pathways. 
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1.1.  THE MACROPHAGE  
 
The recognition of the role of macrophage as an immune cell has a history of more 
than 100 years, since Elie Metchnikoff first described phagocytosis, winning the 
Nobel Prize. Macrophages are present in all tissues. They arrive from circulating 
monocytes, which migrate into tissues and undergo differentiation. Therefore, they 
may be present as osteoclasts in the bone, microglial cells in the central nervous 
system, histiocytes in the connective tissue, Kupffer cells in the liver, alveolar and 
peritoneal macrophages, macrophages of the gastrointestinal tract, of the adipose 
tissue or other (Gordon and Taylor, 2005). In certain cases, such as the microglial 
cells of the central nervous system, mature macrophages may rise in the tissue 
from local proliferation of tissue-resident colony-forming cells and not from 
monocytes (Cuadros and Navascues, 1998, Naito et al., 1996). 
 
Besides its function in the immune response, the macrophage has a very 
important homeostatic role. Indeed, macrophages are prodigious phagocytic cells 
that clear debris and cells that have undergone apoptosis or necrosis. They clear 
approximately 2x1011 erythrocytes each day contributing in the recycling of iron 
and haemoglobin (Beaumont and Delaby, 2009). Several receptors mediate this 
homeostatic clearance including scavenger receptors, phosphatidyl serine 
receptors, the thrombospondin receptor, integrins and complement receptors 
(Erwig and Henson, 2007). 
 
While clearing the debris of necrotic cells, macrophages detect different „danger‟ 
signals. The interaction of invading pathogens with macrophages can be either by 
 23 
direct binding to surface receptors (nonopsonic) or mediated by opsonins coating 
the bacterial surface. Complement-opsonised bacteria bind to macrophages via 
the complement receptors but interaction of macrophages with non-opsonised 
bacteria is based on the recognition of evolutionary conserved microbial motifs 
known as pathogen-associated molecular patterns (PAMPs) by pattern-recognition 
receptors (PRRs) such as Toll-like receptors (TLRs). Pathogens are able to exploit 
receptor interactions crucial to their survival or to use secretion systems to 
transport molecules into the cell altering the process of phagocytosis (Pluddemann 
et al., 2006).   
 
Macrophages have been sub-divided as M1 macrophages for classically activated 
macrophages and M2 macrophages for alternatively activated macrophages. 
Another classification of the macrophages is based on the fundamental 
macrophage functions which are: host defence, wound healing, and immune 
regulation (Mosser and Edwards, 2008). One of the main characteristics of these 
cells is their plasticity that allows them to efficiently respond to environmental 
signals changing their phenotype (Stout and Suttles, 2004).  These signals can 
arrive from both innate and adaptive immune response.     
 
The classically activated macrophages are activated by a combination of tumor 
necrosis factor  (TNF-) -produced after TLR stimulation- and interferon- (IFN-) 
(Edwards et al., 2006). Certain TLR agonists may induce both TNF- and IFN-, 
therefore activating macrophages without the requirement of additional IFN-. 
Classically activated macrophages are characterized by the enhanced killing of 
intracellular pathogens, and the increased secretion of cytokines.  This production 
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of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and IL-23, 
although an important component of host defence, can cause extensive host-
tissue damage. Classically activated macrophages also produce reactive oxygen 
radicals (ROS) and nitric oxide (NO), both of which have antimicrobial activity.   
 
The alternatively activated macrophages arise through the presence of IL-4 or    
IL-13 (Gordon, 2003).  These cells secrete components of the extracellular matrix 
and their main function is related to wound healing. They can also contribute to 
defence against helminths and nematodes (Mylonas et al., 2009) and they have 
also been associated with allergy (Kurowska-Stolarska et al., 2009). 
 
Regulatory macrophages are the result of stress responses (Sternberg, 2006) or 
they can arise during the later stages of adaptive immune responses (Mosser, 
2003). Their primary role is to dampen the immune response limiting inflammation. 
The production of the anti-inflammatory cytokine IL-10 is the most important and 
reliable characteristic of regulatory macrophages (Edwards et al., 2006). Many 
parasitic, bacterial and viral pathogens interfere with macrophage activation or 
induce the development of regulatory macrophages, therefore resulting defective 
pathogen killing (Mahalingam and Lidbury, 2002).        
 
The phenotype of macrophages can change over time. Often, this phenotypic 
switch is associated with pathology. One characteristic example of switching from 
classically activated macrophages to regulatory macrophages is the case of 
cancer. The production of free radicals that the classically activated macrophages 
produce may lead to DNA damage and mutations that can predispose host cells to 
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neoplasia. As cancer progresses, these macrophages change their physiology 
towards a phenotype which resembles regulatory macrophages by producing high 
levels of IL-10 and de-activating neighbouring macrophages (Pollard, 2008). On 
the other hand, the switch from wound-healing macrophages to classically 
activated macrophages, which takes place in obesity may contribute to chronic 
inflammation in the adipose tissue, leading to insulin resistance and type 2 
diabetes (Lumeng et al., 2007).      
 
Another important function of macrophages is their role as an antigen-presenting 
cell (APC) (Gregg and Denis, 1991). As well as being resident in tissues, 
macrophages are also found in lymphoid organs.  Resting macrophages have few 
or no major histocompatibility complex II (MHC II) molecules on their surface and 
do not express the B7 co-stimulatory molecules. When macrophages ingest 
microorganisms and recognise their PAMPs they become activated and the 
expression of MHC II and B7 molecules is induced (Nolan et al., 2009). Different 
macrophage populations express distinct levels of these molecules (Edwards et 
al., 2006) and, therefore, may have different potentials to present antigens to       
T-cells. Thus, classically activated macrophages express relatively high levels of 
MHC II and co-stimulatory molecules, alternatively activated macrophages only 
minimally up-regulate expression of these molecules, whereas regulatory 
macrophages often express high levels. Mature macrophages can divert the fate 
of naïve T cells via three signals. Signal 1 is the result of the interaction of the 
pathogen-presented peptide by MHC II molecules with the T-cell receptor (TCR).  
Signal 2 results from the binding of the co-stimulatory molecules B7.1 (CD80) and 
B7.2 (CD86) to the T-cell.  Signal 3 is the result of the cytokine microenvironment. 
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However, there is very little evidence that macrophages initiate T-cell immunity 
(Lipscomb et al., 1986, Lyons et al., 1986), and the expression of the co-
stimulatory molecules may just reflect an expansion of responses already initiated 
by dendritic cells (Ding et al., 1993). 
 
 
 
Figure 1.1: Macrophage receptors in bacterial recognition 
Macrophages have multiple receptors both on the surface and in intracellular compartments that 
recognise Gram (+) and Gram (-) bacteria.  
Abbreviations: CR3, complement receptor 3; DC-SIGN, dendritic-cell-specific intracellular-
adhesion-molecule-3-grabbing non-integrin; FEEL-1, fasciclin, EGF-like, laminin-type EGF-like, and 
link-domain-containing scavenger receptor 1; LOX-1, lectin-like oxidised low-density lipoprotein 
receptor 1; MR, mannose receptor; NOD, nucleotide-binding oligomerisation domain; SR, 
scavenger receptor; SREC, scavenger receptor for endothelial cells; SR-PSOX, scavenger 
receptor for phosphatidylserine and oxidised low-density lipoprotein. Taken from (Pluddemann et 
al., 2006). 
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Figure 1.2: Cytokines produced by immune cells can give rise to macrophages with distinct 
phenotypes. 
Classically activated macrophages arise in response to IFN- and TNF and have microbicidal 
activity. Wound-healing (alternatively activated) macrophages arise in response to IL-4 and have a 
role in tissue repair. Regulatory macrophages are generated in response to various stimuli, 
including immune complexes, prostaglandins, G-protein coupled receptor (GPCR) ligands, 
glucocorticoids, apoptotic cells or IL-10 and they suppress immune responses by producing high 
levels of IL-10. Taken from (Mosser and Edwards, 2008). 
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1.2.  TLRs AND THE IMMUNE RESPONSE 
 
1.2.1.  Introduction 
 
The immune response is initiated when the innate immune system is able to detect 
microbial intruders such as protozoa, bacteria, fungi, and viruses via PRRs. The 
Toll family of receptors have a central role as PRRs in the initiation of innate 
immune responses (Kaisho and Akira, 2006) and in the establishment of adaptive 
immunity. They recognise conserved microbial products known as PAMPs.  These 
are motifs of microorganisms that are essential for their metabolism and survival. 
In addition, they recognise endogenous mediators that are released from dying 
cells termed “alarmins” or danger-associated molecular patterns (DAMPs), which 
further amplify the inflammatory response via TLRs. 
 
TLRs are highly conserved through evolution. Toll was initially discovered in 
Drosophila as an essential receptor involved in embryogenesis and host defence 
against fungal infection (Lemaitre et al., 1996). This was followed by cloning and 
characterization of a human homologue, which has been shown to signal through 
the NF-B pathway, inducing the expression of genes for inflammatory cytokines, 
as well as the expression of the co-stimulatory molecule B7.1, which is required for 
the activation of naive T cells by APCs (Medzhitov et al., 1997). 
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1.2.2.  Mammalian TLRs and their localisation in cells and tissues 
 
To date 11 TLRs have been identified in humans (TLR1-11) and 13 in mice (TLR1-
13) (Akira and Hoshino, 2003). TLRs 1-9 are conserved between the human and 
the mouse.   
 
Certain TLRs (TLR1, 2, 4, 5, 6, 10) are localised in the plasma membrane 
whereas others (TLR3, 7, 8, 9) are preferentially expressed in intracellular 
compartments such as endosomes (Takeda and Akira, 2005) (Fig 1.3). The 
subcellular localization is believed to be important for the discrimination of viral 
nucleic acids from self nucleic acids (Barton et al., 2006). For most TLRs it has 
been shown that endosomal maturation is a requirement for TLR-mediated 
recognition of their ligands (Hacker et al., 1998, Heil et al., 2004). Therefore, 
phagosomal/lysosomal or endosomal/lysosomal compartments could be the main 
sites for TLR recognition of microbial components (Takeda and Akira, 2005). Even 
TLR2 is recruited to macrophage phagosomes after exposure to zymosan, despite 
the fact that it is expressed on the cell surface (Underhill et al., 1999). 
 
TLRs are expressed on different types of immune and non-immune cells. They are 
differentially expressed among immune cells (Muzio et al., 2000). Their surface 
expression appears very low and corresponds to a few thousand molecules per 
cell in monocytes and a few hundred in immature dendritic cells (Visintin et al., 
2001). In addition to, TLR bearing cells may express different levels of TLRs 
according to their strategic position in the body. For example, peritoneal 
macrophages express significantly higher levels of TLR2 and TLR4 than splenic 
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macrophages (Liu et al., 2006). TLR expression is also modulated positively and 
negatively in response to a variety of stimuli. However, there is a complicated 
discrepancy between mRNA expression and responsiveness to TLR ligands and a 
lack of reliable antibodies to TLRs. Therefore, the expression of a TLR by a cell 
type does not necessarily mean that stimulation of this receptor will result cell 
activation. CpG, for example, does not stimulate neutrophils, despite the fact that 
they express TLR9 (Hornung et al., 2002). 
 
Figure 1.3: Human TLR localisation in the cell. 
Cellular orientation of TLRs and examples of ligands showing the accessory factors associated 
with their signalling function.  
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1.2.3.  Pathogen-associated Molecular Patterns 
 
Representative ligands/PAMPs for TLRs include bacterial cell wall components 
such as lipopolysaccharide (LPS) of Gram (-) bacteria, which is recognised by 
TLR4 (Hoshino et al., 1999) or peptidoglycans and lipopeptides carried by Gram 
(+) bacteria recognised by TLR2 (Hirschfeld et al., 1999). Mycoplasma does not 
possess a cell wall but its plasma membrane contains lipopeptides (Razin et al., 
1998). TLRs can also recognise proteins such as flagellin of flagellated bacteria 
recognised by TLR5 (Hayashi et al., 2001) and nucleic acids such as bacterial and 
viral DNA containing high frequency of CpG motives recognised by TLR9 (Hemmi 
et al., 2000) or viral single-stranded RNA (ssRNA) recognised by TLR7 and TLR8 
(Lund et al., 2004), whereas TLR3 recognises viral double-stranded RNA (dsRNA) 
(Alexopoulou et al., 2001). TLR11 is involved in the recognition of uropathogenic 
bacteria (Zhang et al., 2004). TLR10 is believed to be an orphan member of the 
TLR family but has the ability to form homodimers and heterodimers with TLR1 
and TLR2 (Hasan et al., 2005). Therefore, it is possible that TLR10 may recognise 
still unidentified ligands.  
 
TLRs do not recognise only exogenous ligands but have the ability to recognise 
„endogenous‟ ligands or „alarmins‟ or DAMPS. Such ligands include heat-shock 
proteins (HSP; TLR2 or TLR4) (Ohashi et al., 2000, Vabulas et al., 2001), uric acid 
(TLR2) (Foell et al., 2007), hyaluronan (TLR2) (Scheibner et al., 2006), surfactant 
protein (TLR4) (Guillot et al., 2002), and fibronectin (TLR4) (Okamura et al., 2001).  
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One group of pathogens is not exclusively recognised by one TLR and one TLR 
can correspond to structurally unrelated ligands, often derived from different 
groups of pathogens (Janssens and Beyaert, 2003). There are, however, TLRs, 
which seem to be more ligand specific such as TLR3, TLR5, and TLR9. 
 
 
 
Figure 1.4: Mammalian TLRs and their ligands. 
TLR1 and TLR6 do not signal as separate entities but act in cooperation with TLR2. TLR4 acts in a 
complex with CD14 and MD-2. RSV, respiratory syncytial virus; EDA, extra domain A. Taken from 
(Janssens and Beyaert, 2003). 
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1.2.3.1.  LPS 
 
Bacterial endotoxin (LPS) is a component of the outer membrane of Gram (-) 
bacteria and a causative agent of endotoxin shock. It is a glycolipid composed of a 
hydrophilic polysaccharide part and a hydrophobic domain known as lipid A, which 
is responsible for the molecule‟s biologic activity (Raetz, 1990). Lipid A, which is 
the only part of LPS recognised by TLR4, is conserved among species but is not a 
single molecule showing diversity among different bacteria (Miller et al., 2005). 
The receptor complex for LPS is composed of three proteins: TLR4, CD14 and 
myeloid differentiation protein-2 (MD-2) (Miller et al., 2005) (Fig 1.5). N-linked 
glycosylations of both MD-2 and TLR4 are important in maintaining the integrity of 
the LPS receptor complex (Ohnishi et al., 2001). In the bloodstream, 
enterobacterial LPS is carried by a serum LPS-binding protein (LBP), an acute-
phase protein which binds to LPS and transfers an LPS monomer from the 
bacterial cell wall to CD14 (Schumann et al., 1990).  
  
C3H/HeJ is a mutant mouse strain hyporesponsive to LPS. A loss-of –function 
mutation of these LPS-hyporesponsive mice lead to the discovery of the first 
mammalian Toll protein, which is known as TLR4 (Poltorak et al., 1998). Although 
TLR4 is the established receptor for LPS from enterobacteria, it has been 
observed that there are types of LPS such as those derived from Porphyromonas 
gingivalis (Asai et al., 2005), Leptospira interrogans (Werts et al., 2001), and 
Legionella pneumophila (Girard et al., 2003), which activate macrophages via 
TLR2.  However, neither human nor murine TLR2 participates in LPS signalling 
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and it is believed that bacterial lipoproteins in LPS preparations are responsible for 
the TLR2-mediated activity (Hirschfeld et al., 2000).   
 
 
 
Figure 1.5: The LPS receptor complex on macrophages. 
LPS is recognised by a complex of 3 proteins: CD14, TLR4, and MD-2. A serum LBP transfers LPS 
to CD14, which in turn concentrates LPS and presents it to TLR4-MD-2. MD-2 plays a role in LPS 
recognition and regulates the cellular distribution of TLR4. TLR4 acts as the signal-transducing 
receptor for LPS. All known TLR adaptor proteins are responsible for the TLR4-mediated signalling. 
LRR, Leucine-rich repeats; TIR, Toll-IL-1 receptor. Adapted from (Fujihara et al., 2003). 
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1.2.3.2.  Lipoproteins  
 
Lipoproteins and lipopeptides of the outer membrane of bacteria -abundant in 
Gram (+) microorganisms- are among the TLR2 ligands (Hirschfeld et al., 1999). 
TLR2 agonists are recognised by heterodimers between TLR2 and other TLR 
family members. For example, synthetic bacterial lipopeptide (MALP-2) is 
recognised between TLR2 and TLR6 (Takeuchi et al., 2001), whereas bacterial 
lipopeptide is recognised by TLR2 and TLR1 (Alexopoulou et al., 2002). 
 
1.2.3.3.  Double-stranded RNA 
 
Viral replication within infected cells results in generation of dsRNA recognised by 
TLR3. TLR3-deficient mice showed reduced responses to a viral RNA mimic 
called polyinosine-polycytidylic acid (poly (I:C)) indicating the role of TLR3 in 
recognition of dsRNA (Alexopoulou et al., 2001).  
 
1.2.3.4.  Flagellin 
 
Flagellin is a 55-kDa monomer obtained from bacterial flagella which helps the 
organism move through its aqueous environment. It is a conserved TLR ligand 
recognised by TLR5 (Hayashi et al., 2001) and forms an ideal PAMP since no host 
cells possess such a protein. Flagellated Proteobacteria such as Helicobacter 
pylori have evolved in such a way that they can avoid TLR5 by mutating the amino 
acid residues responsible for flagellin recognition by TLR5 (Andersen-Nissen et 
al., 2005). 
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1.2.3.5.  Imidazoquinolines 
 
Imidazoquinoline family contains members such as imiquimod and resiquimod, 
which have potent antiviral and antitumor properties (Miller et al., 1999) and are 
recognised by TLR7 (Hemmi et al., 2002). 
 
1.2.3.6.  Cytosine-phosphodiesterguanine (CpG) DNA 
 
CpG DNA is DNA containing unmethylated CpG motifs, which is largely equivalent 
to bacterial DNA and is recognised by TLR9 (Hemmi et al., 2000). Unmethylated 
CpG-dinucleotide-containing sequences (CpG ODNs) are not frequent in 
vertebrate genomes, which are usually methylated therefore lack 
immunostimulatory activities (Hare and Taylor, 1985).   
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1.2.4.  TLR structure 
 
The cytoplasmic part of TLRs shows high similarity to that of the IL-1 receptor 
family, termed as Toll/IL-1 receptor (TIR) domain (Rock et al., 1998). The 
extracellular part is structurally unrelated to the IL-1 receptor and it bears leucine-
rich repeats (LRRs) (Chiang and Beachy, 1994). How LRRs are involved in ligand 
recognition and signal transduction still remains unclear. It is still not understood 
how each TLR can recognise different ligands of such diversity.  
 
The binding of a PAMP to a TLR causes dimerisation of the receptor. TLR2 forms 
a heterodimer with TLR1 or TLR6, but the other TLRs were believed to form 
homodimers (Saitoh et al., 2004). Recently however, the formation of a new 
heterodimer comprising TLR4 and TLR6 has been discovered, which recognises 
endogenous ligands such as low-density lipoprotein (LDL) and amyloid-, 
promoting sterile inflammation (Stewart et al., 2010).   
 
LRR
TIR
Figure 1.6: TLR structure 
Schematic illustration of TLRs, based on 
the structure of the TLR3 ectodomain and 
the TLR2 TIR motif. TLR ectodomains are 
all likely to be dimerized, composed of 
numerous repeating LRRs. The 
cytoplasmic domains are compact, 
consisting mostly of a TIR motif. It is 
believed that ligands elicit a conformational 
change, allowing recruitment of specific 
adaptor proteins. Adapted from (Beutler et 
al., 2006). 
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1.2.5.  TLR signalling pathways 
 
1.2.5.1.  Adaptor proteins 
 
The intracellular signalling of TLR ligands is initiated by the TIR domain which 
contains adaptor molecules such as Myeloid differentiation primary response 
protein 88 (MyD88), TIR-domain-containing adaptor inducing IFN- (TRIF), TIR 
domain–containing adaptor protein (TIRAP) also known as MAL, and TRIF-related 
adapter molecule (TRAM) (Dunne and O'Neill, 2005). All TLRs use the adaptor 
protein MyD88 with the exception of TLR3, which exclusively uses TRIF 
(Yamamoto et al., 2002). Therefore, there are two distinct TLR signalling 
pathways: the MyD88-dependent and the MyD88-independent/TRIF dependent 
pathway. TLR4 is the only member of the TLR family that contains all adaptor 
proteins mentioned above and therefore it may signal through both TLR pathways. 
The major pathways activated by TLRs are passed through IkB kinase (IKK), 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase 
(PI3K)/Akt pathways.   
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Figure 1.7: Adaptor proteins for the TLR/IL-1R superfamily. 
Each receptor complex differentially uses each adaptor to positively regulate transcription factor 
activation. Sterile - and armadillo-motif-containing protein (SARM) is the exception, which inhibits 
TRIF-mediated transcription factor activation. Adapted from (O'Neill and Bowie, 2007).  
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1.2.5.2.  MyD88-dependent pathway 
 
MyD88 has a TIR domain, which is involved in the interaction with TLRs, and a 
death domain (Watters et al., 2007), which is responsible for the recruitment of   
IL-1 receptor associated kinases (IRAKs) (Medzhitov et al., 1998). These are 
IRAK-1, IRAK-2, IRAK-4, and IRAK-M.  IRAK-1 and IRAK-4 possess 
serine/threonine protein kinase activity (Wang et al., 2006) whereas IRAK-2 and 
IRAK-M negatively regulate TLR signalling (Hardy and O'Neill, 2004, Kobayashi et 
al., 2002). IRAKs are sequentially phosphorylated and dissociated from MyD88 
and have binding motives for interaction with Tumor necrosis factor receptor-
associated factor 6 (TRAF6) (Qian et al., 2001). TRAF6 belongs to an E3 ubiquitin 
ligase family and activates through ubiquitination TGF--activated kinase (TAK) 1 
and the canonical IB kinases IKK and IKK that phosphorylate IB and degrade 
it leading to the translocation of NF-B to the nucleus (Deng et al., 2000). TAK1 
phosphorylates two members of the MAP kinase kinase (MKK) family, MKK3 and 
MKK6, which activate Jun N-terminal kinase (JNK) and p38 (Irie et al., 2000). 
Extra-cellular signal related kinase (ERK) is activated through the activation of 
MAPK/ERK kinase 1 (MEK1) and MEK2 (Crews et al., 1992).  
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1.2.5.3.  MyD88-independent/ TRIF-dependent pathway 
 
Responses to poly (I:C) are relatively normal in MyD88-deficient mice indicating 
that TRIF is the sole adapter used by TLR3 (Yamamoto et al., 2003). TRIF may 
also lead to the activation of NF-B and MAPKs (Yamamoto et al., 2003). It 
possesses 3 TRAF-6 binding domains that mediate interaction with TRAF6 (Sato 
et al., 2003). It also contains Rip homotypic interaction motif (RHIM), which 
mediates interaction with members of the receptor interacting protein (RIP) family 
(Meylan et al., 2004). Both TRIF-RIP1 and TRIF-TRAF6 interactions induce 
activation of NF-B.  
 
In addition, TRIF can activate the IFN- promoter (Yamamoto et al., 2002). TRIF 
can interact with the canonical IB kinases IKK and TANK-binding kinase 1 
(TBK1) (McWhirter et al., 2004). IFN response factor 3 (IRF-3) is then 
phosphorylated by these kinases and it translocates to the nucleus inducing 
several target genes.   
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Figure 1.8: TLR signalling pathways. 
Diagram showing the signalling complexity followed by each TLR. Both MyD88-dependent and 
TRIF-dependent pathway lead to the activation of NF-B and the induction of inflammatory 
cytokines.
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1.2.5.4.  Transcription factors 
 
TLR signalling can lead to activation of several transcription factors, including    
NF-B (Doyle and O'Neill, 2006), Activating protein-1 (AP-1) (Jones et al., 2001a), 
and IRFs (Honda et al., 2005, Schoenemeyer et al., 2005, Yamamoto et al., 2003). 
As described previously, both signalling pathways activate NF-B and the MAPKs 
(ERK1/2, JNK, p38) resulting in the expression of numerous genes encoding 
cytokines such as IL-6 and TNF- and other inflammatory molecules such as 
platelet-activating factor, prostaglandins, enzymes, and free radicals, such as NO 
(Akira and Hoshino, 2003, Chi et al., 2006, Hu et al., 2008b, Jones et al., 2001a, 
Jones et al., 2001b, Yamamoto et al., 2002). In addition, the MyD88-independent 
signalling pathway activates IRF3, inducing the production of type I IFN 
(Toshchakov et al., 2002, Toshchakov et al., 2003). TLR7, TLR8 and TLR9 may 
also induce type I IFNs, including IFN- and IFN-, depending on MyD88 and 
using IRF7 as a transcription factor (Honda et al., 2005).   
 
1.2.5.4.1.  TLRs and NF-B 
 
NF-B is not a single and unique molecule but a family of transcription factors that 
play an important role in the regulation of a variety of events such as inflammation, 
immunity, cell proliferation and apoptosis. It includes a collection of proteins 
containing a highly conserved DNA-binding and dimerisation region, the Rel 
homology (RH) domain (Hoffmann et al., 1999). This family includes two distinct 
groups of proteins. The first group includes p105, p100 and Drosophila Relish (Li 
and Stark, 2002). These proteins have long C-terminal domains containing 
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multiple copies of ankyrin repeats and can give rise to active shorter proteins such 
as p50, and p52 (Lin and Ghosh, 1996). Members of this group form dimers with 
members of the second group, which includes p65 (RelA), Rel (c-Rel), RelB, and 
Drosophila Rel proteins (Li and Stark, 2002). This second group of proteins 
possess one or more C-terminal transcriptional activation domains. Therefore, 
members of NF-B proteins may form homodimers and heterodimers. 
 
In unstimulated cells, NF-B-family proteins exist as heterodimers or homodimers 
in the cytoplasm that are associated with a member of the IB family of inhibitory 
proteins (Baeuerle and Baltimore, 1996). The IB family includes IB, IB, IB, 
and Bcl3. These proteins have an ankyrin repeat motif, important for the 
maintenance of NF-B in the cytoplasm. Several extracellular signals such as TLR 
ligands activate signal transduction pathways leading to the activation of IB 
kinase (IKK), which phosphorylates 2 serine residuals on IB proteins (S32 and 
S36 of IB) (Ghosh et al., 1998). IKK is composed of 3 subunits: the catalytic 
subunits IKK and IKK, and the regulatory subunit IKK, formerly known as     
NF-B essential modifier (NEMO) (Karin, 1999). Other kinases involved in NF-B 
activation are IKK/IKKi and TBK/NAK/T2K (Fitzgerald et al., 2003a). Phospho-IB 
is then ubiquitinated by ubiquitin ligase and degraded by the proteasome (Karin 
and Ben-Neriah, 2000). The dissociation of NF-B from the IB proteins unmasks 
the nuclear localisation signal of NF-B, leading to its nuclear translocation and 
binding to the promoters of target genes. In addition to, there is also a second 
level of regulation of NF-B, based on the phosphorylation of the second group of 
NF-B proteins, resulting in the activation of transcriptional activity. Therefore, the 
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p65 subunit may be phosphorylated at serine residues within the two 
transactivation domains (TA1 and TA2) located in the C-terminus (Schmitz and 
Baeuerle, 1991).  
 
Signalling through all TLRs leads to activation of NF-B, which binds to a 
nucleotide sequence in genes producing proinflammatory cytokines such as IL-1, 
IL-6, and  TNF-. In fact, the first ever stimulus shown to activate NF-B was the 
TLR4 ligand LPS (Sen and Baltimore, 1986).  
 
In the MyD88-dependent pathway, the adaptor protein MyD88 associates with the 
TIR domain of the TLRs and recruits IRAK4 to the TLR receptor complex (Li et al., 
2002). This facilitates IRAK4-mediated phosphorylation of IRAK1, which in turns 
dissociates from the receptor complex and associates with TRAF6 (Cao et al., 
1996). Subsequently, TRAF6 interacts with a membrane bound pre-associated 
complex of TGF- activated kinase (TAK1) and two TAK-1 binding proteins, 
termed TAB1 and TAB2 (Wang et al., 2001). A series of ubiquitinations occur on 
TRAF6 and TAK1. Phosphorylation activates TAK1, which in turn can 
phosphorylate the IKKs, subsequently leading to NF-B activation (Karin and Ben-
Neriah, 2000). 
 
The MyD88-independent pathway signals through the adaptor protein TRIF. TLR3 
exclusively uses TRIF (Yamamoto et al., 2002). On the other hand, TLR4 can also 
signal through the MyD88-independent pathway, but it requires both TRIF and 
TRAM (Fitzgerald et al., 2003a). TRIF binding to TLR3 recruits TRAF6 leading to 
TAK1 activation and subsequent NF-B activation in an IRAK1 and IRAK4 
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independent manner (Sato et al., 2003). TRIF can also activate NF-B in a 
TRAF6-independent way, through the association of a RHIM with RIP1 (Meylan et 
al., 2004). 
 
The NF-B activation associated with the MyD88-dependent pathway occurs 
approximately 30 min earlier than activation mediated by the MyD88-independent 
pathway (Covert et al., 2005). This is due the fact that the MyD88-independent 
pathway requires protein synthesis. In specific, the MyD88-independent pathway 
activates TNF- production and secretion independent of NF-B activation, 
mediated through the transcription factor IRF3. The secreted TNF- subsequently 
binds to its receptors leading to activation of NF-B (Covert et al., 2005). 
 
The discovery of IB revealed specificity in the regulation of different NF-B 
subunits. In specific, IB, induced by different TLR ligands, localises in the 
nucleus and it interacts with the p50 subunit. IB overexpression results in 
increased IL-6 production in response to LPS, but it inhibits TNF- production 
(Motoyama et al., 2005). 
 
A breakthrough in the field of NF-B has been the discovery that NF-B activation 
follows an oscillatory pattern, which can be revealed using electrophoretic mobility 
shift assay (EMSA) (Hoffmann et al., 2002). This is based on the cycle of IB, 
which results in a strong negative feedback allowing turn-off of the NF-B 
response. The expression of IB is linked to NF-B since its activation induces 
the IB gene expression, which in turn binds to NF-B, shutting down its 
 47 
activation. On the contrary, the levels of IB and IB remain low post-TLR 
stimulation, since their expression is not linked to NF-B. Therefore, IB and IB 
induce a monotonic increase in nuclear NF-B and dampen the system‟s 
oscillatory potential, stabilizing NF-B response during longer stimulations 
(Hoffmann et al., 2002).  The number, period, and amplitude of oscillations 
determine the dynamics of gene expression (Nelson et al., 2004).  
 
Although TNF- and a wide variety of other stimuli induce oscillations in NF-B 
activation dynamics, when cells were stimulated with LPS, a non-oscillatory 
pattern was observed (Covert et al., 2005). It was noticed that the NF-B 
activation through TLR4 could be due to an interaction of the MyD88-dependent 
and TRIF-dependent pathway. Indeed, when LPS stimulated MyD88-deficient and 
TRIF-deficient fibroblasts an oscillatory pattern was revealed for both NF-B and 
IB, whereas MyD88-TRIF-doubly deficient fibroblasts showed no NF-B 
activation (Fig 1.9).  In addition to, the model indicated that the MyD88-
independent pathway requires a time delay of approximately 30min before NF-B 
is activated, because it is dependent on the TNF- synthesis through the 
activation of IRF3 (Covert et al., 2005).  
 
Recently, however, another level of regulation of the inflammatory response has 
been discovered (Rao et al.). Although it has been known that the degradation of 
IBs leads to the translocation of NF-B to the nucleus and the initiation of the 
gene transcription, it has been reported that post-stimulation with LPS, IB is re-
synthesized in a hypophosphorylated form that can be detected in the nucleus 
(Rao et al.). This hypophosphorylated IB can bind DNA with p65 and c-Rel, 
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forming complexes, which selectively bind to the TNF- promoter, augmenting its 
transcription. Therefore, IB leads to the prolonged expression of TNF-. In 
concert with these results, IB-/- mice are resistant to LPS-induced septic shock 
(Rao et al.). 
 
 
 
 
Figure 1.9: Modelling the activation of NF-B.  
The predicted time-courses of nuclear NF-B activation and IB protein levels in LPS-stimulated 
WT, TRIF-deficient, and MyD88-deficient mouse embryo fibroblasts. Taken from (Covert et al., 
2005).  
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1.2.5.5.  Negative regulation of TLR signalling 
 
When the inflammatory molecules induced by TLRs are produced in excess, they 
may cause serious systemic disorders. Therefore, mechanisms of control act to 
limit the exaggerated innate responses that may cause damage to the host.   
 
Naturally expressed active soluble forms of TLRs capable of modulating cell 
activation have been discovered in human plasma, breast milk (LeBouder et al., 
2003), and saliva (Zunt et al., 2009). These soluble TLRs provide the first line of 
regulation by functioning as decoy receptors (Liew et al., 2005). 
 
Exposure of TLRs to a PAMP results in a severely reduced response to a 
subsequent challenge by the same PAMP. Therefore, when macrophages are 
treated with a sublethal dose of LPS, the cells become refractory to a subsequent 
exposure to LPS and this is a deactivation phenomenon, which in the case of LPS 
is known as endotoxin tolerance or LPS desensitization (Beeson, 1947b, Beeson, 
1947a).  
 
TLR signalling can be further controlled by intracellular regulators. Therefore, 
several molecules such as the short form of MyD88 (MyD88s), the kinase IRAK-M 
(Kobayashi et al., 2002), SOCS1 (Yasukawa et al., 2000), nucleotide-binding 
oligomerisation domain 2 (NOD2) (Pauleau and Murray, 2003), PI3K (Fukao and 
Koyasu, 2003), Toll-interacting protein (TOLLIP) (Didierlaurent et al., 2006), and 
A20 (Boone et al., 2004) negatively regulate TLR signalling. Transmembrane 
proteins such as single immunoglobin IL-1 receptor-related molecule (SIGIRR) 
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(Wald et al., 2003), T1/ST2 (Brint et al., 2004), and TRAILR (Diehl et al., 2004) 
can also downregulate TLR signalling.   
 
Regulation may also occur through a reduction in the number of TLRs on the cell.  
This can take place by downregulation of the transcription and translation of TLR 
genes, or by degradation of TLR proteins (Liew et al., 2005). Such a mechanism is 
the ubiquitination–mediated degradation of TLRs (Chuang and Ulevitch, 2004).  
Certain anti-inflammatory cytokines such as transforming growth factor- (TGF-) 
(McCartney-Francis et al., 2004) and IL-10 can also downregulate the function of 
TLRs (Muzio et al., 2000). 
 
In addition, if all mechanism of negative regulation fail, apoptosis may occur 
ensuring that the hyper-responsive cells are eliminated (Aliprantis et al., 1999). 
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1.2.6.  Cross-talk between TLRs 
 
TLRs have a synergistic effect inducing their neighbour TLRs upon appropriate 
stimulation. Therefore, when macrophages were stimulated with TLR4 ligand LPS, 
their TLR9 expression increased and thus responded to CpG DNA more efficiently 
(An et al., 2002). Similarly, different combinations of TLR ligands have been used 
as stimulants in order to investigate the „interaction‟ of TLRs in the induction of 
other inflammatory molecules. Thus, the TLR3 ligand poly (I:C) and the TLR9 
ligand CpG-ODN demonstrated synergy in NO,  IL-12, TNF-, and IL-6 production 
after stimulation of murine macrophages (Whitmore et al., 2004). In addition, 
synergy between poly (I :C) and ODN was demonstrated in vivo for serum IL-6 
and IL-12p40 levels (Whitmore et al., 2004). The differential effects of Gram (+) 
versus Gram (-) bacteria on the induction of nitric oxide synthase II (NOSII) and 
TNF- were also investigated, proving a synergy between the two in NO 
production (Paul-Clark et al., 2006). A study performed by Bagchi et al using 
different TLR agonists to stimulate bone marrow-derived macrophages (BMDMs), 
showed that simultaneous activation of MyD88-dependent pathway and MyD88-
independent pathway causes synergy whereas sequential activation causes 
priming (Bagchi et al., 2007). In addition, agonists that act through the same 
pathway induce tolerance (Bagchi et al., 2007). On top of this, MyD88-dependent 
and –independent agonists induced marked synergy in cytokine production in vivo 
(Bagchi et al., 2007). 
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1.2.7.  TLR cooperation with other PRRs 
 
Synergistic induction of cytokine production has also been observed in immune 
cells such as macrophages and dendritic cells when several TLR agonists were 
combined with ligands for other PRRs. Therefore, many TLR ligands synergise 
with NOD1 and NOD2 ligands for the induction of TNF and IL-12 p40 (Fritz et al., 
2005, Tada et al., 2005, van Heel et al., 2005). In addition, several studies have 
reported a cooperation between TLRs and NALPs, NLR ICE-protease-activating 
factor (IPAF), receptors that recognise mannans and -glycans such as dectin-1, 
and immunoreceptor tyrosine-based activation motif (ITAM) associated cell 
surface receptors such as TREM1 and TREM2 (Trinchieri and Sher, 2007). 
Moreover, a direct cooperation of TLR signalling and Notch signalling has been 
demonstrated, which results in different regulation of pro-inflammatory responses 
by macrophages (Palaga et al., 2008).         
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1.2.8.  Toll like receptors and cell migration 
 
The immune system relies on cell migration for the clearance of invading 
pathogens. There are two types of cell migration: inducible migration, which is the 
result of sensing of pathogens through PRRs such as TLRs, and homeostatic 
migration, which allows naive lymphocytes to circulate in lymphoid tissues.   
 
Innate immunity relies on inducible migration. The recognition of PAMPs by TLRs 
initiates the immune response mediated by diffusible chemotactic factors and cell 
surface adhesion molecules, which recruits cells to infection sites. The activation 
of TLRs induces the expression of such molecules i.e. selectin, chemokines, and 
chemokine receptors. The procedure is initiated with the rolling of leukocytes on 
the vascular endothelial cells, a process mediated by selectins. Next, chemokines 
produced after the activation of TLRs bind to the luminal surface of the vascular 
epithelium inducing conformational changes to the integrins (Laudanna et al., 
2002). This allows firm adhesion of the leukocytes to the vascular epithelium. 
Finally, the leukocytes migrate between the endothelial cells and extravasate into 
the tissue infection site.   
 
TLR signaling may guide actin cytoskeleton rearrangements. It has been reported 
that LPS treatment may cause dendritic cells to strongly adhere, with some visible 
veils and actin cables, a process mediated by the scavenger receptor MARCO 
(Granucci et al., 2003). The polarization of dendritic cells after TLR activation may 
render the cells able to migrate. Their migration to lymph nodes and spleen is 
regulated by CCR7 expression, rendering the cells responsive to CCL19 and 
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CCL21 (Ohl et al., 2004). Another molecule that has been reported to regulate the 
dendritic cells migration has been the MHC II –associated invariant chain CD74 
(Faure-Andre et al., 2008). TLR agonists may also regulate CCR expression in 
other cells types such as monocytic cells, changing the adhesive and migratory 
capacities of these cells (Nijhuis et al., 2007). In specific, stimulation of monocytic 
cells with TLR2 and TLR4 agonists resulted in a autocrine pathway of chemokine 
production and homologous down-regulation of the cognate receptors CCR1 and 
CCR2 (Parker et al., 2004). In neutrophils, stimulation with TLR agonists resulted 
in L-selectin shedding and chemokine expression, suggesting that TLR-stimulated 
neutrophils recruit, cells of the innate but not acquired immune system, to sites of 
inflammation (Hayashi et al., 2003). Therefore, after TLR stimulation, neutrophils 
expressed MIP-1α/CCL3, MIP-1β/CCL4 (active on monocytes/natural killer cells), 
IL-8/CXCL8, GRO-α/CXCL1 (active on neutrophils), and MIP-3α/CCL20 (active on 
immature dendritic cells) (Hayashi et al., 2003). In addition to, it has been reported 
that neutrophil migration may be regulated by the cross-talk of TLR2 with the cell 
surface protein CD47 (Chin et al., 2009).  In macrophages, engagement of TLRs 
may increase cells motility via the iNOS/Src/FAK axis (Maa et al., 2011). The 
importance of CCR4 in leukocyte recruitment and lethality rate of mice after 
challenge with TLR ligands has also been addressed finding that there was a 
reduced lethality rate in response to TLR-induced endotoxaemia in the CCR4-/- 
mice and this was associated with excessive early leukocyte migration (Ness et 
al., 2006).  
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1.2.9.  TLRs and adaptive immunity 
 
TLRs link innate and adaptive immunity (Iwasaki and Medzhitov, 2004). TLR-
stimulated APCs activate T-cells together with antigen-presentation and promote 
the differentiation of naïve T-cells into TH1 cells secreting IFN-, which mediates 
antiviral or antibacterial immunity or into TH2 cells secreting IL-4 and IL-13, which 
are involved in allergic reactions and immunity against helminths (Abbas et al., 
1996). Most TLR ligands support TH1-skewed immune responses (Schnare et al., 
2001) but this is not always the case (Eisenbarth et al., 2002).  
 
Stimulation of TLRs on B cells can lead to polyclonal activation and production of 
low-affinity immunoglobin M (IgM) antibodies (Hayashi et al., 2005). B cell may 
respond to TLRs differently to ensure both self-tolerance and rapid response to 
reinfection (Iwasaki and Medzhitov, 2004). 
 
Moreover, TLR3, TLR4, TLR7, and TLR9 may induce the production of type I IFN 
through different signalling pathways. Besides the role of interferons in antiviral 
activity, they have a critical involvement in controlling adaptive immune responses. 
Therefore, type I IFNs can promote memory T cell proliferation and prevent T cell 
apoptosis (Tough et al., 1999). In addition, type I IFN can induce IFN- secretion 
by CD4+ T cells in humans (Sareneva et al., 1998). On top of this, IFN-/ enables 
B cells to differentiate into plasma cells through the activation of dendritic cells (Le 
Bon et al., 2001). 
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1.2.10.  TLRs and allergy 
 
The hygiene hypothesis suggests that the increased incidence of allergy observed 
in western societies results from a decrease of infectious diseases in the early life 
of individuals (Strachan, 1989).  According to this, the early exposure to bacterial 
or viral infections can lead to a TH1 deviation of the immune status and a decrease 
of TH2 cytokines associated with allergic conditions. Specifically, TLR9 signalling 
activated by CpG DNA is the strongest inducer of TH1 differentiation (Kim et al., 
1999). A number of studies have reported successful effects of CpG DNA to 
prevent murine and primate models of allergen-induced airway 
hyperresponsiveness (Broide et al., 1998, Fanucchi et al., 2004). However, 
contrary to the hygiene hypothesis, certain infections such as influenza virus 
infection can exacerbate allergic episodes (Dahl et al., 2004). Moreover, parasitic 
infections that provoke robust TH2 cellular responses are associated with 
protection from the development of atopy (Lynch et al., 1993). On top of this, 
MyD88 null mice spontaneously developed higher levels of serum IgE than wild-
type (WT) mice (Schnare et al., 2001). 
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1.2.11.  TLRs and autoimmune disorders 
 
TLR signalling appears to be critically involved the pathogenesis of autoimmune 
disorders when on a susceptible genetic background. As described previously, 
nucleic acid TLR ligands are recognised in different cellular departments from lipid 
and protein TLR ligands. This can protect the host from potential autoimmune 
reactions.  However, in certain conditions such as deficient clearance of apoptotic 
cells, host-derived nucleic acids may trigger TLRs and lead to autoimmunity 
(LeBouder et al., 2003). Therefore, several pathogen-derived antigens, antigens 
from commensals, and endogenous self-antigens have the potential to induce TLR 
signalling (Ehlers and Ravetch, 2007).  
 
The “Hydrophobicity Hypothesis‟ may represent a way of understanding the 
possible involvement of TLRs in the pathogenesis of autoimmunity (Seong and 
Matzinger, 2004). According to this, many of the immune system receptors have 
evolved to recognize and react to the hydrophobic portions (hyppos) of molecules 
when they become exposed. Therefore, a hyppos receptor normally binds to 
endogenous physiologically exposed hyppos but in certain cases can also bind to 
hyppos that are exposed because of injury, initiating inflammation.   
 
Another form of self-reactivity is mimicry, where cells of the adaptive immune 
system cross-react with self-antigens (Fujinami and Oldstone, 1985). In this case, 
an acute or chronic infection might be associated directly with the onset of 
autoimmunity. During central B-cell and T-cell development in the bone marrow 
and thymus, respectively, a high percentage of self-reactive cells are generated, a 
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mechanism which is controlled by an initial checkpoint for tolerance. However, 
TLR signalling in different types of immune cells has been implicated in the 
breakdown of tolerance (Marshak-Rothstein, 2006).  
 
In addition, nucleic acids TLR ligands, in contrast to protein or lipid TLR ligands, 
induce type I IFNs (Honda et al., 2005, Schoenemeyer et al., 2005, Yamamoto et 
al., 2003). LPS acting through TLR4 can induce IFN- but not IFN- (Toshchakov 
et al., 2002). TLR activation leading to type I IFNs may contribute to the 
pathogenesis of autoimmune disorders such as systemic lupus erythematosus 
(SLE) (Sibbitt et al., 1985). Other example is the activation of B cells to produce 
Rheumatoid factor (RF) by stimulation with CpG DNA (Viglianti et al., 2003).  
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1.3. PATHOPHYSIOLOGY OF SEPSIS  
 
Although clinical manifestations of sepsis were known to Hippocrates and 
Avicenna, it was not until 1914 that Hugo Schottmuller realised that infection is a 
fundamental component of the disease. Sepsis can now be defined as a systemic 
inflammatory response syndrome (SIRS) that can occur during infection (Bone et 
al., 1992) and can be caused by Gram (-), Gram (+) bacteria, fungi and viruses.  
The incidence of sepsis is rising and the mortality reaches 25-30% in patients with 
severe sepsis and 50-60% in those who develop septic shock (Martin et al., 2003).   
 
During sepsis, there is a release of high levels of PAMPs from invading pathogens 
and/or damaged host tissue. Therefore, the first stage of sepsis is a hyper-
inflammatory state that is accompanied by an imbalanced cytokine response 
known as cytokine storm (Beutler et al., 1985, Fischer et al., 1992, Ohlsson et al., 
1990, Tracey et al., 1987).  For many years, it was believed that sepsis was the 
result of this overwhelming inflammatory reaction, which is characterised by 
cytokine-mediated pathology, coagulation and complement activation, which led to 
early mortality due to acute organ dysfunction.  However, clinical trials with anti-
inflammatory therapies failed to alter the outcome of patients with sepsis (Remick, 
2003).  Most current antisepsis therapies such as corticosteroids, drotrecogin-alfa 
activated, intensive insulin therapy, vasopressin, also have uncertain outcomes 
(Russell, 2006).      
 
Although some patients die during the initial phase of hyper-inflammation, most 
succumb at later time points. It is now believed that sepsis involves both 
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exaggerated inflammation and immune suppression. During this 
immunosuppressive state neutrophils can undergo “immune paralysis” in which 
important intracellular pathways such as TLR signalling are shut-down (Marsik et 
al., 2003, Salomao et al., 2009, Salomao et al., 2008). In addition, there is a 
dysfunction of the adaptive immune system characterised by a diversion from an 
initial TH1- to a TH2-response (Song et al., 2000).  Furthermore, increased 
apoptosis in lymphocytes and dendritic cells contributes to this 
immunosuppressive state (Lang and Matute-Bello, 2009).   
 
Sepsis not only affects the immune system and the coagulation system but the 
autonomic nervous system (ANS) as well.  More specifically, the initial 
inflammatory state activates afferent signals that are relayed to the nucleus tractus 
solitarius of the brain.  This activates the vagus nerve and the cytokine release is 
inhibited via cholinergic receptors present on macrophages and other cells (the 
inflammatory reflex) (Borovikova et al., 2000, Tracey, 2002). It has been shown 
that electrical stimulation of the vagus nerve improves survival by decreasing the 
release of pro-inflammatory mediators in experimental sepsis (Huston et al., 
2007). 
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Figure 1.10: Net Immunological response in sepsis over time. 
Early in sepsis the proinflammatory response predominates and deaths are due to 
cytokine storm-mediated events. As sepsis progresses, the anti-inflammatory 
response becomes predominant, secondary infections and viral reactivation may 
occur, and deaths are due to failure to control pathogens. Taken from (Hotchkiss 
et al., 2009).
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1.3.1.  Factors implicated in the pathogenesis of sepsis 
 
1.3.1.1.  Microbial pathogenesis 
 
Gram (+) bacteria such as Staphylococcus aureus and Streptococcus pneumoniae 
are the most predominant microorganisms causing sepsis, whereas the most 
common Gram (-) bacteria are Escherichia coli, Klebsiella spp, and Pseudomonas 
aeruginosa (Opal et al., 2003). Several virulence characteristics contribute to the 
pathogenesis of sepsis, including virulence genes scattered across the bacterial 
genome (Merrell and Falkow, 2004), genomic islands (Hacker and Kaper, 2000), 
bacterial toxins (Schiavo and van der Goot, 2001), and quorum sensing (the ability 
of bacteria to assess their population density) (Bassler, 2002).   
 
1.3.1.2. Host-pathogen interactions 
 
1.3.1.2.1.  The Coagulation system 
 
The coagulation system is activated in patients with sepsis and it has been 
suggested that sepsis-related disseminated intravascular coagulation (DIC) is 
associated with organ failure and high mortality. In severe sepsis, activated 
monocytes, endothelial cells, and circulating microvesicles are sources of Tissue 
Factor- the primary initiator of coagulation in sepsis (Aras et al., 2004). Blood 
clotting is controlled by Tissue-factor-pathway inhibitor (TFPI), Antithrombin, 
Activated Protein C, and by the fibrinolytic system. During severe sepsis all these 
factors are impaired, resulting in a net procoagulant state. Although the 
administration of each of these factors was tested in clinical trials having as a 
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result the attenuation of coagulopathy (Abraham et al., 2005, Abraham et al., 
2003, Warren et al., 2001), only Activated protein C was efficient in reducing 
mortality in patients with severe sepsis (Bernard et al., 2001).  
 
1.3.1.2.2.  The complement system 
 
Complement may be activated by 3 pathways: classic, alternative, and lectin-
binding pathway. Increased plasma concentrations of complement anaphylatoxins 
C3, C4, and C5 were found in clinical and experimental sepsis (Czermak et 
al., 1999, Ward, 2004). C5 is a central mediator at sepsis because it modulates 
other systems such as the coagulation cascade and TLR4-mediated responses 
such as the release of macrophage migration inhibitory factor (MIF) (Riedemann et 
al., 2004) and high mobility group box 1 protein (HMGB1) (Rittirsch et al., 2008). 
Anti-C5 antibodies reduced sepsis mortality caused by E.Coli (Stevens et al., 
1986) and caecal ligation and puncture (CLP) (Czermak et al., 1999).  
 
1.3.1.2.3.  HMGB1  
 
HMGB1 is a nuclear protein present in almost all eukaryotic cells, which is 
released by necrotic cells and from macrophages after activation by infectious 
agents (Lotze and Tracey, 2005), and its function is to stabilise nucleosome 
formation (Lichota and Grasser, 2003). HMGB1 is a late-acting proinflammatory 
cytokine in the pathogenesis of sepsis (Wang et al., 1999, Yang et al., 2004) and 
can be detected in high concentrations is sepsis patients (Sunden-Cullberg et al., 
2005). Extracellular HMGB1 may interact with PRRs such as the receptor for 
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advanced glycation end-products (RAGE), TLR2 and TLR4 (Park et al., 2004). 
Interaction between C5 and its other receptor C5-like receptor 2 (C5L2) triggers 
the release of HMGB1 in sepsis (Rittirsch et al., 2008), whereas activation of the 
cholinergic pathway suppresses its secretion by macrophages improving survival 
(Wang et al., 2004). Anti-HMGB1 antibodies improved survival in several 
experimental models of sepsis (Wang et al., 1999, Yang et al., 2004). 
 
1.3.1.2.4.  MIF 
 
MIF is highly expressed by endocrine tissues and organs involved in stress such 
as hypothalamus, pituitary gland and adrenal glands.  It is also produced by cells 
of the immune system such as macrophages, dendritic cells, neutrophils and T-
cells (Calandra et al., 2003). Therefore, it is believed that MIF links the immune 
system with the endocrine system.  
 
MIF is constitutively expressed by leukocytes and it is stored intracellularly 
(Calandra and Roger, 2003). When MIF is released, it acts as a classic pro-
inflammatory cytokine by inducing phosphorylation and activation of 
ERK1/ERK2/MAPK pathway (Lue et al., 2006) and this is associated with 
increased PLA2 activity (Sampey et al., 2001). MIF promotes the expression of 
cytokines such as TNF-, IL-6 and molecules such as NO (Bernhagen et al., 
1993) by increasing the expression of Cyclooxygegase-2 (COX-2) (Calandra and 
Roger, 2003, Sampey et al., 2001).  
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MIF secretion is induced by GCs and it acts as a physiological antagonist of GC 
activity (Calandra and Bucala, 1995). MIF interferes with GCs at a transcriptional 
and post-transcriptional level, overrides the immunosuppressive effects of GCs, 
and reverses GC-induced inhibition of TNF, IL-1, IL-6, IL-8, PLA2 activity and 
arachidonic acid release and proliferation of T-cells (Mitchell et al., 1999). It is 
believed that MIF and GCs function together to modulate innate and acquired 
immune response. 
 
Increased tissue and circulating levels of MIF have been observed in mice with 
sepsis (Calandra et al., 2000) whereas the administration of neutralising Abs for 
MIF reduced TNF- and protected mice from lethal endotoxic shock or sepsis by 
E.Coli or CLP. Increased levels of MIF were detected in blood of patients with 
severe sepsis or sepsis shock, whereas neutralization of MIF improved survival 
(Calandra et al., 2000).  
 
MIF is released by cells of the anterior pituitary gland after exposure to the 
endotoxin LPS (Bernhagen et al., 1993). MIF-/- macrophages are hyporesponsive 
to LPS and Gram (-) bacteria and produce reduced levels of TNF- and IL-6 
(Roger et al., 2001), whereas MIF-/- mice are resistant to lethal endotoxaemia 
(Roger et al., 2003). MIF upregulates TLR4 expression and therefore enables 
macrophages to respond rapidly to invasive bacteria. Therefore MIF-/- 
macrophages have reduced levels of TLR4 mRNA and protein (Roger et al., 
2001). MIF has also been implicated in the pathogenesis of Gram (+) sepsis and 
parasitic and viral infections (Assuncao-Miranda et al., 2010, Hou et al., 2009).    
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1.3.1.2.5.  IL-17A 
 
IL-17A is a proinflammatory cytokine mainly produced by TH17 cells (Bettelli et al., 
2006). It mediates the production of many other cytokines such as IL-1, IL-6, and 
TNF-. It has been shown that increased IL-17A levels are associated with 
adverse effects during experimental sepsis (Flierl et al., 2008) and that 
neutralization of IL-17A may improve survival (Flierl et al., 2008). In addition, the 
inflammatory response of macrophages to LPS was increased in the presence of 
recombinant IL-17A (Flierl et al., 2008).  
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1.3.2.  Involvement of TLRs in sepsis pathogenesis  
 
Epidemiological studies suggest a strong genetic component in the outcome of 
sepsis (Holmes et al., 2003).  Several single-nucleotide polymorphisms (SNPs) in 
TLR genes have been associated with susceptibility to infectious diseases and the 
progression of sepsis in humans. The most extensively studied polymorphism is 
the Asp229Gly mutation of the TLR4 gene.  Some groups have associated TLR4 
polymorphisms with hyporesponsiveness to endotoxin (Arbour et al., 2000, Michel, 
2003).  Other studies, however, have contradictory results (Erridge et al., 2003, 
Imahara et al., 2005) and suggest that the relatively high frequency of this 
mutation in the Caucasian population may reflect modified response of carriers to 
alternative TLR4 agonists.  The Asp229Gly polymorphism has been associated 
with lower levels of proinflammatory cytokines, acute-phase reactants, and soluble 
adhesion molecules in humans (Kiechl et al., 2002).  Although an association of 
this polymorphism with the risk of several bacterial infections especially Gram (-) 
has been shown (Agnese et al., 2002, Kiechl et al., 2002, Lorenz et al., 2002), no 
correlation has been demonstrated with the incidence or mortality of post-
operative sepsis caused by polymicrobial infection (Feterowski et al., 2003).  Rare 
TLR4 mutations have also been identified that have been shown to influence 
meningococcal infections (Smirnova et al., 2003). Other TLR polymorphisms that 
have been studied include the mutation Arg753Gln of TLR2 gene which has been 
associated with staphylococcal infections (Lorenz et al., 2000), tuberculosis (Ogus 
et al., 2004), Lyme disease (Schroder et al., 2005), and a common stop codon 
polymorphism of TLR5 gene which has been associated with susceptibility to 
pneumonia caused by Legionella (Hawn et al., 2003).  In addition, a study 
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associated hypermorphic genetic variation in TLR1 with organ dysfunction, death, 
and Gram (+) infection in sepsis (Wurfel et al., 2008).     
 
LPS from Gram (-) bacteria is believed to be an important trigger for the 
pathophysiology of sepsis. Several mediators of sepsis interact with TLR4. The 
complement anaphylatoxin C5a, which is produced in large amounts during the 
early stages of sepsis, negatively regulates TLR4-mediated responses (Hawlisch 
et al., 2005).  Plasma levels of MIF, a cytokine that correlates with sepsis severity 
(Calandra et al., 2000), upregulate TLR4 by phagocytes (Calandra and Roger, 
2003).  HMGB1 is a late-acting proinflammatory cytokine in the pathogenesis of 
sepsis and it interacts with PRRs, including TLR2 and TLR4 (Park et al., 2004).  
The proinflammatory cytokine IL-17A has been correlated with adverse effects 
during experimental sepsis and the in vitro production of pro-inflammatory 
mediators in response to LPS was increased in the presence of recombinant      
IL-17A (Flierl et al., 2008). In addition, the activation of TLR4 in platelets initiates 
the formation of neutrophil extracellular traps (NETS) to esnare bacteria in the 
vasculature (Clark et al., 2007).  Antibody-mediated blockade of TLR4 protected 
against polymicrobial sepsis (Daubeuf et al., 2007) and improved survival in 
experimental models of Gram (-) bacterial sepsis when administered both 
prophylactically and therapeutically (Roger et al., 2009).  However, in human 
sepsis, clinical trials in which TLR4 was blocked did not show beneficial effects 
(van der Poll and Opal, 2008). 
 
Besides the involvement of TLR4 in sepsis pathogenesis, it has been reported that 
the mRNA levels and surface expression of TLR2 in monocytes and neutrophils 
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were upregulated in septic patients when compared to healthy individuals 
(Armstrong et al., 2004, Harter et al., 2004, Schaaf et al., 2009, Tsujimoto et al., 
2006).  On the contrary, downregulation of TLR2 has been associated with death 
in septic patients (Schaaf et al., 2009), suggesting that TLR2 expression on 
monocytes could be a valuable sepsis marker (Viemann et al., 2005).  
Furthermore, the expression of TLR2 in macrophages has been upregulated in 
mice with experimental peritonitis induced by CLP (Tsujimoto et al., 2005, Williams 
et al., 2003), whereas TLR2-/- mice displayed a survival advantage in Gram (-) 
sepsis caused by melioidosis (Wiersinga et al., 2007). Bacterial lipoprotein (BLP), 
which exerts its primary effects primarily through TLR2, delayed 
polymorphonuclear apoptosis arising during sepsis (Power et al., 2004). Moreover, 
a neutralizing anti-TLR2 antibody inhibited the release of TNF and prevented 
lethal shock-like syndrome in mice challenged upon lipopeptide (Meng et al., 
2004).  However, the in vitro interaction of HMGB1 with TLR2 (Park et al., 2004) 
could not be confirmed in vivo (van Zoelen et al., 2009).  In addition, in 
polymicrobial infection models such as the CASP model of septic peritonitis, it was 
shown that the survival rates of mice with single or combined deficiency of TLR2 
and TLR4 was comparable to those of WT mice (Weighardt et al., 2002). On the 
contrary, MyD88-/- mice exhibited improved survival suggesting that ablation of 
MyD88 may protect mice from the deleterious effects of polymicrobial sepsis 
(Weighardt et al., 2002). In addition, TLR3 has been suggested to be involved in 
viral sepsis. Indeed, studies have shown that TLR3-/- mice are protected against 
the neurological implications of West Nile virus (Wang et al., 2004) and anti-TLR3 
antibodies attenuate tissue necrosis and decrease sepsis-induced mortality 
(Cavassani et al., 2008).  
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Macrophages produce IL-10 in response to MyD88-dependent and TRIF-
dependent TLR signals (Boonstra et al., 2006). When septic patients were 
challenged with TLR ligands such as LPS and Pam3CysK4, there was a reduction 
of TNF- and an enhancement of IL-10 (Adib-Conquy et al., 2006). It has been 
recently proven that sepsis can be attenuated by bone marrow stromal cells via 
reprogramming of host macrophages to increase their IL-10 production (Nemeth et 
al., 2009), which inhibits macrophage microbicidal activity by blocking the 
endogenous production of TNF- (Oswald et al., 1992). 
 
Besides sepsis caused by infectious agents, injury may lead to the release of 
PAMPs into the circulation. In specific, trauma releases mitochondrial „damage‟-
associated molecular patterns (DAMPs) including formyl peptides and 
mitochondrial DNA rich in CpG repeats. The latter is recognised by neutrophils 
through activation of TLR9, leading to inflammation and SIRS (Zhang et al.). 
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1.4.  ANNEXINS 
 
1.4.1.  The Annexin superfamily 
 
Annexins are a family of Ca2+ and phospholipid binding proteins which are 
evolutionary conserved and are expressed throughout the animal and plant 
kingdom (Gerke and Moss, 2002). More than 500 different gene products are 
present in most species (Morgan and Fernandez, 1997). In vertebrates 13 annexin 
subfamilies (A1-A13) have been identified (Rescher and Gerke, 2004). The name 
annexin is derived from the Greek word annex meaning hold together since nearly 
all annexins are characterised by the binding of membranes. By definition, a 
member of the annexin family must have the ability to bind in a Ca2+-dependent 
manner to negatively charged phospholipids and to contain a structurally 
conserved segment called the annexin repeat. 
 
Each annexin is composed of two domains: a divergent NH2-terminal part and a 
conserved COOH-terminal protein core, which contains the Ca2+ and membrane 
binding sites (Raynal and Pollard, 1994). An annexin core generally comprises 4 
segments of internal homology forming a highly –helical disk (Raynal and 
Pollard, 1994). Ca2+ and possibly membrane binding can trigger exposure of the 
NH2-terminal, which mediates interactions with protein ligands (Rosengarth and 
Luecke, 2003).  
 
The binding of annexins to membranes is reversible, since removal of Ca2+ leads 
to the liberation of annexins from the phospholipids matrix (Raynal and Pollard, 
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1994). Therefore, certain annexins can mediate membrane vesicle aggregation 
(Raynal and Pollard, 1994), are implicated in exocytosis (Chasserot-Golaz et al., 
2005, McArthur et al., 2009, Naidu et al., 2005) and endocytosis (Grewal et al., 
2000, Jost et al., 1997, Morel and Gruenberg, 2009), and they can stabilise 
domains of the plasma membrane and organelle membranes (Hu et al., 2008a, 
Menke et al., 2005).  
 
Besides lipid ligands, annexins have the ability to form complexes with EF hand-
type Ca2+ binding proteins such as the S100 subfamily (Mailliard et al., 1996, 
Streicher et al., 2009), cytoskeletal proteins such as F-actin (Filipenko and 
Waisman, 2001, Locate et al., 2008) and profilin (Alvarez-Martinez et al., 1996, 
Alvarez-Martinez et al., 1997), macromolecules such as glycosaminoglycans 
(Ishitsuka et al., 1998) and a number of other ligands ranging from proteins to 
RNA (Filipenko et al., 2004, Hirata and Hirata, 1999).  
 
Although annexins lack signal sequences guiding them to the canonical secretory 
pathway, they possess extracellular properties leading to responses such as the 
anti-inflammatory action of Annexin A1 (Perretti and Gavins, 2003) and the anti-
thrombogenic action of Annexin A2 (Brownstein et al., 2004, Kwon et al., 2005, 
Ling et al., 2004, Zhu et al.). To date, no human diseases have been described 
which could be attributed solely to an annexin gene but still changes in expression, 
properties or localization of annexins may contribute to the pathophysiology of 
several diseases. The term „annexinopathies‟ applies to such phenotypes, 
characterised by dysregulation of the normal antithrombotic properties of some 
extracellular annexins (Rand, 1999). Therefore, annexins have been associated 
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with diseases ranging from cardiovascular disorders (Cederholm and Frostegard, 
2005, Gavins et al., 2006), cancer (Nair et al., Sharma et al., Song et al., 2009, 
Torosyan et al., 2009, Yan et al.) and diabetes (Lindgren et al., 2001). Although 
the likelihood of functional redundancy between annexins exists, it is a fact that 
changes in the expression of one annexin can affect the expression levels of 
another (Roviezzo et al., 2002). 
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1.4.2.  The multifunctional role of Annexin A1 
 
AnnexinA1 (AnxA1), originally known as lipocortin-1, is an endogenous 37kDa 
Ca2+ and phospholipid binding protein. The gene encoding the protein can be 
located on chromosome 19q24. AnxA1 contains a core with four 70-amino acid 
domains, where the binding sides for Ca2+ and phospholipids lie, and the 49 amino 
acid N-terminus of the protein, which contains canonical phosphorylation and 
proteolysis sites (Raynal and Pollard, 1994) and is believed to be responsible for 
its biological activity (Cirino et al., 1993). In the presence of Ca2+ 1 mM the N-
terminal domain which is normally buried in the core domain, is expelled revealing 
the active form of the protein (Rosengarth and Luecke, 2003).   
 
 
Figure 1.11: AnxA1 structure. 
A. Three-dimensional structure of full-length AnxA1 in the presence of Ca
2+
 ions. 
B. Full-length AnxA1 in the absence of Ca
2+
 ions. Adapted from (Rosengarth and Luecke, 2003). 
N-terminal domainN-terminal domain
A
B
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Although AnxA1 is undetectable in plasma, it is found in many cells and tissues. 
AnxA1 is detected in all leukocyte subsets with the exception of B lymphocytes 
(Morand et al., 1995), whereas it is found in gelatinase granules in neutrophils 
(Perretti et al., 2000). Generally, differentiated cells tend to synthesise higher 
amounts of AnxA1, such as human alveolar macrophages when compared to their 
monocyte precursors (Ambrose et al., 1992).  
 
After cell activation as GC treatment, AnxA1 is mobilised to the cell membrane, 
where it is secreted (Perretti et al., 1996b) and it binds to its receptor.  The 
receptor for AnxA1 in humans is a G-protein-coupled receptor (GPCR) named 
formyl peptide receptor 2 (FPR2), formerly known as FPRL1, which is also the 
receptor for the anti-inflammatory molecule lipoxin A4 (Perretti et al., 2001). 
Peptides derived from the N-terminal domain of AnxA1 activate in vitro all 
receptors of the FPR family (FPR1, FPR2 and FPR3) (Dahlgren et al., 2000). 
Human FPRL1 has a structural homology with FPR2 in the mouse (Panaro et al., 
2006, Selvatici et al., 2006) and therefore Fpr2-/- mice have been used to 
investigate the effect of AnxA1 in the absence of FPRs. 
 
It has been reported that changes in the concentration of AnxA1 in human 
peripheral blood leukocytes can occur after exogenous administration of 
hydrocortisone (Goulding et al., 1990) and that there is a correlation between 
AnxA1 expression in these cells with the levels of serum cortisol (Mulla et al., 
2005). Injection of hydrocortisone or dexamethasone causes an increase of AnxA1 
in rat peritoneal leukocytes (Peers et al., 1993). In addition, treatment with 
dexamethasone may lead to an upregulation of the AnxA1 receptor in leukocytes 
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(Sawmynaden and Perretti, 2006). GCs promote the translocation of AnxA1 from 
intracellular to pericellular sites (Philip et al., 1997, Solito et al., 1994). 
Furthermore, AnxA1-/- mice exhibit resistance to GCs (Hannon et al., 2003). It is 
now long established that AnxA1 is a downstream mediator of GCs, since the 
discovery of its involvement in the inhibition of the enzyme PLA2 activity and 
subsequent inhibition of eicosanoid synthesis induced by GCs (Cirino et al., 1987); 
a mechanism through a „specific interaction‟ with PLA2 (Kim et al., 1994, Kim et al., 
2001).  However, the mechanism by which GCs regulate AnxA1 expression has 
not yet been fully elucidated since the AnxA1 promoter does not contain a 
complete consensus of glucocorticoid-response elements, suggesting that it is 
mediated through an indirect effect. 
 
Besides the effect of AnxA1 on PLA2 activity, administration of dexamethasone in 
LPS-treated rats reduced the expression of iNOS in the lung, an effect that was 
prevented by pretreatment with a neutralizing antiserum to AnxA1 (Wu et al., 
1995). In the same study, an AnxA1 fragment blocked iNOS in macrophages 
stimulated with LPS, indicating that the extracellular release of AnxA1 mediates 
the effect of GCs on the expression of iNOS (Wu et al., 1995). A study using 
microglial cells demonstrated that the N-terminus peptide of AnxA1 Ac2-26 inhibits 
the LPS-induced expression of both iNOS and COX-2 (Minghetti et al., 1999). 
Another study confirmed the down-regulation of iNOS by Ac2-26 in a macrophage 
cell line and supported the notion that the anti-inflammatory effects of AnxA1 may 
be mediated by the release of the cytokine IL-10 (Ferlazzo et al., 2003). Indeed, 
IL-10 is an anti-inflammatory cytokine, which can downregulate the expression of 
both iNOS (Cunha et al., 1992) and COX-2 (Berg et al., 2001). Several TLR 
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ligands may upregulate IL-10 production in macrophages by activating the ERK 
pathway (Qian et al., 2006), which is also activated by endogenous AnxA1 
(Alldridge et al., 1999).        
 
It is now well established that AnxA1 has antimigratory effects on neutrophils and 
monocytes (Cirino et al., 1993, Lim et al., 1998, Perretti et al., 1996b, Perretti and 
Flower, 1993, Walther et al., 2000, Zouki et al., 2000) and anti-inflammatory 
effects when tested in several models of inflammation such as the air-pouch model 
(Cirino et al., 1993, Hayhoe et al., 2006, Perretti et al., 1996a, Perretti and Flower, 
1993, Perretti and Flower, 1994) and the carrageenan paw oedema (Cirino et al., 
1993, Cirino et al., 1989, Duncan et al., 1993).   
 
AnxA1 has also been implicated in the adaptive immune response by acting as a 
molecular „tuner‟ of TCR signalling. In specific, stimulation of naïve T-cells with 
hrAnxA1 and suboptimal doses of anti-CD3/CD28 increased cell activation and 
proliferation by affecting the transcription factors    NF-B, nuclear factor for 
activated T cells (NFAT) and AP-1 (D'Acquisto et al., 2007a). Stimulation of T cells 
via the TCR lead to a secretion of endogenous AnxA1 and externalisation of its 
receptor ALXR (D'Acquisto et al., 2007a). In addition, differentiation of naïve T 
cells in the presence of AnxA1 increased skewing to TH1 cells (D'Acquisto et al., 
2007a). Finally, patients with active rheumatoid arthritis, in which T cells are the 
dominant cell type in synovial infiltrate, had higher levels of AnxA1 in their blood 
CD4+ cells (D'Acquisto et al., 2007a).   
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Besides its role in inflammation, AnxA1 has been reported as a regulator of cell 
proliferation (Alldridge et al., 1999), and apoptosis (McKanna, 1995, Sakamoto et 
al., 1996).  It has also been implicated in the apoptotic cell „eat me‟ signal (Arur et 
al., 2003).  Furthermore, Mycobacterium tuberculosis may block crosslinking of 
AnxA1 and therefore the apoptotic envelope formation on infected macrophages, 
leading to death by necrosis and thus contributing to virulence (Gan et al., 2008). 
 
 
Figure 1.12: Model of glucocorticoid modulation of the AnxA1 pathway in immune 
regulation. 
It has been proposed that endogenous and synthetic glucocorticoids can control innate and 
adaptive immune responses by modulating the expression and release of AnxA1. Exposure of 
innate immune cells, such as neutrophils, monocytes, macrophages and mast cells, to 
glucocorticoids induces the release of AnxA1. By contrast, exposure of T-cells to glucocorticoids 
leads to a reduction of AnxA1 expression. Taken from (Perretti and D'Acquisto, 2009).
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1.4.3.  AnxA1 and the macrophage 
 
AnxA1 mRNA and protein are constitutively expressed in many different tissue 
specific macrophages i.e. peritoneal, alveolar, synovial, and microglial cells 
(Ambrose et al., 1992).  The expression of the protein in macrophages increases 
following exposure to GCs (Ambrose et al., 1992, Cirino et al., 1993, De Caterina 
et al., 1993) depending upon the cell differentiation status (Ambrose et al., 1992).  
Cytokines such as IL-6 can increase cellular and tissue AnxA1 expression (Solito 
et al., 1998).  In macrophages, the ATP-binding cassette (ABC) transporter system 
is responsible for the secretion of the protein (Wein et al., 2004).  In these cells, 
AnxA1 inhibits cell trafficking and trans-endothelial migration (Perretti et al., 2002). 
Several inflammatory mediators produced by macrophages during the 
inflammatory response such as TNF- (Sudlow et al., 1996), PGE2 (Sudlow et al., 
1996) and NO (Yang et al., 1998) can be inhibited by GCs in an AnxA1-dependent 
manner. It has been suggested that the inhibition of NO release and the 
expression of iNOS in the macrophages are associated with the increase of IL-10 
and the decrease in IL-12mRNA (Ferlazzo et al., 2003). Moreover, an impaired 
phagocytic mechanism has been reported in AnxA1 null macrophages (Yona et 
al., 2006).   
 
Interestingly, it has been shown that LPS increases FPR1 mRNA levels in 
macrophages by both enhanced transcription and stabilization of the FPR1 mRNA 
(Mandal and Hamilton, 2007, Mandal et al., 2005). This begs the question of why 
an agonist acting through a different receptor modulates the mRNA levels of a 
receptor belonging to the formyl receptor family. Furthermore, ligands that 
stimulate macrophages through TLR2 and TLR3 were also capable of inducing 
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FPR1 expression, implying that FPR1 modulation probably does not correlate with 
either the MyD88-dependent or MyD88-independent pathways (Mandal and 
Hamilton, 2007). Genes encoding formyl peptide receptors were also upregulated 
by LPS in murine microglial cells (Cui et al., 2002). In addition to, it has been 
reported that the mouse FPR2 is upregulated by TLR2 ligands in synergy with the 
intracellular receptor NOD2 (Chen et al., 2008) or by the TLR3 ligand poly (I:C) in 
synergy with the TLR7 ligand R837 (Chen et al., 2009b) in microglial cells.   
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1.4.4.  AnxA1-/- mice present increased lethality to administration of LPS 
 
A study performed by our group has demonstrated that administration of the TLR4 
agonist LPS to AnxA1-deficient mice, produced a toxic response characterised by 
lethality not seen in WT mice, a phenotype which was partially rescued by 
exogenous administration of the human recombinant protein (Damazo et al., 
2005).  Which is the cause of death is still not understood.  It was associated with 
an increase in the levels of IL-1, IL-6, and TNF- in the plasma indicating that 
AnxA1 has a protective role in the endotoxemic murine microcirculation.  In 
addition, LPS activated the AnxA1 gene in macrophages, a cell type with a critical 
role in the pathophysiology of sepsis since it initiates the immune response.  
Analysis of AnxA1-deficient macrophages has shown an increased response to 
LPS stimulation and an aberrant expression of TLR4.  However, the mechanism 
by which AnxA1 exerts a protective role in endotoxemia and the role of AnxA1 in 
different types of infections (caused by Gram (-), Gram (+) bacteria and by viruses) 
remains unknown. 
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Figure 1.13: Modulation of mouse survival by AnxA1. 
WT and AnxA1 null mice received 10mg/kg LPS intraperitoneally at time 0. A group of AnxA1 null 
mice was rescued by receiving 10ng of hr-AnxA1 at time 0, 4, 8, and 24h (arrows) after LPS 
administration. * P≤0.05 compare with WT mice. § P≤0.05 compared with untreated control mice. 
Taken from (Damazo et al., 2005). 
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1.5  HYPOTHESIS 
 
AnxA1 is an endogenous homeostatic/protective mediator that is implicated in 
the resolution of several types of infection.   
  
1.6  AIMS 
 
 To compare the response of AnxA1-/- to AnxA1+/+ macrophages after 
stimulation with different TLR ligands.   
 To investigate whether stimulation of macrophages with different TLR 
ligands can modulate the AnxA1/FPR system. 
 To analyse the signalling molecules in TLR pathways at which AnxA1 
could exert an effect.  
 To study the response of WT macrophages stimulated with different 
TLR ligands after treatment with hr-AnxA1. 
 To test the effect in vivo of administrating different TLR ligands to 
AnxA1+/+ and AnxA1-/- mice.   
 
Previous research by our group clearly indicated that AnxA1 blocks the 
TLR4 signalling pathway with an as yet unidentified mechanism (Damazo 
et al., 2005). Since TLR4 signalling includes both the MyD88-dependent 
and the TRIF-dependent pathway (Fig 1.14), several approaches have 
been used to investigate the exact „checkpoint(s)‟ on the TLR4 pathway at 
which AnxA1 could exert an effect (Fig 1.15). In addition, we extended our 
investigation in different types of inflammation caused by other TLR 
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ligands. In order to achieve these aims a panel of different TLR agonists 
has been used. Different adaptor protein(s) are recruited to each TLR after 
stimulation (Table 1.1). 
  
Figure 1.14: TLR4 signalling pathway 
Both MyD88-dependent and TRIF-dependent pathways are part of the TLR4 signalling. These 
induce a number of transcription factors influencing the gene expression of several mediators of 
inflammation. Adapted from (Covert et al., 2005). 
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Figure 1.15: AnxA1 exerts an effect on TLR4 signalling pathway. 
Exogenous AnxA1 acts on FPR2 but at the same time blocks the TLR4 signalling pathway with an 
as yet unidentified mechanism. Red line: release of AnxA1 upon TLR stimulation. 
 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: Different adaptor molecules are recruited to the receptor after stimulation of 
different TLRs. 
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1. TLR ligands 
 
The TLR agonists used for stimulation of BMDMs were: Heat-killed Listeria 
monocytogenes (HKLM - TLR2 agonist), poly (I:C) (synthetic analogue that 
resembles viral double-stranded RNA - TLR3 agonist), Escherichia coli LPS 
serotype 0111:B4 (principal cell wall component of Gram (-) bacteria - TLR4 
agonist), flagellin from S. thyphimurium (protein component of bacterial flagellar 
filament - TLR5 agonist), loxoribine (synthetic guanosine analogue - TLR7 
agonist), and ODN1826 (synthetic CpG oligonucleotide - TLR9 agonist) and were 
all purchased by InvivoGen (San Diego, U.S.A.). 
 
2.2. Animals 
 
Genetically modified AnxA1 KO mice on a C57BL/6 background and their WT 
littermates were purchased from B&K (UK) and were used throughout these 
experiments. Prior to sending to the commercial breeder, the colony was 
genotyped as previously described (Hannon et al., 2003). All mice were young 
adult males (6-8 weeks old) and had a body weight of 24-28g. Food and water 
were available ad libitum.  Animals were kept under standard conditions and 
maintained in a 12-h light/dark cycle at 221 0C in accordance with United 
Kingdom Home Office regulations (Guidance on the operation of Animals, 
Scientific Procedures Act 1986) and of the European Union directives. 
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2.3. Generation of conditioned medium 
 
L929 fibroblasts were resurrected from aliquots stored in liquid nitrogen (-120 0C). 
L929 cells were gently warmed in a 37 0C water bath, plated in T175 cm2 flasks 
containing DMEM (GIBCO, Paisley, UK) supplemented with 10% heat-inactivated 
foetal calf serum (FCS; GIBCO, Paisley, UK) and were maintained at 37 0C in a 
5% CO2 and 95% O2 atmosphere. When the cells became confluent the medium 
was removed, they were washed with phosphate-buffered saline (PBS) and were 
plated with 100ml of fresh DMEM 10% FCS in T175 cm2 flasks at 37 0C in a 5% 
CO2 and 95% O2 atmosphere. On day 3 of culture, the supernatant medium was 
collected, centrifuged and filtered through a 0.22 m filter (Corning, Schiphol-Rijk, 
Netherlands). The aliquots were stored at –20 oC and were used as and when 
required to make conditioned medium containing Macrophage Colony Stimulating 
Factor (M-CSF) for the generation of BMDMs from bone marrow pre-cursor cells. 
Conditioned medium was considered DMEM medium containing 20% FCS, 30% 
L929 supernatant and 50g/ml gentamicin. 
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2.4. Generation and culture of BMDMs 
  
Young (6-8 weeks) AnxA1 KO mice and their WT littermates were sacrificed by 
cervical dislocation.  The skin of the abdomen and legs were sterilised with 70% 
ethanol spray in a sterile flow cabinet. A transverse cut through the skin of the 
abdomen was performed in order to dissect away the skin and expose the hind 
limbs. In order to expose the femurs and tibia the muscles attaching the hind limbs 
to the pelvis were dissected. The femurs and tibia were washed and cleaned, to 
remove all attached flesh. Thereafter, they were washed for 1 min in 70% ethanol 
and then transferred to new plates containing tissue culture PBS. Each bone was 
held with forceps so that the tips of the bones (epiphyses) could be cut.  The bone 
marrow cells were flushed out with a 10ml syringe containing PBS by placing the 
connected 25-gauge needle into the bone shaft. The procedure was repeated 
several times until the bones became white indicating that all the bone marrow 
was expelled. The marrow plugs were mechanically disrupted by the 25-gauge 
needle. The cells were resuspended into 50ml-falcon tubes and filtered through a 
70m strainer, then centrifuged for 5min at 1200 rpm and resuspended in 
conditioned medium. Viable cell counts using the Neubauer haemocytometer were 
performed. The total number of cells was calculated according to the following 
formula: 
 
Total number of cells= number of cells counted in the grid x dilution factor x104 
(factor of chamber) x volume of cell suspension.  
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Thereafter, cells were plated in a concentration of 2x106/ml in 10 cm sterile Petri 
dishes (Corning, Shiphol-Rijk, Netherlands), and were incubated in a humidified 
atmosphere of 5% CO2 at 37
oC for 7 days in conditioned medium to allow 
proliferation and differentiation.  Fresh conditioned medium was added on day 4. 
Cultures were confluent by day 6 and the adherent cells were harvested gently by 
cell scrapers, counted, and plated in DMEM medium in order to be stimulated with 
different TLR agonists. The bone marrow which was flushed from the femurs and 
tibia of each mouse gave approximately 50-100 x 106 bone marrow cells and 
resulted in approximately 30-60 x 106 macrophages following 7 days of 
differentiation in conditioned medium. The differentiation of macrophages was 
confirmed by morphology using FACS at day 6 for the markers CD40, CD80, 
CD86 and MHC II.  
 
2.5. Stimulation of BMDMs with TLR ligands 
 
AnxA1+/+ and AnxA1-/- BMDMs were seeded at a density of 500.000/well in 
triplicate wells in order to be used for flow cytometry and cytokine assays, and of 
2x106/well for EMSAs and Western blots.  Thereafter, the cells were incubated 
with medium alone or with one of the following TLR agonists: HKLM (final 
concentration 1x108 freeze-dried cells/ml), poly (I:C) (25g/ml), LPS (5g/ml), 
flagellin (0.1g/ml), loxoribine (1mM), and ODN (1M). AnxA1+/+ BMDMs were 
also stimulated with different concentrations of human recombinant AnxA1 (see 
below homology with the mouse protein). The macrophages were incubated at 37 
oC under humidified 5% CO2 for various time-points before use in assays. After 
incubation, supernatants were harvested and frozen at  –20oC prior to analysis for 
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cytokines by ELISA and for NO2
- by the Griess reaction. RNA was extracted from 
cells using commercial column-based kit (Qiagen, West Sussex, UK) for RNA 
extraction or cells were removed by vigorous pipetting for analysis of markers of 
macrophage activation by flow cytometry or they were treated with cell lysis buffer 
to be used for Western blotting or were stored directly at  –20oC for nuclear and 
cytoplasmic extracts.     
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2.6. Flow cytometry 
 
Flow cytometry is a technique which can be used to determine the relative size 
(proportional to forward-scattered light- FCS) and granularity (proportional to side-
scattered light- SSC) of a cell based on the scattering of light and the emission of 
fluorescence. It can also be used to identify specific surface markers on a cell.  
 
Flow cytometry was used to investigate the phenotypic characteristics of AnxA1+/+ 
and AnxA1-/- BMDMs and the cell surface expression of markers of macrophage 
activation. BMDMs were prepared as described in section 2.4 and were treated for 
24 h with the different TLR ligands or medium alone. The plate was centrifuged at 
2000 rpm for 5min and the supernatant was removed. Cells were detached from 
the plates by flashing with PBS and were collected in tubes, centrifuged at 8000 
rpm for 5min and resuspended in FACS buffer (PBS containing 1%FCS and 
0.02% NaN2) containing CD16/CD32 FcIIR blocking antibody (working dilution 
1:1000; clone 93; eBioscience, Wembley, UK) for 30 min at 4oC in order to prevent 
unspecific binding of antibodies.  Thereafter, cells were labelled for 1 h at 4oC with 
the following PE-conjugated antibodies (eBioscience, Wembley, UK): MHC II 
(1:1000; clone M5/114.15.2), CD40 (1:1000; clone 1C10), CD80 (1:1000; clone 
16-10A1), and CD86 (1:1000; clone GL1), prior to analysis by FACScalibur using 
CellQuest software (Becton Dickinson, Fanklin Lakes, NJ).  At least 104 cells were 
analysed per sample. If the FACS acquisition could not be performed the same 
day, the cells were fixed in 1% paraformaldehyde (PFA) at 40C for 1 hour. For 
isotype controls we used an IgG of the same subtype conjugated to the 
chromophore.  
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2.7. Analysis by ELISA 
 
2.7.1. Mouse TNF- and IL-6 ELISA 
 
The collected supernatants of BMDMs stimulated with different TLR ligands were 
analysed for the levels of IL-6 and TNF- by ELISA according to the 
manufacturer‟s instructions (eBioscience, Hatfield, UK).  Briefly, 96-well high-
binding plates were coated with the specific cytokine capture antibody and 
incubated overnight at 4oC.  The standards were diluted as noted on the certificate 
of analysis and 2-fold serial dilutions were performed to make the standard curve. 
100l/well of standard and of each unknown sample was added to the appropriate 
wells. After a 2-h incubation at 37oC in order to allow the antigen present in the cell 
free supernatants to bind to the immobilised antibody already bound to the plate, 
the plates were washed extensively with the wash buffer (PBS 0.05% tween-20) in 
order to remove any sample that was unbound. Then, the samples bound to the 
antibody were detected by the addition of 100 l of a detection antibody specific 
for the desired cytokine following incubation of 1-hour. Thereafter, the plates were 
incubated for 30min with the enzyme Avidin-Horseradish Peroxidase (HRP), and 
after an extensive wash to remove unbound antibody-enzyme reagent, 100 l of 
substrate solution (tetramethylbenzidine TMB) was added to produce colour.  The 
reaction was terminated by the addition of 50 l of 1M H3PO4 turning the samples 
from blue to yellow and the absorbance was read at a wavelength of 450nm using 
a spectrophotometer (Labsystems Multiskan Bichromatic; Helsinki; Finland).  The 
concentration was calculated from the standard curve using the software Graph 
Pad PrismTM. 
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Figure 2.1: Typical standard curve obtained during an IL-6 ELISA assay. 
Absorbance values were read at 450 nm and IL-6 concentration were determined from the 
standard curve; using the Graph Pad Prism
TM
. 
 
2.7.2. Mouse phospho-ERK1/2 ELISA 
 
Cell lysates were prepared as described at section 2.9 and were analysed for the 
levels of phospho-ERK1/2 according to the manufacturer‟s instructions (R&D 
Systems; Abingdon; UK). Briefly, a 96-well plate was coated with the capture 
antibody and was incubated overnight at room temperature. The following day, the 
plate was washed with 0.05% tween-20 in PBS, was blocked by the addition of 
300 l of blocking buffer (1% BSA, 0.05% NaN3 in PBS) per well and was 
incubated at room temperature for 2 h. A standard curve starting at the 
concentration of 20 ng/ml was prepared by serial dilution with IC Diluent 3 (1 mM 
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EDTA, 0.5% Triton X-100, 5 mM NaF, 1M urea in PBS). All the samples were 
diluted 1:1 with IC Diluent Y (1 mM EDTA, 0.5% Triton X-100, 5 mM NaF, 2M 
urea in PBS) in order to have a final concentration of urea 1M.  100 l of standard 
or diluted sample was added to the appropriate wells and the plate was incubated 
for 2 h at room temperature. Thereafter, the detection antibody was added and the 
plate was incubated for another 2 h before the addition of streptavidin HRP and 
the incubation for 20 min. Finally, 100 l of substrate solution (prior to use equal 
quantities of Color Reagent A- H2O2 and Color Reagent B- Tetramethylbenzidine 
were mixed) was added per well and the plate was incubated until the colour 
changed (approximately 1 hour). The reaction was terminated by the addition of 50 
l of 1 M H3PO4 per well and the optical density was determined at a wavelength 
of 450 nm using a spectrophotometer (Labsystems Multiskan Bichromatic). The 
software Graph Pad PrismTM was used for determination of the concentration of 
unknown samples from the standard curve. 
 
 
Figure 2.2: Typical standard curve obtained during a p-ERK1/2 ELISA assay. 
Absorbance values were read at 450 nm and p-ERK1/2 concentration were determined from the 
standard curve; using the Graph Pad Prism
TM
. 
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2.8. Bradford protein assay 
 
200 l per well of the Bradford reagent (1:5 of commercial stock solution in distilled 
water) was added in a 96-well flat bottom plate. 2 l of each sample was added 
per well followed by incubation for 10min at room temperature. The absorbance 
was read at 595nm in a microplate reader (Labsystems, Waltham, MA). The 
protein concentration was calculated using the software Graph Pad PrismTM 
knowing that the absorbance of 0.06 corresponds to 1 g protein. 
 
2.9. Preparation of whole cell lysates 
 
The cells were lysed in ice-cold lysis buffer containing protease and phosphatase 
inhibitors for 5 min (1% Triton-X; 20mM Tris, pH 7.5; 150mM NaCl; 1mM MgCl2; 
1mM EGTA; 1mM DTT; 0.5mM phenylmethylsulfonyl fluoride (PMSF), 1M 
Aprotinin, 1M Leupeptin; 1M Pepstatin; 50mM NaF; 10mM Na4P2O7; 1mM 
sodium orthovanadate (NaVO4) and 1mM - glycerophosphate).  The lysates were 
centrifuged at 14,000 rpm for 5 min at 4oC, and the supernatants were collected.  
The protein content was quantified by the Bradford method described at section 
2.8.  
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2.10. Western blotting by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Western blotting is a technique, which allows the detection of proteins of interest 
and their separation according to their molecular weight. It firstly includes 
electrophoresis on a gel, secondly the transfer of separated proteins onto a 
membrane and thirdly incubation of the membrane with specific antibodies which 
may be detected using the ECLTM system. 
 
The samples were denatured with hot 6x Laemmli sample buffer (60% 4x Tris-
HCl/SDS, pH 6.8; 36% glycerol; 0.1 g/ml SDS; 0.093 g/ml dithiothreitol (DTT); 0.12 
mg/ml bromophenol blue). The SDS disrupts the hydrogen bonds and makes the 
proteins negatively charged. The reducing agent DTT cleaves disulphide bonds to 
completely unfold the protein structure, whereas bromophenol blue was added to 
identify the proteins as they migrate through the gel.   
 
A discontinuous buffer system (Laemmli) was used for protein electrophoresis, 
constructed of a low percentage (4%) stacking and a higher percentage resolving 
gel, allowing proteins to concentrate prior to separation resulting in a far greater 
resolution. Throughout the experiments 8%, 10%, and 12% resolving gels were 
used according to the molecular weight of the protein of interest, the formulations 
of which are shown in Table 2.1. The resolving and stacking gels were prepared 
by combining all reagents except for the polymerization catalysts ammonium 
persulfate (APS) and N,N,N‟,N‟-Tetramethylenediamine (TEMED), which were 
added immediately before pouring the gels.  
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Table 2.1: Formulations for SDS-PAGE resolving and stacking gels. 
    REAGENTS                                 RESOLVING                                 STACKING                                
                                                                                                                                   
                                       8%                    10%                   12%                    4% 
Polyacrylamide 
(37.5:1) (ml) 
10.6 13.3 16 3.9 
 
4xResolving 
buffer (ml) 
 
10.4 10.4 10.4 - 
dH2O (ml) 18.6 15.8 13.2 18.3 
Stacking 
buffer (ml) 
- - - 7.5 
10% APS (l) 400 400 400 150 
TEMED (l) 40 40 40 30 
 
 
Polyacrylamide: Proto Gel Acrylamide: 30% acrylamide and 0.8%bis-acrylamide (National 
Diagnostics, Atlanta, USA)  
Resolving buffer: 1.5M Tris-HCl 0.4% SDS, pH 8.8 (National Diagnostics, Atlanta, USA)  
Stacking buffer: 0.5M Tris-HCl 0.4% SDS, pH6.8 (National Diagnostics, Atlanta, USA)  
APS: Ammonium Persulphate 
TEMED: N,N,N‟,N‟-Tetramethylenediamine 
 
 
The gels were clipped onto the western blot apparatus. The bottom tray and the 
space behind each gel were filled with SDS running buffer (diluted from a stock 
solution of 5x concentrate: 0.12 M Tris-base, 0.96 M glycine, 0.017 M SDS). 
Thereafter, the gels were loaded with 5 l of molecular marker (New England 
Biolabs, USA) in the first lane and the unknown denatured samples in the following 
lanes. The samples were then subjected to electrophoresis until the blue marker 
reached the bottom of the gel. 
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Once electrophoresis was complete, the gels were removed from the western blot 
apparatus, the stacking gel was discarded and the resolving gel was detached 
from the plate and placed into a bath of transfer buffer (0.02 M Tris-base, 0.14 M 
glycine, 20% ethanol). The gels were sandwiched firmly between Polyvinylidene 
Fluoride (PVDF; Millipore, Watford, UK) membranes and two pieces of blotting 
paper and foam inside a transfer cage. Protein was transferred onto PVDF 
membranes inside a transfer chamber (Hoefer) in the presence of transfer buffer. 
 
Membranes were blocked for 1h at RT in 5% non-fat dry milk in Tris-buffered 
saline solution containing Tween-20 (TTBS: 130mM NaCl; 2.68mM KCl; 19mM 
Tris-HCl; 0.001% v/v Tween-20, pH 7.4)]. Membranes were then incubated with 
the primary antibody of interest diluted in 5% non-fat dry milk in TTBS at 4oC. 
Following 3 x  5 min washes with TTBS, the membranes were incubated for 1 h at 
RT with a horseradish peroxidase (HRP) conjugated IgG secondary antibody.   
 
Membranes were washed 5 times for 5 min in TTBS prior to incubation with 
enhanced chemiluminescence (ECL) solution for protein detection. Briefly, an 
equal volume of solution ECL1 (2.5 mM luminol, 0.44% p-coumaric acid; 100 mM 
Tris-base; pH 8.5) was mixed with solution ECL2 (0.02% H2O2, 100 mM Tris-base; 
pH 8.5), 2.5ml was poured onto each membrane and incubated for 1 min at RT. 
Membranes were wrapped in Saran Wrap, placed in an X-ray film cassette, and 
transferred to the dark room. A sheet of X-ray film (Fujifilm, USA) was placed on 
top of the membrane, the cassette was closed and film was exposed for a 
minimum of 5 sec and up to 15 min in most instances.  
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The following primary Abs were used: pERK (Santa Cruz, Santa Cruz, USA; sc-
7383; 1:500), ERK1/2 (Santa Cruz, Santa Cruz, USA; sc-94, sc-154; 1:5000), 
COX2 (Santa Cruz, Santa Cruz, USA; sc-1747; 1:1000), IB (Santa Cruz, Santa 
Cruz, USA; sc-371; 1:500), NOS2 (Santa Cruz, Santa Cruz, USA; sc-650; 1:1000), 
AnxA1 (ZYMED, San Francisco, USA; 71-3400; 1:5000) and AnxA2 (Santa Cruz, 
Santa Cruz, USA; sc-9061; 1:1000).  The following secondary antibodies were 
used: polyclonal goat anti-rabbit/ HRP (Dako, Cambridgeshire, UK; P0448; 
1:2000), polyclonal rabbit anti-goat/ HRP (Dako, Cambridgeshire, UK; P0449; 
1:2000), polyclonal goat anti-mouse/ HRP (Dako, Cambridgeshire, UK; P0447; 
1:5000).  
 
2.11. Immunoprecipitation 
 
The supernatant of BMDMs stimulated with the TLR ligands was collected in 
tubes. For each 500 l of supernatant 2 l of antibody (AnxA1 or AnxA2) and 35 l 
of protein G coated sepharose beads were added. The beads were centrifuged 3 
times in order to throw away the upper layer washing away the ethanol and were 
resuspended in TNT buffer before addition to the samples. The tip was cut for the 
sepharose beads. The tubes were agitated at 4 oC overnight. The following day, 
the samples were centrifuged at maximum velocity and the supernatant was 
discarded. The pellets were denatured with 6x sample buffer for 3-5 min. The 
usual procedure of the western blot was followed as described in section 2.10.  
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2.12. Preparation of nuclear and cytoplasmic extracts 
 
Nuclear extracts were harvested from BMDMs according to previously described 
protocols (Jorritsma et al., 2003). Briefly, the cells were centrifuged and 
resuspended in ice cold hypotonic NAR A (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 
mM EDTA in distilled H2O) followed by the addition of NP-40 1%. They were 
vortexed and centrifuged giving a pellet of nuclei and a supernatant, which 
contained the cytoplasmic extracts. After washing again with ice cold NAR A, high 
salt NAR C (20 mM Hepes pH 7.9, 0.4 M NaCl, 1 mM EDTA in distilled H2O) was 
added without resuspending. The samples were vortexed and centrifuged and the 
supernatant containing the nuclear extracts was collected and stored at –80 oC.     
 
2.13. Elecrophoretic mobility shift assays 
 
Nuclear extracts were harvested from 3 to 5 x 106 cells. Briefly, aliquots (3-5 g) 
were incubated with 2g poly (dI:dC) in 20l of binding buffer with 32P end-
labelled, double-stranded oligonucleotide probes (5x105 cpm) and fractionated on 
a 4% polyacrylamide gel (37.5:1 cross-linking ratio) in 0.5% tris-borate-EDTA 
(TBE) for 2.5 h at 150 V. The NF-B binding buffer (10x) was 100mM Tris-HCl (pH 
7.5), 500mM NaCl, 10mM EDTA, 50% glycerol, 10 mg/ml albumin, 30mM GTP, 
and 10 mM dithiothreitol (DTT). The NF-B double-stranded oligonucleotide probe 
was purchased from Santa Cruz, Santa Cruz, USA.   
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2.14. Real-Time Reverse Transcription PCR 
 
2.14.1 Isolation of RNA  
 
Total RNA was extracted from BMDMs using a commercial kit according to the 
manufacturer‟s protocol (Qiagen, West Sussex, UK). Briefly, cells were pelleted 
and lysed using RLT lysis buffer (contains guanidine isothiocyanate which 
inactivates RNases) with -Mercaptoethanol. The lysates were homogenised by 
passing through a 20-gauge needle fitted to an RNAse free syringe for at least 5 
times and resuspended in 70% ethanol. The samples were applied to an RNeasy 
mini column placed in a 2ml collection tube and were centrifuged for 15 sec at 
10000 rpm to allow absorption of RNA onto the column membrane. Following 
several washes with wash buffers RW1 and RPE to remove contaminants, the 
RNA was eluted in RNAse free dH2O.  
 
2.14.2 Reverse transcription (cDNA synthesis) 
 
cDNA was synthesized by reverse transcription using the AMV transcriptase kit 
(Promega, UK). Briefly, 5-10g RNA samples were mixed with 0.5 g oligo d(T) 
(Promega, UK) and RNase-free dH2O and incubated at 70 
oC for 10 min. 
Thereafter, the mix was transferred on ice and supplemented with 1l RNase 
inhibitor (Promega, UK), 4l AMV 5x first strand buffer (Promega, UK; contains 
DTT that forms precipitates and therefore it must be vortexed thoroughly), 1l 
(10mM) dNTP‟s (Bioline, UK), and 1 l dH2O. After incubation at 4 
oC for 5 min, 
1l AMV reverse transcriptase (Promega, UK) was added directly into each 
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sample and incubated to the PCR machine at 42 0C for 60 min followed by 70 oC 
for 10 min. The cDNA samples were stored at 4 oC until use. For long-term 
storage, cDNA was kept at  –20 oC.  
 
2.14.3 Real-Time Polymerase Chains Reaction (PCR) 
 
Real-time PCR was performed using SYBR Green PCR Mix and fluorescent 
primers for the genes mTNF-, mIL-6, mCOX-2, mCXCL10, mIFN-, mISG54, 
mNOSII, and for each TLR gene specific primer (all from Qiagen; West Sussex, 
UK). Cycling conditions were set according to manufacturer‟s instructions. 
Sequence-specific fluorescent signal was detected by 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Foster City, CA). Gene expression was 
determined relative to the abundance of the housekeeping gene mGAPDH.  We 
used the comparative Ct method to measure the gene transcription in samples. 
The results are expressed as relative units based on calculation of 2-Ct, which 
gives the relative amount of gene normalized to endogenous control (GAPDH) and 
to the sample with the lowest expression set as one. 
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2.15. Measurement of nitrites  
 
To evaluate NO production, nitrite concentration in the supernatants of BMDMs 
was measured using the Griess reaction.  Briefly, 100l of the culture supernatant 
was mixed with an equal volume of Griess reagent, made after mixing immediately 
before use a 1:1 ratio of Griess A (1% sulphanilamide in 5% orthophosphoric acid) 
and Griess B (0.1% 2-(1-naphthylamino)ethylamine dihydrochloride)) in a flat 
bottom 96-well plate. The absorbance was read at 540nm using a 
spectrophotometer (Labsystems Multiskan Bichromatic; Helsinki; Finland), and the 
nitrite concentration was calculated using a standard curve of NaNO2 starting at a 
concentration of 1 mM.     
 
2.16. PGE2 enzyme immunoassay 
 
The method was conducted according to the manufacturer‟s instructions (Cayman 
Chemical Company, Michigan, USA). The method is based on the competition of 
PGE2 and PGE2-acetylcholinesterase conjugate (PGE2 tracer) for a limited amount 
of PGE2 specific monoclonal antibody.  Samples were diluted 1:1 with PBS. A 
standard curve was prepared starting with a concentration of 1ng/ml by serial 
dilution with the culture medium. A microtitre plate pre-coated with the secondary 
antibody was used. Initially, 50 l of enzyme immuno assay (EIA) buffer was 
added to the non-specific binding (NSB) wells and 50 l of culture medium to the 
NSB wells and the maximum binding (Bo) wells. 50 l of each standard and each 
unknown sample (B) was added to the appropriate wells. Thereafter, 50 l of 
PGE2 tracer was added to each well except the total activity (TA) wells, followed 
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by 50 l of PGE2 monoclonal antibody except the TA, NSB, and Blank wells. The 
plate was incubated for 18 h at 4 oC. Thereafter, the plate was emptied and rinsed 
5 times with wash buffer in order to remove any unbound ligand and 200 l of 
Ellman‟s reagent was added per well. In the TA wells, 5 l of tracer was also 
added. The plate was developed in the dark for 60-90min and was read at 405nm 
using a spectrophotometer (Labsystems Multiskan Bichromatic). The 
concentration of PGE2 in the unknown samples was calculated using the software 
Graph Pad PrismTM by plotting the standard curve of %B/Bo versus Log [PGE2].  
 
 
 
Figure 2.3: Typical standard curve obtained for the PGE2 EIA system assay. 
Absorbance values were read at 405 nm and PGE2 concentration were determined from the 
standard curve; using the Graph Pad Prism
TM
. 
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2.17. In vivo experiments 
Male AnxA1-null mice on a C57BL/6 background and WT littermates were used 
throughout these experiments. In survival studies, peritoneal and systemic 
inflammation was produced by injection of 10µg/mouse or 20µg/mouse of poly 
(I:C) (InvivoGen, San Diego, U.S.A.). Control animals were injected 
intraperitoneally with an equal volume of PBS. Mice were monitored in 12h 
intervals for up to 96h. 
 
2.18. Statistical analysis 
 
Graph Pad PrismTM software was used to create the graphs. All data were tested 
for normal distribution using the Shapiro-Wilk test. Normally distributed data was 
analysed by Student‟s t-test for two selected groups and two-way analysis of 
variance (ANOVA) using the Bonferroni post-tests correction.  When data were not 
normally distributed, multiple sets were analysed using the Kruskal-Wallis test with 
Dunnet‟s post-test correction. When two data sets were compared, the Mann-
Whitney test was applied. P-values lower than 0.05 (*P0.05), 0.01 (**P0.01) and 
0.001 (***P0.01) were sufficient to reject the null hypothesis and differences 
between groups were considered significant. Data are presented as means  
standard error of the means (S.E.M.) of n samples per group. 
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CHAPTER 3: 
RESULTS 
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3.1. AnxA1 expression is modulated by TLR agonists 
 
The activation of different cell types with inflammatory stimuli causes an increased 
expression and release of intracellular AnxA1 (D'Acquisto et al., 2007a, Damazo et 
al., 2005, Rescher et al., 2006). Using western blotting, we set to investigate if 
AnxA1 expression in BMDMs was modulated after stimulation with different TLR 
ligands. 
  
As shown in Fig 3.1, AnxA1 is highly expressed in the cytosol of BMDMs. After   
24 h stimulation with the TLR ligands at the concentrations seen in Table 3.1, it is 
constitutively released in to the culture supernatant. The peak and the time-course 
of this secretion differed between TLR agonists, and it was accompanied by 
depletion of the intracellular store, followed by resynthesis at later time-points. The 
peak of the intracellular AnxA1 depletion occurred approximately at 6 h after 
stimulation with HKLM and poly (I:C) (Fig 3.2A), followed by a return to the basal 
condition approximately at 24 h after stimulation.  A similar depletion of 
intracellular AnxA1 was observed also for the TLR agonists LPS, flagellin, 
loxoribine, and ODN at later time-points (Fig 3.2B and Fig 3.2C). 
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Table 3.1: Toll-like receptor agonists used for stimulation of BMDMs  
 
 
Toll-like Receptor Ligand Concentration 
TLR 2 
Heat Killed Listeria Monocytogenes 
(HKLM) 
       1x108/ml 
TLR 3                          Poly (I:C)        25g/ml 
TLR 4 
      Lipopolysaccharide 
                (LPS) 
        5g/ml 
TLR 5               Flagellin         0.1g/ml 
TLR 7              Loxoribine           1mM 
TLR 9              ODN1826           1M 
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Figure 3.1: AnxA1 is secreted by bone marrow-derived macrophages after TLR stimulation.  
(A) Western blotting analysis of AnxA1 expression in culture supernatants and cell lysates of bone 
marrow-derived macrophages stimulated with the TLR agonists for 24 h. To assess AnxA1 levels in 
culture supernatants, samples were immunoprecipitated with an anti-AnxA1 antibody and then 
immunoblotted. Data shown are from a single experiment.   
(B) Bar graphs in the figure indicate the densitometric analysis of AnxA1 expression of the 
corresponding blots.  
IP: Immunoprecipitation; IB: Immunoblotting 
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Figure 3.2: AnxA1 is modulated by TLR ligands.  
Western blotting analysis of AnxA1 protein expression in whole cell lysates of BMDMs stimulated 
with the TLR agonists HKLM, poly (I:C) (A), LPS, flagellin (B), loxoribine,  ODN (C) for the indicated 
times. Data shown are from a single experiment and are representative of n=2 experiments. 
37kDa: Molecular weight of full-length AnxA1 
33kDa: Molecular weight of cleaved form of AnxA1 (N-terminus absent) 
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                               SUMMARY 
 
In this section the production and release of 
AnxA1 by BMDMs was investigated 
 
 HKLM, poly (I:C), LPS, flagellin, loxoribine 
and CpG increased the intracellular content 
of AnxA1 as well as its release into the 
supernatant 
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3.2 Treatment of macrophages with human recombinant AnxA1 
 
In order to investigate whether AnxA1 exerts an anti-inflammatory effect on 
macrophages, we used two different types of cells: a. RAW 264.7 cells- a 
macrophage cell line and b. BMDMs isolated from wild-type C57/BL6 mice. In both 
cases, the plated macrophages were incubated with one TLR agonist alone or in 
combination with hr-AnxA1 (at 3 different concentrations). The culture supernatant 
was collected at different time-points of incubation. Following this, the IL-6 and   
TNF- content was measured by ELISA.  
 
3.2.1 RAW macrophages 
 
RAW macrophages were treated with one of the different TLR agonists at the 
concentrations seen in Table 3.2 alone or in combination with hr-AnxA1 (0.1, 0.01 
or 0.001ng/ml). After 3 and 24h of incubation the supernatant was collected in 
order to perform ELISA for IL-6 and TNF-. 
 
The IL-6 release after 3h of incubation with different TLR agonists was 
undetectable and therefore is not reported. At 24h incubation with all the tested 
TLR ligands, the expected increase in the supernatant IL-6 content occurred (Fig 
3.3). When the cells were treated in combination with hr-AnxA1, we observed a 
different response to each TLR agonist. Indeed, hr-AnxA1 lowered the content of 
IL-6 after treatment with the ligands poly(I:C), flagellin, loxoribine and CpG. This 
did not seem to be concentration-dependent since all 3 different concentrations of 
hr-AnxA1 had a similar effect, significantly decreasing IL-6 to a similar extent.  The 
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results were different, however, for the TLR4 ligand LPS, where only the lowest 
concentration of hr-AnxA1 had as an effect reducing IL-6. On the contrary, after 
stimulation with the TLR2 ligand HKLM, hr-AnxA1 had no effect on IL-6 release at 
any concentration tested. 
 
The production of TNF- was recorded at both time-points for all the tested TLR 
ligands (Fig 3.4). At   3h of incubation, hr-AnxA1 effectively decreased the TNF- 
release after treatment with the TLR5 ligand flagellin at the two higher 
concentrations, whereas for the other ligands no effect was recorded. However, 
when the 24h release was measured, hr-AnxA1 appeared more effective. Similarly 
to IL-6, hr-AnxA1 decreased TNF- when combined with the ligands poly (I:C), 
flagellin, loxoribine and CpG. This phenomenon appeared concentration-
dependent. For certain ligands (poly (I:C), flagellin) the highest concentration used 
was the most effective, whereas for others (loxoribine, CpG) the lowest. Again for 
the TLR4 ligand LPS, only the lowest concentration of hr-AnxA1 significantly 
decreased TNF-, whereas after stimulation with HKLM, hr-AnxA1 had no effect at 
any concentration. 
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Table 3.2: Toll-like receptor agonists used for stimulation of RAW 
macrophages  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toll-like Receptor Ligand Concentration 
TLR 2 
Heat Killed Listeria Monocytogenes 
(HKLM) 
       1x107/ml 
TLR 3 Poly (I:C)        25g/ml 
TLR 4 
    Lipopolysaccharide 
               (LPS) 
       500ng/ml 
TLR 5              Flagellin        10ng/ml 
TLR 7             Loxoribine           1mM 
TLR 9              ODN1826         100nM 
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Figure 3.3: AnxA1 decreases IL-6 in RAW cells after stimulation with TLR ligands 
RAW macrophages were incubated with different TLR ligands alone or in combination with 3 
different concentrations of hr-AnxA1 for 24h. The supernatants were collected and analyzed for the 
content of IL-6 by ELISA. Bar graphs show the values from a single experiment representative of 
n=4 experiments with similar results.  * p0.05; ** p0.01; *** p0.001 
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Figure 3.4: AnxA1 decreases TNF- in RAW cells after stimulation with TLR ligands. RAW 
macrophages were incubated with different TLR ligands alone or in combination with 3 different 
concentrations of hr-AnxA1. The supernatants were analysed for TNF- by ELISA. Bar graphs 
show the values from a single experiment representative of n=4 experiments with similar results.  
* p0.05; ** p0.01; *** p0.001
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3.2.2 Bone marrow-derived macrophages 
 
After the results using the RAW macrophage cell line, we repeated the experiment 
using BMDMs. In this case different concentrations (Table 3.1) of TLR ligands 
were used to stimulate the cells to produce pro-inflammatory cytokines. 
 
At 3h of culture, hr-AnxA1 did not lower significantly the IL-6 release after 
treatment with any TLR ligand (Fig 3.5). When IL-6 was measured at 24h the 
results were ligand-specific (Fig 3.5). For HKLM and loxoribine hr-AnxA1 did not 
have any effect. On the other hand, hr-AnxA1 at the lowest concentration 
(0.001ng/ml) was effective in significantly reducing the IL-6 release post-
stimulation with poly(I:C), LPS, flagellin, and CpG. Surprisingly, however, the 
highest concentration hr-AnxA1 (0.1ng/ml) was effective in reducing IL-6 release 
only after stimulation with flagellin.  
 
When the TNF- release was measured at 3h, no significant differences were 
observed after treatment with hr-AnxA1 (Fig 3.6). On the contrary, at 24h post-
stimulation the hr-AnxA1 was effective in reducing TNF- release at the lowest 
concentration (0.001ng/ml) post-treatment with HKLM, poly(I:C), loxoribine and 
CpG, whereas after stimulation with flagellin, only the highest concentration of 
0.1ng/ml was the effective (Fig 3.6).  
                                   SUMMARY 
In this section the effect of exogenous AnxA1 in the 
release of IL-6 and TNF-α from BMDMs was investigated. 
 
 hr-AnxA1 seems to have an anti-inflammatory effect 
in respect to IL-6 and TNF-α in a TLR-ligand 
specific and concentration-specific manner. Lower 
concentrations were the most effective. 
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Figure 3.5: AnxA1 decreases IL-6 release from BMDMs after stimulation with TLR ligands 
BMDMs were incubated with different TLR ligands alone or in combination with 3 different 
concentrations of hr-AnxA1 for the indicated times. The supernatants were collected and analyzed 
for the content of IL-6 by ELISA. Bar graphs show the values from a single experiment 
representative of n=2 experiments with similar results.         * p0.05; ** p0.01; *** p0.001 
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Figure 3.6: AnxA1 decreases TNF- release from BMDMs after stimulation with TLR ligands 
BMDMs were incubated with different TLR ligands alone or in combination with 3 different 
concentrations of hr-AnxA1. The supernatants were analysed for TNF- by ELISA. Bar graphs 
show the values from a single experiment representative of n=2 experiments with similar results.    
* p0.05; ** p0.01; *** p0.001
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3.3 Comparison of AnxA1+/+ and AnxA1-/- BMDMs 
 
Since the TRIF-dependent TLR ligand poly (I:C) and the MyD88-dependent TLR 
ligands and LPS which uses both pathways, do not behave in a consistent way in 
RAW cells and in BMDMs and since endogenous AnxA1 is secreted extracellularly 
probably acting at a surface receptor, we decided to further investigate the effect 
of complete deletion of AnxA1. Therefore, all the following experiments used 
BMDMs isolated from knockout mice (AnxA1-/-) and compared them to BMDMs 
from wild-type (AnxA1+/+) mice. Several different parameters of their function were 
assessed to establish the possible involvement of AnxA1 in different types of 
inflammation. 
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3.3.1 AnxA1-/- BMDMs exhibit a different phenotype for activation markers 
 
To compare the phenotypic characteristics of AnxA1+/+ and AnxA1-/- macrophages, 
flow cytometric analysis was used to assess expression levels of several 
molecules related to macrophage activation such as MHC II and the co-stimulatory 
molecules CD40, CD80, and CD86. 
 
The results revealed an increased expression of all activation markers in AnxA1-/- 
BMDMs compared to AnxA1+/+ BMDMs at 24 h of cell culture (Fig 3.7 and Fig 3.8). 
Four independent experiments were performed and the Median Fluorescence 
Intensity (MFI) readings at the basal condition revealed a consistent 20% 
difference of all markers in the AnxA1-/- cells compared to the AnxA1+/+ cells. This 
indicates that the AnxA1-/- BMDMs have a different phenotype even before the 
addition of the TLR ligands. 
 
Subsequently, we stimulated the BMDMs with the 6 different TLR ligands for 24 h 
at the concentrations shown in Table 3.1. The cells were collected and we 
performed the same analysis as above. The results showed that almost all TLR 
agonists upregulated the expression of MHC II, CD40, CD80, and CD86 in both 
AnxA1+/+ and AnxA1-/- macrophages (Fig 3.7 and Fig 3.8). Moreover, different TLR 
ligands upregulated these markers differentially. This is in agreement with several 
other studies, which describe upregulation of MHC II (Lee et al., 2003, Liu et al., 
2006) and co-stimulatory molecules (Edwards et al., 2006, Hoebe et al., 2003, Lee 
et al., 2003, Liu et al., 2006, Shen et al., 2008) after stimulation of WT 
macrophages with TLR agonists.  
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Although all TLR ligands upregulated MHC II in both AnxA1+/+ and AnxA1-/- 
BMDMs, variations were observed between the different TLR ligands (Fig 3.7A). 
When the AnxA1-/- BMDMS were stimulated with TLR ligands acting exclusively 
through the MyD88-pathway (HKLM, flagellin, loxoribine, CpG), the percentage 
increase over basal MFI MHCII was similar to the AnxA1+/+ BMDMs. In addition, 
when the percentage ratio of MFI of AnxA1-/- to AnxA1+/+ cells was calculated for 
these ligands, the difference was approximately 20%, simply reflecting the higher 
basal MFI of AnxA1-/- cells. On the other hand, stimulation of both AnxA1+/+ and 
AnxA1-/- cells through the TRIF-pathway (poly(I:C), LPS), resulted a much greater 
upregulation of MHC II compared to the MyD88-dependent pathway ligands. 
However, this upregulation after stimulation with TRIF-mediated TLR ligands was 
impaired in the AnxA1-/- compared to the AnxA1+/+ cells, resulting overall a lower 
MFI in these cells. 
 
The MFI of the co-stimulatory molecules CD40, CD80, and CD86 after stimulation 
of the BMDMs with different TLR ligands, was higher in the AnxA1-/- BMDMs, 
reflecting the increased basal MFI in these cells (Fig 3.7B and Fig 3.8). Indeed, 
when the MFI of AnxA1-/- compared to AnxA1+/+ cells was calculated, a difference 
of approximately 20% was revealed for both MyD88-dependent and TRIF-
dependent ligands. However, although the percentage increase over basal MFI 
capacity i.e. the capacity of TRIF-mediated TLR ligands to further upregulate these 
molecules, was overall much higher compared to the MyD88-mediated ligands, it 
was similar when AnxA1+/+ and AnxA1-/- BMDMs were compared. 
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In conclusion, AnxA1 deletion for BMDMs appears to promote a more mature 
basal phenotype. When stimulated with the different TLR ligands, the expected 
cellular upregulation of these markers occurs, giving an overall higher MFI 
compared to their WT littermates. However, the capacity of AnxA1+/+ and AnxA1-/- 
macrophages to upregulate these co-stimulatory molecules, appears similar 
despite the much greater upregulation that occurs after stimulation with the TRIF-
mediated TLR ligands poly(I:C) and LPS. On the other hand, these TRIF-mediated 
TLR ligands also lead to an upregulation of MHC II, yet this MHC II upregulation is 
impaired by the AnxA1-/- cells.     
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Figure 3.7: Phenotypic comparison of AnxA1
+/+
 and AnxA1
-/-
 BMDMs after stimulation with 
different TLR agonists.  
Flow cytometric analysis of (A) MHC II, and (B) CD40 in AnxA1
+/+
 and AnxA1
-/-
 BMDMs after 
stimulation with TLR ligands for 24 h. Numbers in histograms show median fluorescence intensity 
from a single experiment and are representative of n=4 experiments with similar results. 
A 
B 
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Figure 3.8: Phenotypic comparison of AnxA1
+/+
 and AnxA1
-/-
 BMDMs after stimulation with 
different TLR agonists.  
Flow cytometric analysis of (A) CD80, and (B) CD86 in AnxA1
+/+
 and AnxA1
-/-
 BMDMs after 
stimulation with TLR ligands for 24 h. Numbers in histograms show median fluorescence intensity 
from a single experiment and are representative of n=4 experiments with similar results. 
 
 
 
 
 
 
 
A 
B 
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3.3.2 Exaggerated cytokine production by AnxA1-/- BMDMs 
 
Stimulation of BMDMs with TLR ligands induces the production of proinflammatory 
cytokines such as IL-6 and TNF- (Akira and Hoshino, 2003, Alexopoulou et al., 
2001, Bagchi et al., 2007, Fang et al., 2004, Heil et al., 2003, Hemmi et al., 2000, 
Hoshino et al., 1999, Rowlett et al., 2008). To investigate whether there was a 
difference in this production in the absence of AnxA1, we stimulated AnxA1+/+ and 
AnxA1-/- BMDMs with 6 different TLR agonists as shown in Table 3.1 for 3, 6 or   
24 h, and then measured IL-6 and TNF- production by ELISA.    
 
Firstly, the levels of IL-6 and TNF- at the basal level were measured in 
unstimulated AnxA1+/+ and AnxA1-/- cells. As seen in Fig 3.9, the basal release of 
TNF- was similar at the two types of cells. However, the IL-6 release by the 
AnxA1-/- macrophages was significantly reduced compared to their WT littermates.  
 
As expected (Hoshino et al., 1999, Fang et al., 2004, Bagchi et al., 2007, Rowlett 
et al., 2008, Alexopoulou et al., 2001, Heil et al., 2003, Hemmi et al., 2000), all 
TLR agonists tested stimulated the BMDMs to produce IL-6 (Fig 3.10) and TNF- 
(Fig 3.12) in a time-dependent manner. The peak release of TNF- was seen 
approximately 6 h after which a plateau was reached in the case of LPS, 
loxoribine, and CpG.  On the contrary, HKLM, poly (I:C) and flagellin induced 
maximal cytokine production at later time-points. The extent of cytokine production 
differed between TLR ligands. In WT macrophages, certain ligands such as LPS 
strongly induced the production of IL-6 and TNF- whereas others, such as 
flagellin, induced only low levels of these cytokines. 
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The activation of AnxA1-/- BMDMs with all the TLR ligands tested also resulted in 
the production of IL-6. However, the IL-6 production by the AnxA1-/- BMDMs was 
enhanced compared to WT cells after stimulation with the ligands LPS (Fig 3.10C), 
loxoribine (Fig 3.10E), and CpG (Fig 3.10F). On the other hand, in the first 6 h 
post-stimulation with flagellin, similar IL-6 levels were induced in   AnxA1-/- and 
AnxA1+/+ BMDMs, whereas 24 h post-stimulation there was an impaired 
production of the cytokine by the AnxA1-/- cells (Fig 3.10D). A different pattern was 
also revealed after stimulation with the TLR3 ligand poly (I:C), where the 
production of IL-6 was markedly reduced by about 50% in the AnxA1-/- compared 
to the AnxA1+/+ BMDMs at all time points (Fig 3.10B). More specifically, the 
cumulative results of 6 independent experiments revealed that the ratio of IL-6 
production between AnxA1-/- and AnxA1+/+ BMDMs after stimulation with the 
ligands LPS, loxoribine and CpG was greater than 1, indicating the increased 
production of this cytokine by the AnxA1-/- cells.  After stimulation with poly (I:C) 
the ratio was approximately 0.5, mirroring the decreased production of the 
cytokine in the  AnxA1-/- BMDMs.   
 
The production of TNF- was enhanced in the AnxA1-/- BMDMs compared to 
AnxA1+/+ BMDMs after stimulation with all tested TLR agonists with the exception 
of the TRIF-dependent ligand poly (I:C) (Fig 3.12). The ratio of TNF- production 
in AnxA1-/- cells to AnxA1+/+ cells after stimulation with all the MyD88-dependent 
TLR ligands was greater than 1 at all time-points, revealing the increased 
production of this cytokine by AnxA1-/- BMDMs. 
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Figure 3.9: Impaired basal IL-6 but not TNF- production by AnxA1
-/-
 BMDMs. 
Bar graphs showing the IL-6 (A) and TNF- (B) secreted into the culture supernatant by AnxA1
+/+ 
and AnxA1
-/- 
BMDMs after incubation for 24 h with medium alone. Values are meanS.E.M of 4 
experiments with similar results. 
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                                      SUMMARY 
 
In this section the effect of endogenous AnxA1 in the 
release of IL-6 and TNF-α from BMDMs stimulated 
with TLR agonists was investigated 
 
 AnxA1-/- BMDMs expressed higher levels of  
IL-6 after stimulation with the ligands LPS, 
flagellin and CpG 
 
 AnxA1-/- BMDMs expressed reduced levels of 
IL-6 after stimulation with poly (I:C) 
 
 AnxA1-/- BMDMs expressed higher levels of 
TNF-α after stimulation with HKLM, LPS, 
flagellin, loxoribine and CpG 
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Figure 3.10: Production of IL-6 by AnxA1
-/-
 BMDMs stimulated with TLR agonists. Bone 
marrow-derived AnxA1
+/+
 and AnxA1
-/-
 macrophages were incubated with different TLR agonists for 
the indicated times, and supernatants were collected and analyzed for IL-6 content. Values are 
meansS.E.M of a single experiment in triplicate wells. Data a‟re representative of n=4 different 
experiments. Continuous line: AnxA1
+/+
 BMDMs; Dashed line: AnxA1
-/-
 BMDMs  
* p0.05; ** p0.01; *** p0.001 
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Figure 3.11: Production of IL-6 by AnxA1
-/-
 BMDMs in response to different TLR ligands.  
Bone marrow-derived AnxA1
-/- 
and AnxA1
+/+
 macrophages were incubated with the different TLR 
agonists for the indicated times, and supernatants were collected and analyzed for the content of 
IL-6.  Values are expressed as cumulative meansS.E.M. of the Δ of control for IL-6 release.  Data 
are from n=4 different experiments.   
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Figure 3.12: Exaggerated production of TNF- by AnxA1
-/-
 BMDMs after stimulation with 
MyD88-dependent TLR ligands. Bone marrow-derived AnxA1
+/+
 and AnxA1
-/-
 macrophages were 
incubated with different TLR agonists for the indicated times, and supernatants were collected and 
analyzed for content of TNF-. Values are meanS.E.M of a single experiment in triplicate wells. 
Data are representative of n=4 different experiments. Continuous line: AnxA1
+/+
 BMDMs; Dashed 
line: AnxA1
-/-
 BMDMs  
p0.05; ** p0.01; *** p0.001   
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Figure 3.13: Exaggerated production of TNF- by AnxA1
-/-
 BMDMs relative to AnxA1
+/+
 
BMDMs after stimulation with MyD88-dependent TLR ligands.   
Bone marrow-derived AnxA1
-/- 
and AnxA1
+/+
 macrophages were incubated with the different TLR 
agonists for the indicated times, and supernatants were collected and analyzed for TNF- content.  
Values are expressed as cumulative meansS.E.M. of the Δ of control for TNF- content.  Data are 
from n=4 different experiments.   
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3.3.3 Impaired NO production of AnxA1-/- BMDMs after stimulation with        
poly (I:C) 
 
The production of NO was measured by the Griess reaction in the culture 
supernatants of BMDMs after stimulation for 3, 6, and 24 h with the different TLR 
agonists.  The results of our experiments showed that there was no production of 
nitrite at 3 and 6 h post-stimulation with any TLR ligand (data not shown), but a 
significant production at 24 h after stimulation with the ligands poly (I:C) (Fig 3.14 
B), LPS (Fig 3.14C), and CpG (Fig 3.14F) in both AnxA1+/+ and AnxA1-/- BMDMs. 
 
The production of nitrite in the AnxA1-/- BMDMs was compared to the AnxA1+/+ 
BMDMs. When the results of 4 independent experiments were combined, we 
observed a similar secretion of nitrite in the supernatant of the two types of cells 
after stimulation with LPS (Fig 3.14C) and CpG (Fig 3.14F). However, the 
production of NO after stimulation with the TLR3 ligand poly (I:C) was significantly 
impaired in the AnxA1-/- BMDMs (Fig 3.14B).  
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Figure 3.14: Impaired production of NO in AnxA1
-/-
 BMDMs after stimulation with poly (I:C).  
Bar graphs indicate the content of NO2
-
 present in the cell supernatant revealed by the Griess 
reaction. Values are meansS.E.M. of n=3 experiments.  
* p0.05; ** p0.01 compared to control; ++ p0.01 AnxA1
-/- 
compared to AnxA1
+/+
 BMDMs. 
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3.3.4 Enhanced PGE2 secretion of AnxA1
-/- BMDMs after stimulation with 
CpG   
 
Since PGE2 is secreted by BMDMs after stimulation with certain TLR ligands 
(Buczynski et al., 2007, Chen et al., 2004, Chen et al., 2009a, Pindado et al., 
2007, Steer et al., 2006, Uematsu et al., 2002, Yeo et al., 2003), PGE2 enzyme 
immunoassay was performed in the culture supernatant in order to investigate 
whether the PGE2 production in the AnxA1
-/- cells was different to the expected. 
Indeed, our results were consistent with the literature since the ligands HKLM,  
poly (I:C), LPS and CpG induced the secretion of PGE2 of both the AnxA1
+/+ and 
AnxA1-/- macrophages after a 24 h incubation (Fig 3.15 A, B, C, F). On the other 
hand, the ligands flagellin and loxoribine did not induce the PGE2 production in the 
AnxA1+/+ or in the AnxA1-/- BMDMs (Fig 3.15 D, F). Interestingly, although the 
concentration of PGE2 detected in the AnxA1
-/- cells was similar to that seen in the 
AnxA1+/+ cells after stimulation with HKLM, poly (I:C), and LPS, the PGE2 detected 
was significantly increased in the AnxA1-/- cells after stimulation with the TLR9 
ligand CpG (Fig 3.15 F). 
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Figure 3.15: Increased PGE2 production by AnxA1
-/-
 BMDMs triggered by CpG. 
Bar graphs indicate the content of PGE2 present in the cell supernatants revealed by ELISA. Data 
are from a single experiment.  
** p0.01; *** p0.001 compared to corresponding control;  
++p0.01 AnxA1
-/- 
compared to AnxA1
+/+
 BMDMs.
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3.3.5 AnxA1-/- BMDMs express higher levels of TLRs 
 
Variable TLR expression in BMDMs could provide an explanation for the 
differences regarding cytokine production observed between AnxA1-/- and 
AnxA1+/+ BMDMs. A higher receptor expression could trigger different cell 
response and enhanced production of pro-inflammatory cytokines. Therefore, we 
performed real-time PCR in order to investigate the relative TLR mRNA 
expression in unstimulated AnxA1+/+ and AnxA1-/- BMDMs.  Indeed, as shown in 
Fig 3.16, the expression of all the TLRs that are involved in the ligation of our 
tested agonists (TLR2, TLR3, TLR4, TLR5, TLR7, TLR9) was markedly increased 
in the AnxA1-/- BMDMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Increased TLR expression of AnxA1
-/-
 BMDMs.  
Analysis of TLR expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs by real time PCR. Values are from a 
single experiment.
Control
Control
Control
Control
Control
Control
AnxA1+/+
AnxA1-/-
D
E
F
A
B
C
 139 
3.3.6 Enhanced NF-B DNA-binding in AnxA1-/- BMDMs 
 
Both MyD88-dependent and MyD88-independent/TRIF-dependent pathways lead 
to the activation of NF-B (Kawai and Akira, 2007). More specifically, both 
pathways are characterised by proteosomal degradation of the IB complex and 
translocation of NF-B to the nucleus where it acts as the major transcription 
factor of the signalling pathway and leads to the expression of numerous 
proinflammatory genes such as IL-6 and TNF-.  One gene activated by NF-B is 
the gene responsible for its own inhibitor IB. After the synthesis of IB, it is 
translocated to the cytoplasm to bind to NF-B, preventing it from entering the 
nucleus and binding to DNA. Therefore, IB is responsible for a strong negative 
feedback in the NF-B cycle.  Oscillations in the NF-B activity by electrophoretic 
mobility shift assay (EMSA) have been described, controlled by the three IB 
isoforms (IB, IB, and IB) (Hoffmann et al., 2002). The number, period, and 
amplitude of these oscillations may control the dynamics of gene expression 
(Nelson et al., 2004), in a similar way that the quality of sound is altered by 
pressing the keys and pedals of a piano. Since we observed important differences 
in IL-6 and TNF- between the two genotypes, we set out to investigate whether 
there was also a difference in the NF-B DNA binding that could explain our 
results. Therefore, we performed EMSA for NF-B DNA binding and western 
blotting for IB expression. Initially pilot studies were performed using 5µg of 
nuclear extract, which was changed to 10µg of nuclear extract to increase the 
quality of the signal. 
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As seen in Fig 3.17, even under basal conditions, before stimulation with any TLR 
ligand, there were differences between the two genotypes. The NF-B DNA 
binding in AnxA1-/- was decreased compared to AnxA1+/+ BMDMs. At the same 
time, the IB protein expression by AnxA1-/- BMDMs was increased indicating 
less degradation of the complex and reduced translocation of NF-B to the 
nucleus (Fig 3.17). 
 
After addition of the different TLR agonists to the WT cells, the normal activation of 
NF-B occurred (Fig 3.18), as described elsewhere (Alexopoulou et al., 2001, 
Bagchi et al., 2007, Hemmi et al., 2000, Muller et al., 2001, Yamamoto et al., 
2003), followed by parallel degradation of IB (Fig 3.19). Densitometric analysis 
of both NF-B EMSA and IB western blotting revealed a different kinetic of NF-
B activation/ IB degradation for each TLR ligand and important differences 
between AnxA1+/+ and AnxA1-/- cells (Fig 3.20, 3.21, and 3.22).  
 
An oscillatory pattern for NF-B activation and IB degradation was seen after 
stimulation with all the MyD88-dependent TLR ligands and the TRIF-dependent 
ligand poly (I:C) (Fig 3.20, 3.21, 3.22). On the other hand, the NF-B activation 
after stimulation with LPS followed a linear pattern (Fig 3.22), as described by 
Covert et al (Covert et al., 2005). Indeed, when both MyD88 and TRIF-pathways 
were stimulated, as in the case of TLR4 stimulation, NF-B followed a non-
oscillatory behaviour, possibly due to the interaction of the two pathways (Covert 
et al., 2005).  
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Stimulation with all TLR ligands provoked a different kinetic of NF-B activation/ 
IB degradation by AnxA1-/- BMDMs. Surprisingly, AnxA1-/- cells exhibited NF-B 
oscillations of higher amplitude after stimulation with all TLR ligands (Fig 3.20, 
3.21 and 3.22). This was accompanied by an analogous profile of IB 
degradation (Fig 3.20, 3.21 and 3.22). Enhanced NF-B DNA-binding occurred by 
AnxA1-/- BMDMs at 30min post-stimulation with all the strictly MyD88-dependent 
TLR ligands. On the contrary, the peak of NF-B activation was delayed after 
stimulation with poly (I:C) or LPS (Fig 3.22). Therefore, higher NF-B DNA-binding 
occurred by AnxA1-/- cells at 60min after TRIF stimulation. 
 
 
 
 
 
. 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
                                SUMMARY 
 
In this section the differences in NF-B DNA 
binding and IB expression between AnxA1-/- 
and AnxA1+/+ BMDMs after stimulation with TLR 
ligands were investigated. 
 
 AnxA1-/- BMDMs exhibit NF-B activation 
oscillations of higher amplitude after 
stimulation with all the TLR ligands.  
 
 Enhanced NF-B DNA-binding by AnxA1-/- 
BMDMs occurred within 30min of 
stimulation with MyD88-dependent TLR 
ligands but required 60min to trigger TRIF 
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Figure 3.17: Impaired NF-B DNA binding in AnxA1
-/-
 BMDMs under basal conditions.                
A) Electrophoretic mobility shift assay showing NF-B/DNA-binding activity in increasing 
concentrations of nuclear extracts of AnxA1
+/+ 
and AnxA1
-/-
 BMDMs.        
B) Western blot showing IB expression in increasing concentration of cytoplasmic extracts of 
AnxA1
+/+ 
and AnxA1
-/-
 BMDMs. Data are from a single experiment representative of n=4 
experiments.
A 
B 
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Figure 3.18: Increased NF-B DNA binding in AnxA1
-/-
 BMDMs after stimulation with different 
TLR agonists.  
Electrophoretic mobility shift assay showing NF-B/DNA-binding activity in nuclear extracts of 
AnxA1
+/+ 
and AnxA1
-/-
 BMDMs stimulated with the TLR ligands for the indicated times. Data are 
from a single experiment representative of n=4 experiments.
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Figure 3.19: Profile of IB degradation in AnxA1
-/-
 BMDMs.  
Western blotting analysis of IB degradation profile in AnxA1
+/+
 and AnxA1
-/-
 BMDMs treated with 
the TLR ligands for the indicated times.
 145 
                    
 
Figure 3.20: Profile of NF-B DNA binding and IB degradation by BMDMs in response to 
HKLM and flagellin. 
Graphs showing together the densitometric analysis of EMSA of NF-B/DNA-binding activity 
(above) and western blot of IB expression (below) in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs stimulated 
with HKLM or flagellin for the indicated times. Data are from a single experiment representative of 
n=4 experiments. 
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Figure 3.21: Profile of NF-B DNA binding and IB degradation by BMDMs in response to 
loxoribine and CpG. 
Graphs showing together the densitometric analysis of EMSA of NF-B/DNA-binding activity 
(above) and western blot of IB expression (below) in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs stimulated 
with loxoribine or CpG for the indicated times. Data are from a single experiment representative of 
n=4 experiments. 
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Figure 3.22: Profile of NF-B DNA binding and IB degradation by BMDMs in response to 
poly (I:C)  and LPS. 
Graphs showing together the densitometric analysis of EMSA of NF-B/DNA-binding activity 
(above) and western blot of IB expression (below) in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs stimulated 
with poly (I:C) or LPS for the indicated times. Data are from a single experiment representative of 
n=4 experiments. 
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3.3.7 Enhanced ERK1/2 activation in AnxA1-/- BMDMs 
 
Next, as an effort to explain our previous results, we attempted to determine the 
exact difference in the TLR signalling pathway and the FPR2 signalling pathway, 
between the AnxA1-/- and AnxA1+/+ BMDMs by assessing several proteins involved 
in the TLR signalling pathway such as the MAP kinases ERK1/2, JNK, and p38. 
Unfortunately, despite our intense efforts, we were unable to resolve this using 
western blotting techniques. One possible reason for this is the presence of 
phosphatases in the 5% low-fat milk used throughout these experiments. 
Therefore, we tried a different approach by utilising a commercially available 
ELISA. 
 
Firstly, we investigated whether differential activation of ERK1/2 could be involved 
in the increased cytokine release observed in AnxA1-/- BMDMs after stimulation 
with TLR ligands. As expected (Kawai and Akira, 2007), all TLR agonists induced 
ERK1/2 activation, as measured by phosphorylation of ERK1/2 in AnxA1+/+ and 
AnxA1-/- BMDMs, with a peak approximately at 30 min after stimulation (Fig 3.23). 
When the two types of cells were compared, we observed that the phosphorylation 
in the AnxA1-/- BMDMs was enhanced at all time-points relative to the WT controls, 
indicating an increased ERK1/2 activation (Fig 3.23). 
 
To validate this result, we incubated WT BMDMs with each tested TLR ligand 
alone or in combination with 2nM hr-AnxA1. As seen in Fig 3.24, the cells that 
were treated with the hr-AnxA1 exhibited less ERK1/2 phosphorylation compared 
to the cells that were treated with the TLR ligands alone.  
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Therefore, it has been shown that utilising an as yet unidentified mechanism, the 
presence of AnxA1 in these cells seems to reduce the phosphorylation of ERK1/2 
induced by the TLR agonist cascade thereby leading to a less pronounced 
inflammatory response. This also may explain the increased ERK1/2 
phosphorylation and proinflammatory response seen in the absence of AnxA1. 
 
 
Figure 3.23: Increased phospho-ERK1/2 by AnxA1
-/-
 BMDMs.   
Analysis by ELISA of the levels of phospho-ERK1/2 present in cell lysates of AnxA1
+/+
 and    
AnxA1
-/- 
BMDMs stimulated with the different TLR ligands for the indicated times. Graphs are from 
a single experiment representative of n=3 experiments. 
0 15 30 45
0
1000
2000
3000
4000
0 15 30 45
0
1000
2000
3000
4000
0 15 30 45
0
1000
2000
3000
4000
0 15 30 45
0
1000
2000
3000
4000
0 15 30 45
0
1000
2000
3000
4000
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
Time post-HKLM (min) Time post-Poly(I:C) (min) Time post-LPS (min)
Time post-Flagellin (min) Time post-Loxoribine (min) Time post-CpG (min)
AnxA1+/+
AnxA1-/-
0 15 30 45
0
1000
2000
3000
4000
A B C
D E F
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
p
-E
R
K
1
/2
(p
g
 p
e
r 
1
0
6
c
e
ll
s
)
 150 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: Decrease of phospho-ERK1/2 after treatment with AnxA1.  
Analysis by ELISA of the levels of phospho-ERK1/2 of cell lysates of AnxA1
+/+
 BMDMs stimulated 
with the different TLR ligands and treated with 2nM AnxA1 or medium alone for the indicated times. 
Graphs are from a single experiment representative of n=2 experiments. 
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3.3.8 Analysis of MyD88- and TRIF-dependent gene expression in AnxA1-/- 
BMDMS 
 
When the gene expression profiles of wild-type cells and IRF-3 knockout cells 
were compared following viral infection, 3 sets of induced genes were revealed. 
These are IRF-3-dependent, IRF-3-independent, and IRF-3-augmented (not 
strictly dependent on IRF-3) direct response genes (Andersen et al., 2008). Since 
IRF-3 is a transcription factor involved in the TRIF-dependent pathway and not in 
the MyD88 pathway, we set to investigate the gene expression profiles of a set of 
these genes that belongs to these 3 categories (Fig 3.25) after stimulation of 
BMDMs with a strictly TRIF-dependent TLR ligand (poly (I:C)), a strictly MyD88-
dependent TLR ligand (CpG) and a ligand which stimulates both pathways (LPS). 
Thereafter, Real-time PCR was performed to reveal the gene expression profiles 
of AnxA1+/+ and AnxA1-/- BMDMs.  
 
IFN-1 and Ifit2 (ISG54) are considered IRF3-dependent genes when TLR3 is 
stimulated (Andersen et al., 2008). When we stimulated BMDMs with poly (I:C), 
we observed a higher expression in AnxA1-/- (Fig 3.26, 3.27). In addition, when 
BMDMs were stimulated with LPS, a different delayed kinetic was recorded in 
AnxA1-/- cells (Fig 3.26, 3.27). On the other hand, when cells were stimulated with 
the MyD88-dependent TLR ligand CpG, no differences were seen between the 
two genotypes. 
 
The IRF-3 dependent gene NOS II (Youn et al., 2005, Youn et al., 2008) was more 
highly expressed in   AnxA1-/- BMDMs at the basal level (Fig 3.28). In addition, we 
observed a different profile of gene expression after stimulation with all the tested 
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TLR ligands when AnxA1+/+ and AnxA1-/- BMDMs were compared. After 
stimulation with poly (I:C), NOS II gene expression peaked at 3h in AnxA1-/- 
BMDMs. On the other hand, the gene expression was more gradual in AnxA1+/+ 
BMDMs. Therefore, although at earlier time-points NOS II expression was higher 
in AnxA1-/-, there were no differences between the two genotypes by 24h. After 
stimulation with LPS or CpG, AnxA1-/- BMDMs induced a peak of gene expression 
at 3h and thereafter gradually decreased. However, although at earlier time-points 
the gene expression had been enhanced in AnxA1-/- BMDMs, it was severely 
impaired at the following 24h-time-point. Overall, different kinetics were observed 
between the two genotypes post stimulation with all tested TLR ligands. 
 
IL-6 gene expression was increased in AnxA1-/- cells under basal conditions      
(Fig 3.29). After stimulation with LPS or CpG, the gene expression of AnxA1-/- 
BMDMs peaked at 3h and was importantly higher than AnxA1+/+ BMDMs           
(Fig 3.29). After stimulation with poly (I:C), although at 3h the gene expression had 
been slightly higher in AnxA1-/- BMDMs, the levels were similar at the following 
time-points (Fig 3.29). 
 
TNF- is considered an IRF3-independent gene (Andersen et al., 2008, Tian et al., 
2005a, Tian et al., 2005b). When BMDMs were stimulated with poly (I:C), we did 
not observe major differences in gene expression between the two genotypes. On 
the other hand, when cells were stimulated with LPS or CpG, a delayed kinetic 
yielding a much higher gene expression at 6h was seen by AnxA1-/- BMDMs     
(Fig 3.30).  
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The CXCL10 gene (IRF-3 augmented gene) expression was exaggerated in 
AnxA1-/- BMDMs both at the basal level and after stimulation with all tested TLR 
ligands (Fig 3.31). However, the degree of upregulation of CXCL10 gene 
expression was lower in AnxA1-/- compared to AnxA1+/+ BMDMs after stimulation 
with all the tested TLR ligands. This indicates that the enhanced gene expression 
post TLR-stimulation mainly reflects the increased basal level observed in AnxA1-/- 
BMDMs. 
 
COX2 is considered an IRF3-dependent gene when triggering TLR3 (Youn et al., 
2005, Youn et al., 2008) but a MyD88-dependent gene when triggering TLR4 
(Bjorkbacka et al., 2004, Kawai et al., 2001). Post-poly(I:C) stimulation, an 
enhanced gene expression was seen in AnxA1-/- cells (Fig 3.32). After stimulation 
with LPS or CpG, a different kinetic was also observed (Fig 3.32). 
 
                           SUMMARY 
 
In this section the gene expression profiles of 
AnxA1-/- and AnxA1+/+ BMDMs were 
compared after stimulation with TRIF-
dependent and MyD88-dependent TLR 
ligands. 
 
 AnxA1 regulates the TLR signalling 
pathway at two levels: chiefly by 
blocking the MyD88 pathway and to a 
lesser extent by interacting with the 
IRF3-dependent TRIF pathway.  
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Figure 3.25: Diagram illustrating MyD88-dependent and IRF3-dependent genes post-
stimulation with different TLR ligands. 
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Figure 3.26: Analysis of IFN-1 gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs.  
Real-time PCR analysis of the IFN- gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs incubated 
with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-points. Values 
arise from a single experiment. 
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Figure 3.27: Analysis of ISG54 gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs 
Real-time PCR analysis of the ISG54 gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs incubated 
with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-points. Values 
arise from a single experiment.  
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Figure 3.28: Analysis of iNOS gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs 
Real-time PCR analysis of the iNOS gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs incubated 
with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-points. Values 
arise from a single experiment.  
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Figure 3.29: Analysis of IL-6 gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs 
Real-time PCR analysis of the IL-6 gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs incubated 
with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-points. Values 
arise from a single experiment.  
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Figure 3.30: Analysis of TNF- gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs.  
Real-time PCR analysis of the TNF- gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs incubated 
with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-points. Values 
arise from a single experiment.  
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Figure 3.31: Analysis of CXCL10 (IP10) gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs. 
Real-time PCR analysis of the CXCL10 (IP10) gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs 
incubated with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-
points. Values arise from a single experiment.  
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Figure 3.32: Analysis of COX2 gene expression in AnxA1
+/+
 and AnxA1
-/-
 BMDMs.  
Real-time PCR analysis of the COX2 gene expression in AnxA1
+/+ 
and AnxA1
-/-
 BMDMs incubated 
with medium (control) or a TLR ligand (poly (I:C), LPS or CpG) for the indicated time-points. Values 
arise from a single experiment. 
Time (h)
Poly(I:C)
AnxA1
+/+
AnxA1
-/-
C
O
X
2
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
)
0 3 6 24
0
10
20
30
40
Time (h)
LPS
C
O
X
2
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
)
0 3 6 24
0
10
20
30
40
50
Time (h)
CpG
C
O
X
2
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
)
0 3 6 24
0
20
40
60
80
C
O
X
2
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
)
C
O
X
2
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
)
C
O
X
2
m
R
N
A
(r
e
la
ti
v
e
 e
x
p
re
s
s
io
n
)
 162 
3.4 In vivo experiments: Poly (I:C)-induced Lethality 
 
Treatment of mice with 2 different dosages of poly (I:C) (10g/mouse or 
20g/mouse) induced early clinical signs of SIRS, which yielded a high rate of 
mortality in both AnxA1+/+ and AnxA1-/- mice by 12h (Fig 3.33). However, when the 
percentage survival of the two genotypes was compared, we observed a 20% 
difference favouring the AnxA1-/- mice, independent of the dosage of poly (I:C) 
administered (Fig 3.33). Therefore, in contrast to the administration of LPS, 
characterised by a high mortality rate of the AnxA1-/- mice (Damazo et al., 2005), 
the intraperitoneal injection of the TRIF-mediated ligand poly (I:C) reveals a 20% 
increased survival by AnxA1-/- mice.   
 
 
Figure 3.33: Increased survival of AnxA1
-/-
 mice post-administration of poly (I:C).  
AnxA1
+/+
 and AnxA1
-/-
 C57/BL6 mice received 10g/mouse or 20g/mouse of poly (I:C) 
intraperitoneally at time 0 and survival rate was monitored at 12h-intervals up to 96h after          
poly (I:C).  
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                                  SUMMARY 
 
In this section the effect on poly (I:C) on lethality 
rate of  AnxA1+/+ and AnxA1-/- mice was 
investigated 
 
 AnxA1-/- mice showed a 20% increased 
survival post-poly (I:C) administration 
independent of the sublethal dosage used. 
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CHAPTER 4: 
DISCUSSION 
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Introduction 
 
Our group has shown an exquisite protective role of AnxA1 in experimental 
endotoxemia induced by the TLR4 agonist LPS (Damazo et al., 2005). In this 
thesis, we have extended these observations demonstrating a modulation of 
endogenous AnxA1 by TLR ligation. We have also compared in vitro the response 
of AnxA1-/- and AnxA1+/+ macrophages after stimulation with different TLR ligands. 
We showed a different inflammatory response of AnxA1-/- macrophages to a panel 
of TLR agonists. Furthermore, we have investigated the pathophysiological 
mechanism by which AnxA1 could influence TLR signalling in macrophages. 
Overall, our studies provide insight into the role of AnxA1 as a protective mediator 
in several types of infection. 
 
4.1. AnxA1 expression in BMDMs 
 
AnxA1 is constitutively expressed in many different tissue specific macrophages 
i.e. peritoneal, alveolar, synovial, and microglial cells (Ambrose et al., 1992), and it 
increases following exposure to GCs (Ambrose et al., 1992, Cirino et al., 1993, De 
Caterina et al., 1993) and IL-6 (Solito et al., 1998). Our data clearly show the 
expression of the protein by BMDMs. The activation of different cell types with 
inflammatory stimuli increases expression and release of endogenous AnxA1 
(D'Acquisto et al., 2007a, Damazo et al., 2005, Rescher et al., 2006). We have 
demonstrated the modulation and secretion of AnxA1 in to the extracellular matrix 
following stimulation of macrophages with TLR ligands. This novel observation 
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applies to all the tested TLR agonists, acting as they do through their different 
TLRs.  
 
The N-terminal of AnxA1 is responsible for the biological action of the molecule 
(Cirino et al., 1993). After neutrophil activation this protein is externalized and 
cleaved by enzymes such as proteinase 3 (PR3) (Vong et al., 2007) and neutrophil 
elastase (HNE) (Rescher et al., 2006), yielding an N-terminal and the 33 kDa C-
terminal. In our experiments, we observed both forms of AnxA1 (37/33 kDa) in the 
BMDMs under resting condition with the majority of the molecule to remain as the 
full-length 37 kDa form. However, after stimulation with all the TLR agonists under 
investigation (HKLM, poly (I:C), LPS, flagellin, loxoribine, CpG) additional cleavage 
occurred in 37 kDa AnxA1 and at 1 h the AnxA1 33 kDa predominated. At 
subsequent time-points, intracellular AnxA1 was decreased, indicating the 
secretion into the extracellular matrix. This was followed by resynthesis of the 
protein in the cytoplasm and return to the resting condition. This result could imply 
that when the macrophage detects a pathogen invasion through TLR ligation, it 
leads to a cleavage of the cytosolic 37 kDa AnxA1 in to its two domains followed 
by secretion to the extracellular milieu, therefore releasing the active N-terminal to 
interact with its receptor and possibly switching on an anti-inflammatory 
mechanism.  This would be an unusual mechanism that has never been observed 
hitherto. It is possible, however, that full-length AnxA1, which is secreted by 
macrophages after stimulation with the TLR ligands, is cleaved extracellularly and 
then the N-terminal protein enters into the cells. 
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4.2. Treatment of macrophages with human recombinant AnxA1 
 
Since we have proved that endogenous AnxA1 is secreted by the macrophage 
after TLR stimulation and therefore may act on FPR2 as an autocrine regulatory 
exogenous protein, it would be interesting to know if treatment of macrophages 
with the human recombinant protein has an anti-inflammatory effect.  
 
Indeed, when both RAW and BMDMs were treated with hr-AnxA1, we observed 
decrease of IL-6 and TNF- in the culture supernatant. This, however, was not 
always the case. For example hr-AnxA1 was not as effective post-stimulation with 
HKLM. Nevertheless, for most TLR ligands the recombinant protein inhibited both   
IL-6 and TNF-.  
 
The effect of hr-AnxA1 on the two cytokines showed a concentration-dependent 
pattern. Initially, the results were opposite to our expectations since the lowest 
concentration was the most effective, whereas the highest concentration usually 
did not show any effect. On the other hand, AnxA1 could exert an anti-
inflammatory action only in very low concentrations, at conditions that mimic the 
physiological endogenous state. In addition, maybe the higher tested 
concentrations lead to a desensitisation of the FPR-family receptor responsible for 
the exogenous action of the protein.  
 
Unfortunately, when the results of MyD88 pathway-dependent and TRIF pathway-
dependent TLR ligands were compared in RAW cells or BMDMs, we were unable 
to conclude whether AnxA1 influence either of the two pathways. In both RAW 
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cells and BMDMs, treatment of macrophages with hr-AnxA1 at specific 
concentrations lowered the content of both IL-6 and TNF- post-stimulation with 
poly (I:C), implying an influence of the protein on the TRIF-pathway. On the other 
hand, hr-AnxA1 also lowered the pro-inflammatory response seen after stimulation 
of macrophages with pure MyD88-dependent TLR ligands such as loxoribine and 
CpG. Does this mean that AnxA1 has an influence on both pathways? If this is 
true then we could not understand why a similar effect was not observed in the 
case of stimulation with HKLM.  
 
In addition, we were unable to explain why different types of macrophages such as 
RAW and bone marrow-derived cells exhibited different responses after treatment 
with the human recombinant protein. Therefore, we focused our investigation at 
the comparison of wild-type and AnxA1 null macrophages. After all, the 
observation that initiated our investigation was the difference in lethality rate of 
wild-type and AnxA1 knockout mice after LPS administration (Damazo et al., 
2005). Studying cells in which the protein was completely absent seemed at the 
time to be a conclusive direction for our study. 
 
4.3. Comparison of AnxA1+/+ and AnxA1-/- BMDMs 
 
4.3.1. Markers of macrophage activation 
 
A phenotypic characteristic under investigation has been the expression of 
markers of macrophage activation that are induced by TLRs. Since macrophages 
are APCs, we have chosen to examine MHC II and the co-stimulatory molecules 
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B7.1 (CD80) and B7.2 (CD86), which correspond to signal 1 and signal 2 of T-cell 
activation. MHC II interacts with the TCR of the CD4 TH cells whereas CD80 and 
CD86 both bind to CD28 and to cytotoxic T-lymphocyte associated protein 3 (CTL-
4) priming T-cells against presented antigens (Blander, 2008, Kaye, 1995, 
Mondino and Jenkins, 1994). Another marker under investigation has been the co-
stimulatory molecule CD40, which binds to CD40 ligand (CD40L) on the surface of 
TH cells and is required for the activation of APCs (Diehl et al., 2000). The role of 
AnxA1 in adaptive immune response as a modulator of T-cell activation has been 
established by our group (D'Acquisto et al., 2007a, D'Acquisto et al., 2007b). 
However, the role of AnxA1 in the macrophage antigen presentation had remained 
unexplored.  
 
In light of these considerations, the current study showed a different phenotype in 
the unstimulated AnxA1-/- macrophages. This is in agreement with another study of 
our group, which investigated the role of AnxA1 in the dendritic cell, and indicated 
a heightened mature phenotype of AnxA1-/- dendritic cells (Huggins et al., 2009).  
 
Several studies describe the upregulation of co-stimulatory molecules in 
macrophages by different TLR agonists (Edwards et al., 2006, Hoebe et al., 2003, 
Lee et al., 2003, Liu et al., 2006, Shen et al., 2008). It has been reported that the 
upregulation of co-stimulatory molecules in APCs induced by TLR ligands occurs 
by TRIF-dependent and TRIF-independent pathways involving an autocrine or 
paracrine loop (Hoebe et al., 2003). However, the capacity of AnxA1-/- and 
AnxA1+/+ BMDMs to upregulate these co-stimulatory molecules was similar after 
stimulation with all TLR agonists. Results shown by our experiments, such as the 
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increased expression of these markers by the AnxA1-/- macrophages after 
stimulation with most TLR agonists, may simply reflect the increased expression at 
the basal level. Indeed, AnxA1 could down-regulate co-stimulatory molecules, and 
subsequently antigen-presentation, in the macrophage. However, the finding that 
AnxA1-/- and AnxA1+/+ macrophages exert a similar capacity to upregulate co-
stimulatory molecules after stimulation with a panel of TLR agonists supports the 
notion that this effect is probably independent of TLR signalling.   
 
The increased MHC II basal level of the AnxA1-/- macrophages indicated that 
AnxA1 may down-regulate MHC II expression. However, an impaired upregulation 
of MHC II in AnxA1-/- BMDMs was evident following stimulation with the TLR3 
ligand poly (I:C), which ensures the presentation of less epitopes of the antigen to 
the T-cells. Since TLR3 is the receptor for viral double-stranded RNA (Alexopoulou 
et al., 2001), this finding supports a potentiating role of AnxA1 in antigen-
presentation specifically in viral infections.    
 
TLR4 is the only TLR that uses all adaptor proteins and may trigger responses 
through both the MyD88-dependent and the MyD88-independent/TRIF-dependent 
pathway (Yamamoto et al., 2003). However, the upregulation of co-stimulatory 
molecules in macrophages after activation of the TLR4 is dependent only on the 
adaptor protein TRIF and the secretion of type I IFNs that is a result of TRIF-
dependent pathway, and therefore is independent of MyD88 (Hoebe et al., 2003, 
Shen et al., 2008). On the contrary, although TLR3 uses only TRIF as an adaptor 
protein, upregulation of co-stimulatory molecules after stimulation with poly (I:C) is 
only partly-dependent on the TLR3-TRIF axis, indicating that certain viruses 
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possess the capacity to upregulate co-stimulatory molecules independently of 
TLRs (Hoebe et al., 2003). In our experiments we could not identify any 
differences between AnxA1-/- and AnxA1+/+ macrophages in the upregulation of co-
stimulatory molecules after stimulation with poly (I:C) or LPS, although our result 
has indicated a much higher upregulation of the co-stimulatory molecules by poly 
(I:C) and LPS compared to the other MyD88-dependent ligands. We did find, 
however, a difference in the upregulation of MHC II after stimulation with poly (I:C) 
in the AnxA1-/- macrophages. Could AnxA1 be interfering with a molecule of the 
TRIF-dependent pathway in the macrophage, changing MHC II expression and 
therefore antigen-presentation only in TLR3-dependent viral infections? Since the 
upregulation of MHC II by viruses is not strictly TRIF-dependent but takes place 
via a non-TLR pathway, our finding could support a role for AnxA1 in the 
macrophage antigen-presentation, which is independent of TLR signalling. 
However, a similar impaired MHC II upregulation by AnxA1-/- BMDMs was also 
seen after treatment with LPS, supporting the hypothesis of an „influence‟ of 
AnxA1 on the TRIF pathway.  
 
4.3.2. Cytokine production 
 
We, and others, have showed that following activation with different TLR ligands 
macrophages normally produce cytokines (Alexopoulou et al., 2001, Bagchi et al., 
2007, Fang et al., 2004, Heil et al., 2003, Hemmi et al., 2000, Hoshino et al., 1999, 
Rowlett et al., 2008). To investigate whether the increased lethality of AnxA1-/- 
mice after administration of LPS (Damazo et al., 2005), is due to a „cytokine 
storm‟, we compared the production of IL-6 and TNF- in AnxA1-/- and AnxA1+/+ 
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BMDMs after stimulation with LPS. Indeed, we have demonstrated that the 
production of these cytokines was heightened in AnxA1-/- macrophages post-
stimulation with LPS.  
 
Moreover, we showed that other TLR agonists also result in the same increased 
pro-inflammatory reaction by AnxA1-/- macrophages, suggesting that the „influence‟ 
of AnxA1 signalling pathway and TLR signalling pathway may take place at a point 
that is common to certain TLRs. Indeed, although our results regarding IL-6 were 
contradictory in the case of certain TLR ligands, the TNF- results clearly showed 
an increased pro-inflammatory response in the AnxA1-/- BMDMs by all the MyD88-
dependent ligands and by LPS which uses both MyD88 and TRIF as adaptor 
proteins. Therefore, the most plausible explanation would have been an interaction 
of AnxA1 at a certain point of the MyD88-dependent pathway. In conclusion, 
AnxA1 somehow seems to block specifically the MyD88-dependent pathway. 
Furthermore, we can expand our observations and support the notion that AnxA1 
does not only have a protective role against Gram (-) bacterial infections but in 
other types of sepsis such as those of Gram (+) and viral origin.  
 
TNF- is considered a classical pro-inflammatory cytokine (Tracey and Cerami, 
1994). Besides the fact that it is overproduced and released systemically during 
sepsis (Girardin et al., 1988), the first studies of exposure to human recombinant 
TNF revealed that it induces a syndrome indistinguishable from septic shock 
syndrome (Tracey et al., 1986). In addition, anti-TNF antibodies prevented the 
development of septic shock (Tracey et al., 1987). It has long been known that 
TNF- is induced after stimulation of macrophages with TLR ligands such as LPS, 
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contributing to macrophage-mediated cytotoxicity (Zacharchuk et al., 1983). 
Therefore, the fact that in our experiments this cytokine was found to be increased 
in the AnxA1-/- BMDMs after stimulation with different TLR ligands is not surprising 
and it supports our previous in vivo observations (Damazo et al., 2005), signifying 
that AnxA1 is an endogenous protective anti-inflammatory factor in different 
infections. 
 
Although the pro-inflammatory role of TNF- remains unquestionable, this is not 
the case for IL-6. Indeed, IL-6 has been assigned both pro-inflammatory and anti-
inflammatory characteristics since during an infection it directs the immunological 
switch from neutrophil to mononuclear cell population and therefore from innate to 
acquired immunity by influencing both arms of the immune response (Jones, 
2005). In specific, it blocks neutrophil accumulation at sites of infection or 
inflammation (Xing et al., 1998), whereas it promotes trafficking of T-cells 
(McLoughlin et al., 2005) and rescues T-cells from entering apoptosis (Teague et 
al., 1997). Nevertheless, despite its established characterisation as a pro-
inflammatory cytokine, a protective role of  IL-6 in the development of septic shock 
has been reported (Barton and Jackson, 1993, Diao and Kohanawa, 2005). 
Therefore, the impaired release of IL-6 by the AnxA1-/- BMDMs at the basal level 
does not necessarily reflect a pro-inflammatory role for AnxA1 in the macrophage. 
These findings, however, suggest a different role of endogenous AnxA1 in the 
macrophage compared to other cell types such as the fibroblast, where a negative 
regulatory role of AnxA1 in the expression of IL-6 was revealed (Yang et al., 
2006).   
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Besides the induction of co-stimulatory molecules by APCs, TLRs have another 
mechanism to control the adaptive immune response. Normally, regulatory T cells 
(TR cells) have the role of preventing activation of autoreactive T-cells. Upon 
recognition of PAMPs, APCs induce the production of IL-6, which blocks the 
suppressive effect of TR cells on the T cells (Pasare and Medzhitov, 2003). 
Therefore, during infection, where activation of the adaptive immune response is 
necessary, the secreted IL-6 by APCs renders T cells refractory to the suppressive 
activity of TR cells (Pasare and Medzhitov, 2003). In addition, AnxA1 increases the 
TH1 arm of the adaptive immune response in apparent contrast to its established 
anti-inflammatory role in the neutrophil (D'Acquisto et al., 2007a, D'Acquisto et al., 
2007b). Therefore, since the macrophage is an APC, it would not be surprising for 
AnxA1 to have distinct roles in relation to the TLR3-driven viral infections in 
macrophages by promoting adaptive immune responses through the increase of 
both IL-6 and MHC II.  
 
TLR3 is the receptor responsible for recognition of double-stranded RNA, which is 
the result of viral replication within infected cells (Alexopoulou et al., 2001). The 
contrasting effects of poly (I:C) compared to the other TLR ligands in the induction 
of IL-6 could be explained by the fact that TLR3 differs from the other TLRs since it 
uses only TRIF as an adaptor protein and not MyD88, which is used by all the 
other TLRs (Yamamoto et al., 2003, Yamamoto et al., 2002). Although both 
MyD88-dependent signalling pathway and TRIF-dependent signalling pathway 
lead to NF-B and MAPK activation, important differences exist in their 
„downstream‟ signals. For example, RIP1 is an essential mediator of TLR3-
induced NF-B activation (Meylan et al., 2004). Ubiquitin ligase Peli 1 is needed 
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for the transmission of TRIF-dependent TLR signals through binding and 
ubiquitination of RIP1 (Chang et al., 2009). Therefore, Peli 1 mediates IKK-NF-B 
activation in the TRIF-dependent pathway (Chang et al., 2009). On the other hand, 
EMSA did not reveal impaired NF-B DNA binding after stimulation with poly (I:C) 
compared to the other TLR ligands, suggesting that  probably NF-B is not the key 
to the impaired IL-6 production observed in the AnxA1-/- BMDMs post-stimulation 
with poly (I:C). Therefore, AnxA1 seems to have a most distinct role especially in 
viral infections. The „check-point‟ on the TRIF-dependent signalling pathway at 
which AnxA1 acts altering IL-6 expression still remains puzzling. 
 
TRIF can activate the IFN- promoter (Yamamoto et al., 2003) through the 
transcription factor IRF-3 (Yamamoto et al., 2003) and lead to the production of 
the signature cytokine of this pathway i.e. IFN-. Therefore, IFN--/- macrophages 
presented diminished activation of the intracellular molecules STAT1 Tyr-701, 
STAT1 Ser-727, and Akt after stimulation with LPS (Thomas et al., 2006). In 
addition, treatment with exogenous recombinant IFN- to IFN--/- macrophages 
increased levels of LPS-induced gene expression of monocyte chemotactic protein 
5 (MCP5), iNOS, IP-10, and IL-12 p40 mRNA (Thomas et al., 2006). However, no 
modulation of IL-6 has been recorded in IFN--/- macrophages, indicating that the 
impaired IL-6 in AnxA1-/- macrophages after stimulation with poly (I:C) could not be 
caused by an „influence‟ of AnxA1 on the levels of  IFN-. Indeed, comparison of 
gene expression profiles in cells from IRF-3-/- mice following viral infection, 
revealed that the gene for IL-6 is an IRF-3-independent direct response gene 
(Andersen et al., 2008). 
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Finally, what could be the pathophysiological mechanism in AnxA1-/- BMDMs that 
results in normal production of TNF- and impaired IL-6 during viral infections? It 
has been reported that the production of IL-6 induced by certain TLR ligands is 
mediated by COX2 (Chen et al., 2006). Moreover, engagement of TLR3 by viral 
RNA or poly (I:C) increases the levels of PGE2 by COX2 through a mechanism of 
cytosolic phospholipase A2 (cPLA2)-mediated arachidonic acid mobilization 
(Pindado et al., 2007, Steer et al., 2006). In addition, it has been reported that 
PGE2 can upregulate the levels of IL-6 produced by alveolar macrophages 
(Williams et al., 2000). Conclusively, PGE2 enhances the release of IL-6 in 
macrophages (Treffkorn et al., 2004) and therefore a modulation in COX2 and 
PGE2 production could result in decreased IL-6, offering an explanation for our 
result. On the other hand, AnxA1 blocks PLA2 activity (Wallner et al., 1986) and 
therefore indirectly the production of PGE2 and therefore, it is expected that 
AnxA1-/- BMDMs would have increased levels of PGE2 and subsequently IL-6. 
Moreover, we did not find statistically significant differences in the PGE2 
production between AnxA1-/- and AnxA1+/+ BMDMs after stimulation of TLR3 that 
could support this hypothesis.  
 
Nevertheless, another mechanism could exist that downregulates IL-6 in AnxA1-/- 
BMDMs, specific in response to viral infections, which is independent of PGE2. For 
example, Palaga et al reported that several TLR agonists upregulate Notch1 
protein expression in BMDMs, whereas inhibiting processing of Notch receptor by 
-secretase and blocking Notch signalling caused a decrease in IL-6 and NO 
production (Palaga et al., 2008), a similar phenotype to the AnxA1-/- BMDMs after 
stimulation with poly (I:C). It is believed that Notch signalling is required for IL-6 
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expression since the binding partner of Notch, CBF-1, can bind to and regulate the 
IL-6 gene (Kannabiran et al., 1997). However, poly (I:C) was not the only TLR 
agonist which was able to trigger up-regulation of Notch 1 (Palaga et al., 2008) 
suggesting that this is not an effect restricted to viral infections.  
 
Finally, could the identification of TLR3–independent effects induced by poly (I:C) 
such as the upregulation of co-stimulatory molecules (Hoebe et al., 2003) and 
COX-2 expression (Steer et al., 2006) also apply to the poly (I:C)-mediated IL-6 
production? Overall, it is possible that certain viruses can influence the IL-6 
production of the macrophage using mechanisms independent of TLR3.     
 
Another important observation has been the intriguing role of the TLR5 agonist 
flagellin.  In both AnxA1-/- and AnxA1+/+ BMDMs, the cytokine production induced 
by flagellin was severely impaired compared to that induced by the other TLR 
agonists. This could be explained by a lower expression of the TLR5 in BMDMs 
and was supported by previous studies that reported no production of IL-6 and 
TNF- in BMDMs after stimulation with flagellin (Feuillet et al., 2006, Hawn et al., 
2007), possibly due to an absence of TLR5 in these cells (Uematsu et al., 2006). 
Another mechanism, which could be responsible for a low level of expression of 
TLR5 without altering the TLR5 mRNA level, is the overexpression of TRIF (Choi 
et al.). Indeed, if TRIF is overexpressed by BMDMs, then the functionality of TLR5 
at a post-translational level may be influenced, since TRIF induces TLR5 
proteolytic degradation (Choi et al.). Alternatively, TRIF could be over-expressed 
in BMDMs but not in RAW macrophages. Therefore, there was a sufficient 
cytokine production in RAW cells after stimulation with flagellin despite the fact 
 178 
that the concentration for stimulation was 1/10 of that used for BMDMs. Moreover, 
although it was originally thought that since flagellin uses the same adaptor protein 
as HKLM, LPS, loxoribine, and CpG, and should therefore induce a similar 
phenotype, the production of IL-6 was impaired by the AnxA1-/- macrophages at  
24 h post-stimulation. Interestingly, a recent study has proven that flagellin can 
directly induce adaptive immune responses without previous activation of the 
innate immune response or TLR5 (Sanders et al., 2009). Therefore, like poly (I:C) 
acting independently of TLR3, the impaired IL-6 found in AnxA1-/- macrophages 
after stimulation with flagellin could be a TLR5-independent effect.  
 
4.3.3. Nitric Oxide and PGE2 
 
It has been reported that certain TLR agonists such as poly (I:C) (Heitmeier et al., 
1998, Snell et al., 1997), LPS (Hauschildt et al., 1990, Jones et al., 2008, Mulsch 
et al., 1993) and CpG (Li et al., 2005) induce the production of NO in 
macrophages. On the contrary, stimulation with HKLM or flagellin alone cannot 
induce the production of NO in macrophages but requires the addition of IFN- 
(Beckerman et al., 1993, Mizel et al., 2003). Nothing has been reported 
concerning NO in these cells after stimulation of TLR7 with loxoribine. In 
agreement with this, we did not observe a production of nitrites after stimulation 
with HKLM, flagellin or loxoribine. Moreover, the result of our experiment showed 
that after stimulation with poly (I:C), LPS or CpG there was a significant production 
of NO.   
 
The production of NO after stimulation of TLR4 and TLR9 was not statistically 
different in the AnxA1-/- compared to the AnxA1+/+ BMDMs. On the other hand, 
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poly (I:C) significantly impaired production of nitrites by AnxA1-/- BMDMs 
compared to AnxA1+/+ BMDMs. This result could offer another important 
observation that focuses again on the TLR3 ligand poly (I:C). Again, a possible 
involvement of AnxA1 at a certain point of TRIF-dependent TLR-signalling 
pathway, could explain these differences.  
  
Contrasting effects were recorded by the western blotting of the enzyme iNOS in 
comparison to the Griess reaction for detection of production of nitrites (data not 
shown). As expected, we did not detect an upregulation of iNOS expression after 
stimulation with flagellin. However, we observed an increase in expression of the 
enzyme after stimulation of the AnxA1-/- BMDMs with HKLM and loxoribine, which 
was not accompanied by an increase in the level of secreted NO in the 
supernatant.  
 
After stimulation with poly (I:C), the upregulation of iNOS expression was 
increased in the AnxA1-/- BMDMs (data not shown), whereas we recorded an 
impaired production of NO. If decreased NO in the supernatant of AnxA1-/- BMDMs 
accompanied by increased iNOS expression in the cytoplasm after stimulation with 
the TLR3 ligand poly (I:C) is indeed correct, then a different pathophysiological 
mechanism could offer an explanation. For example, there is a group of hydrolytic 
enzymes namely arginases, which can compete with NO synthases for their 
common substrate arginine (Modolell et al., 1995, Munder et al., 1999). A study by 
Kasmi et al has reported that intracellular pathogens may induce expression of 
Arginase 1 (Arg1) in mouse macrophages through the TLR pathway depending on 
the adaptor protein MyD88 (El Kasmi et al., 2008). Besides intracellular infections, 
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macrophages lacking Arg1 produce more NO after stimulation of TLR4 with LPS 
(El Kasmi et al., 2008, Ryan et al., 1980, Sonoki et al., 1997), suggesting that 
regulation of Arg1 is a mechanism restricting macrophage NO production common 
to different types of TLR stimulation. If we assume that TLR3 stimulation could 
also induce Arg1 through a MyD88-independent mechanism, an increased Arg1 
expression could be associated with a decreased NO production without 
necessarily being accompanied by an analogous increase in the iNOS expression. 
Therefore, AnxA1 could be implicated in this MyD88-independent pathway 
blocking the induction of Arg1 and therefore leading to an increased production of 
NO in the macrophage. Indeed, if this hypothesis is true, our result of decreased 
NO production and increased iNOS expression in the AnxA1-/- BMDMs could not 
be a random finding.  
 
Several studies have reported activation of the enzyme COX2 and subsequent 
production of PGE2 after stimulation of macrophages with different TLR ligands 
such as poly (I:C) (Pindado et al., 2007, Steer et al., 2006), peptidoglycan (PGN) 
(Chen et al., 2004, Chen et al., 2009a), LPS (Buczynski et al., 2007, Uematsu et 
al., 2002) or CpG DNA (Yeo et al., 2003). However, the signalling pathways 
resulting in the induction of COX2 after stimulation of each corresponding TLR are 
different in important aspects. Although disparities between different TLR ligands 
may exist, it is a fact that several molecules influence the induction of COX2 
negatively or positively. Therefore, both MyD88-dependent and TRIF-dependent 
pathways may lead to NFB-dependent or independent activation of COX2, 
whereas a TLR-independent mechanism specifically for the TLR3 ligand double-
stranded RNA has also been described (Steer et al., 2006).  
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In our experiments, HKLM, poly (I:C), and LPS induced COX2 expression and 
PGE2  production in both AnxA1
+/+ and AnxA1-/- BMDMs in a statistically similar 
way. On the other hand, we were unable to detect induction of COX2 after 
stimulation with CpG whereas there was detection of PGE2 in the corresponding 
culture supernatant (data not shown). Flagellin and loxoribine did not induce the 
enzyme or its product. The fact that there are no studies describing induction of 
COX2 by neither flagellin nor loxoribine supports these results.  
 
The detection of PGE2 after stimulation with poly (I:C) did not suggest any 
statistically important differences between AnxA1+/+ and AnxA1-/- BMDMs. 
However, stimulation of TLR3 revealed several differences in comparison to the 
other TLRs regarding IL-6 and NO production, and a difference in PGE2 between 
AnxA1+/+ and AnxA1-/- BMDMs was also expected. Firstly, we identified impaired 
NO production in AnxA1-/- BMDMs after stimulation with poly (I:C) and NOS2 and 
COX2 signalling pathways may influence each other. Specifically, it has been 
reported that induction of iNOS in these cells takes place via a cPLA2/COX2 
pathway (Pindado et al., 2007). Interestingly, if cPLA2 is involved in TLR3-induced 
COX2, it is surprising that there is no difference in PGE2 in the AnxA1
-/- BMDMs 
since AnxA1 blocks cPLA2 activity (Cirino et al., 1987). Finally, a modulation in 
COX2 and PGE2 production, specifically impairment in PGE2 production, could 
result decreased IL-6, offering an explanation to our previously described 
observations concerning cytokine production (Treffkorn et al., 2004).  
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4.3.4. TLR expression 
 
The exact relationship between the number of TLRs expressed by a cell to its 
response after addition of the ligand still remains obscure. However, LPS tolerant 
macrophages exhibit decreased inflammatory cytokine production, which 
correlates with downregulation of surface TLR4 (Nomura et al., 2000). Therefore, 
differential expression of the TLRs on the surface of macrophages could explain 
the differences in cytokine production between AnxA1-/- and AnxA1+/+ 
macrophages i.e. an increased receptor expression in the AnxA1-/- macrophages 
could induce an exaggerated inflammatory reaction. Unfortunately, we were 
unable to detect the expression of any TLR protein due to the lack of reliable 
antibodies. Nevertheless, we did observe an increased mRNA expression of all 
TLRs in the absence of AnxA1. However, this phenotype was common to all TLRs 
including the TLR3, which presented certain differences to the other TLRs in the 
regulation of MHC II, IL-6 and NO in the AnxA1-/- BMDMs after stimulation with its 
ligand poly (I:C). On the other hand, even if the macrophage response to TLR 
stimuli can be explained by modulation of the number of TLRs expressed by this 
cell, the mechanism by which AnxA1 down-regulates the transcription of these 
receptors still remains unresolved. On top of this, there is a complicated 
discrepancy between mRNA expression and responsiveness to TLR ligands and 
the expression of a TLR by macrophages does not always correspond to cell 
activation after stimulation of this receptor. For example, neutrophils express TLR9 
but are not stimulated by CpG (Hornung et al., 2002). 
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4.3.5. NF-B DNA-binding 
 
TLR signalling through both MyD88-dependent and TRIF-dependent pathways 
leads to dissociation of NF-B from the IB proteins and its nuclear translocation, 
in order to bind to the promoters of target genes (Kawai and Akira, 2007). Several 
studies have demonstrated normal NF-B activation after stimulation with a panel 
of TLR ligands in different types of macrophages (Alexopoulou et al., 2001, Bagchi 
et al., 2007, Hemmi et al., 2000, Muller et al., 2001, Yamamoto et al., 2003).     
NF-B activation regulates several genes leading to the production of proteins 
including the IB, which in turn inhibits NF-B allowing a fast turn-off of the     
NF-B response. On the other hand, IB and IB remain at low levels, since 
their impact on NF-B activity is unidirectional, meaning that they inhibit NF-B but 
NF-B does not regulate their production. In wt cells, the IB cycle leads to the 
production of an oscillatory pattern of NF-B activity observed by EMSA (Nelson et 
al., 2004), and IB and IB are responsible for dampening the system‟s 
oscillatory potential (Hoffmann et al., 2002). Therefore, in mouse knockout cells 
lacking the IB and IB isoforms, undampened NF-B oscillations are produced 
(Hoffmann et al., 2002) (Fig 4.1).   
 
As expected, after stimulation with a panel of TLR ligands, we observed normal 
oscillatory NF-B activation leading to the production of several pro-inflammatory 
mediators such as IL-6 and TNF- by AnxA1+/+ BMDMs. Conversely, after 
stimulation with LPS, we observed a linear increase of NF-B activation as 
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described by Covert et al (Covert et al., 2005), possibly due to interaction of the 
two signalling pathways.  
 
Since AnxA1-/- BMDMs exhibited an augmented pro-inflammatory state after 
stimulation of the MyD88-dependent signalling pathway, we expected to see 
increased NF-B activation. Indeed, our results clearly showed that although 
AnxA1-/- BMDMs started with an impaired NF-B activation at the basal level, 
30min after stimulation with all MyD88-dependent ligands, they presented with an 
increased NF-B binding ability, which could subsequently correspond to the 
enhanced transcription of certain pro-inflammatory genes. Indeed, we observed 
NF-B oscillations of higher amplitude by AnxA1-/- BMDMs. These undampened 
oscillations have also been described in cells lacking the IB and IB isoforms, 
which normally dampen the system‟s oscillatory potential (Hoffmann et al., 2002). 
However, although an influence of AnxA1 in one or both of these IB isoforms 
would have been very tempting, we did not manage to support this hypothesis by 
performing western blotting in cytoplasmic extracts of BMDMs stimulated with 
different TLR ligands (results not shown). On the other hand, a dual role for IB 
has been reported (Rao et al.). Specifically, although initially post-LPS stimulation 
IB degrades, contributing to the initial expression of TNF-, then newly 
synthesized hypophosphorylated IB acts through p65:c-Rel dimers, binds to the 
TNF- promoter, and enhances TNF- transcription (Rao et al.). Therefore, if 
AnxA1 could block IB utilising an as yet unidentified mechanism, it could also 
control indirectly the transcription of TNF-. Our preliminary results obtained by 
western blotting after stimulation with LPS, revealed an increased IB expression 
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by AnxA1-/- cells (data not shown), which could also induce enhanced TNF- 
production.      
 
As described previously, after stimulation with the TLR3 ligand poly (I:C), we 
observed normal TNF- production and impaired IL-6 production by AnxA1-/- 
BMDMs. Consistent with this, at 30min post-stimulation with poly (I:C) we did not 
observe any difference in the NF-B DNA-binding by the AnxA1-/- BMDMs, in 
contrast to the increased NF-B activation seen by the MyD88-dependent ligands. 
However, 60min post-stimulation of TRIF, the NF-B DNA-binding was enhanced 
in AnxA1-/- BMDMs. The TRIF pathway requires a time delay to establish NF-B 
activation compared to the MyD88 pathway, because it requires protein synthesis. 
In specific, the transcription factor IRF3 mediates the activation of TNF-, which in 
turn binds its receptors on the cell leading to the activation of NF-B (Fig 4.2) 
(Covert et al., 2005). This different NF-B activation/ IB degradation kinetic, 
seen in AnxA1-/- BMDMs after stimulation of TRIF, implies an involvement of 
AnxA1 in the TRIF-pathway as well. Nevertheless, this enhanced delayed NF-B 
activation could be responsible for different phenotype characteristics by these 
cells but not for the production of TNF-. Again, this could support a different 
pathophysiological role of AnxA1 in viral infections.  
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Figure 4.1: A computational model based on genetically reduced systems. The NF-B 
signalling pathway in mouse knockout cells lacking IB and IB (A) and in WT cells (B). Taken 
from (Ting and Endy, 2002). Computational modelling of each genetically simplified signalling 
module resulting in characteristic kinetics of the NF-B response (C). Taken from (Hoffmann et al., 
2002).  
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Figure 4.2:  MyD88-independent pathway activation of NF-B requires IRF3-mediated 
expression of TNF-. Scheme of the pathway for activation of NF-B by means of TRIF. Taken 
from (Covert et al., 2005).
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4.3.6 ERK1/2 activation 
 
All TLR ligands acting through TLR MyD88-dependent and/or TRIF-dependent 
signalling pathways lead to activation of MAPKs (Kawai and Akira, 2007). 
Similarly, the FPR signalling pathway activates the MAPK ERK (Selvatici et al., 
2006). We have proved that AnxA1 is secreted from the macrophages after 
stimulation with all the different TLR ligands. In macrophages, FPR2 is expressed 
and is functional (Devosse et al., 2009). Therefore, after its secretion, AnxA1 could 
act on FPR2 receptors activating the corresponding signalling pathway (Perretti et 
al., 2001, Walther et al., 2000). Overall, the MAPK ERK is a common „checkpoint‟ 
in the two signalling pathways (Fig 4.3), which after TLR stimulation are both 
activated in the macrophage, and therefore it can be a candidate molecule for the 
possible interaction of the two signalling pathways. Indeed, if AnxA1 has an effect 
on ERK phosphorylation after TLR stimulation, this could offer an explanation to 
the exaggerated pro-inflammatory response that we observed in AnxA1-/- BMDMs. 
 
A study by Alldridge et al. revealed a dysregulation of the MAPK ERK pathway by 
AnxA1 in a macrophage cell line (Alldridge et al., 1999). In specific, clones with 
decreased AnxA1 expression showed prolonged ERK activity following LPS 
treatment, whereas changes in AnxA1 expression had no effect on p38 or JNK 
(Alldridge et al., 1999). In agreement with this view, we observed increased 
phosphorylation of ERK1/2 in AnxA1-/- BMDMs after stimulation with different TLR 
ligands. These data are also supported by the study of Yang et al. (Yang et al., 
2009), who stimulated macrophages with LPS and demonstrated that AnxA1 is a 
negative regulator of IL-6 and TNF- by acting through MAPK phosphorylation and 
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regulation of the protein Glucocorticoid induced leucine zipper (GILZ) (Yang et al., 
2009). Our data suggest that the downregulation of phospho-ERK1/2 by AnxA1 is 
not only limited to the LPS stimulation but it can be expanded to all the other TLR 
ligands as well.  
 
However, the fact that TLR3, which induced impaired IL-6 production in the  
AnxA1-/- macrophages, also showed a similar ERK phenotype with the other TLRs, 
could suggest a different pathophysiological mechanism, independent of ERK 
phosphorylation. In this case, a difference in the TRIF-dependent pathway due to 
an interaction of AnxA1 at a certain point of the signalling, could offer a more 
reliable explanation, which applies specifically to viral infections. Finally, if AnxA1, 
which is secreted by the macrophage, activates the FPR signalling pathway, 
phosphorylation of ERK should also be induced. Therefore, our finding of 
increased ERK phosphorylation in the absence of AnxA1 is contradictory, since it 
supports the notion that AnxA1 is a negative regulator of ERK phosphorylation. 
Overall, the question of how AnxA1 can be a negative regulator of ERK since it 
induces its phosphorylation after interaction with FPR2 remains unanswered. 
 
 
 
 
 
 190 
 
 
 
 
 
 
Figure 4.3: Both FPR2 and TLR-signalling pathways lead to the activation of ERK1/2. 
Schematic demonstration of the FPR2 signalling pathway after stimulation with AnxA1 leads to 
activation of ERK1/2 (left). TLR stimulation also induces ERK1/2 activation (right). Adapted from 
(Rabiet et al., 2007). 
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4.3.7 Gene expression profile 
 
During a viral infection triggering TLR3, the activated genes can be divided in 3 
sets: IRF-3-dependent, IRF-3-independent, and IRF-3-augmented direct response 
genes (Andersen et al., 2008). For example, the IFN-1, ISG54, NOS II genes are 
considered IRF3-dependent, the IL-6 and TNF- genes IRF3-independent, and 
the CXCL10/ IP10 gene IRF3-augmented (not strictly dependent on IRF-3). 
Therefore, by using TLR ligands stimulating only the MyD88-dependent pathway, 
the TRIF-dependent pathway or both, we tried to investigate whether AnxA1 had 
any effect in any of these pathways. 
 
CpG, which stimulates the MyD88 pathway only, showed enhanced IL-6 gene 
expression in AnxA1-/- cells, suggesting that AnxA1 may interfere at a certain point 
of this pathway blocking it. On the contrary, we did not find important differences in 
the AnxA1-/- BMDMs regarding the IL-6 gene expression after stimulation with the 
TRIF-dependent ligand poly (I:C), whereas the levels of IL-6 in the supernatant of 
AnxA1-/- BMDMs post-stimulation with poly (I:C), were severely impaired. 
Therefore, an interaction of AnxA1 on the TRIF pathway influencing IL-6 cannot be 
excluded. When triggering TLR3, the IL-6 gene is considered an IRF3-
independent gene (Andersen et al., 2008, Thomas et al., 2006). Yet TRIF 
knockout macrophages show a completely abrogated IL-6 production post-
stimulation with LPS (Shen et al., 2008), suggesting that in the case of TLR4, TRIF 
is considered indispensable for the production of IL-6, and that it probably 
synergises with MyD88. In addition, a different result was described for dendritic 
cells (Shen et al., 2008), indicating that the signalling pathway leading to IL-6 
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production may be different for each cell type (Fig 4.4). Nevertheless, the TRIF 
pathway activated after TLR3 stimulation may not be identical to the TRIF pathway 
activated after TLR4 stimulation, since in the second case the adaptor protein 
TRAM is also involved (Fitzgerald et al., 2003b). TRIF signalling includes 
activation of IRF3 but also another, yet unidentified pathway (Fig 4.5) (Kawai et al., 
2001). If indeed the production of IL-6 in the macrophage after stimulation with 
poly (I:C) is IRF-3-independent, then the similar IL-6 gene expression in the 
AnxA1-/- BMDMs after stimulation with poly (I:C) supports the notion that this    
IRF-3-independent pathway is not influenced by AnxA1. It does not exclude, 
however, an interaction of AnxA1 on the IRF-3-dependent TLR3 signalling 
pathway. However, even if we assume that AnxA1 does exert an effect on the  
IRF-3 pathway, we still cannot understand how this influence could change the IL-
6 production by the macrophage. 
 
CpG, by activating only the MyD88-dependent pathway, results in enhanced   
TNF- gene expression in AnxA1-/- BMDMs, supporting again the blockage of 
MyD88 pathway by AnxA1. On the other hand, since the iNOS gene is considered 
an IRF3-dependent gene when triggering TLR3 (Youn et al., 2005, Youn et al., 
2008), it is surprising the fact that we observe different kinetics of gene expression 
in AnxA1-/- BMDMs after stimulation with poly (I:C). This suggests that AnxA1 
somehow does influence the IRF3-mediated gene expression. This hypothesis is 
also supported by the enhanced IFN-1, ISG54, CXCL10/IP10 genes expression 
in AnxA1-/- BMDMs after stimulation with poly (I:C), since they all are considered 
IRF3-dependent or augmented genes (Andersen et al., 2008). In addition, the 
different kinetic in COX2 gene expression after stimulation with the 3 different TLR 
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ligands, supports again an interaction in both pathways since COX2 gene is 
considered IRF-3-dependent when triggering TLR3 (Youn et al., 2005, Youn et al., 
2008) and MyD88-dependent when triggering TLR4 (Bjorkbacka et al., 2004, 
Kawai et al., 2001).  
 
Conclusively, AnxA1 seems to act on both MyD88-dependent and TRIF-
dependent pathways. Specifically for the TRIF-pathway, it probably influences the 
transcription factor IRF-3 pathway. Since IRF-3 activation leads to TNF- 
production, which after secretion binds to the cell receptors activating NF-B, the 
activation of NF-B is also influenced. Indeed, we did observe an increased 
delayed NF-B DNA binding post-poly (I:C) stimulation in AnxA1-/- cells, further 
supporting this hypothesis. Therefore, the levels of several gene products of the 
IRF-3 transcription pathway should also be different in AnxA1-/- cells. To further 
confirm this hypothesis, it would be interesting to measure the production of IFN- 
in these cells after stimulation with poly (I:C).  
 
The influence of AnxA1 on the TLR signalling pathway includes two levels of 
regulation: mainly by blocking the MyD88 pathway and to a lesser extent by 
interacting with the IRF3-dependent TRIF pathway.  
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Figure 4.4: Impact of TRIF or MyD88 signalling on proinflammatory cytokines in bone 
marrow-derived dendritic cells (BMDCs) (A) and glycolate-elicited peritoneal macrophages 
(TGC-PECs) (B).  
Redrawn from (Shen et al., 2008).  
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Figure 4.5: Model of the signalling pathways though TLR2 and TLR4. 
Taken from (Kawai et al., 2001).  
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4.4 In vivo experiments 
 
In contrast to the administration of LPS and the increased lethality rate of AnxA1-/- 
mice (Damazo et al., 2005), the intraperitoneal injection of sublethal doses of poly 
(I:C) revealed different results. The AnxA1-/- mice showed a 20% increased 
survival post-poly (I:C) administration independent of the sublethal dosage used. 
Therefore, the absence of AnxA1 in this case showed beneficial results, which 
were in the opposite direction to those seen following the stimulation of TLR4.  
 
If the AnxA1-/- mice die more easily after LPS administration due to the induced 
„cytokine storm‟, then definitely the in vitro experiments with the BMDMs support 
this hypothesis. Indeed, AxA1-/- BMDMs showed increased TNF- and IL-6 
production after stimulation with LPS. On the other hand, there was no difference 
in TNF- by AnxA1-/- BMDMs after stimulation with poly (I:C). Therefore, we did 
not expect to detect a 20% survival advantage by the AnxA1-/- mice after 
administration of poly (I:C). Does this mean that the presence of AnxA1 instead of 
being „protective/ beneficial‟ can be a disadvantage in the case of viral infections? 
Perhaps the pathophysiological mechanism involved is this case is more 
complicated. Indeed, it is now known that the initial innate immune responses are 
suppressed by the adaptive immune system and specifically by conventional T 
cells (Kim et al., 2007). Therefore, when Rag-deficient mice, which lack all 
lymphocytes, were injected with a sublethal dose of poly (I:C), they experienced a 
very rapid death characterised by increased levels of IFN- and TNF- (Kim et al., 
2007). On the contrary, the WT mice survived because their T cells suppressed 
the early inflammatory response by innate cells in a contact-and MHC II-
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dependent manner (Kim et al., 2007). Poly (I:C) is considered a TH1 stimulus 
(Longhi et al., 2009). Balb/c mice present a predominantly TH2 phenotype 
(Watanabe et al., 2004). In addition to, T cells from AnxA1-/- mice show an 
increased TH2 phenotype (D'Acquisto et al., 2007b). This means that the AnxA1
-/- 
Balb/c mice used in our in vivo experiments, had a highly TH2 adaptive immune 
response and that with the poly (I:C) administration directed their TH-response 
towards a TH1 phenotype.  Possibly, the initial increased TH2 phenotype of the 
AnxA1-/- mice might have helped them to balance more easily the adaptive 
immune response, and therefore has given them a small survival advantage 
compared to their WT littermates.  Moreover, we did observe impaired IL-6 
production by AnxA1-/- BMDMs after stimulation with poly (I:C). If we assume that 
AnxA1-/- mice induce an analogous impaired IL-6 production post-administration of 
poly (I:C), then the suppression of T cells by TR cells in this case is also increased  
(Pasare and Medzhitov, 2003) and the adaptive immune responses more tightly 
controlled, possibly giving them a small survival advantage. 
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4.5 Conclusions 
 
We believe that when the macrophage detects a pathogen invasion through its 
TLRs, it secretes AnxA1 in to the extracellular milieu, in order to interact with its 
receptor. This pathophysiological mechanism possibly switches on an anti-
inflammatory mechanism in Gram (+), Gram (-), and certain viral infections and is 
partly caused by down-regulation of ERK1/2 activation and NF-B activation by 
AnxA1. Therefore, AnxA1 seems to block the MyD88-pathway utilising an as yet 
unidentified mechanism and this results in increased pro-inflammatory response 
and lethality of AnxA1-/- mice after administration of TLR ligands triggering this 
pathway such as LPS (Damazo et al., 2005). On the other hand, the role of AnxA1 
in the TRIF-pathway and against viruses triggering TLR3 remains intriguing. In this 
case, AnxA1 seems to have the opposite effect by enhancing the upregulation of 
MHC II, IL-6, and NO and resulting in a survival advantage of AnxA1-/- mice post 
administration of poly (I:C). In conclusion, more detailed investigations are 
warranted in order to resolve the exact point in the TLR signalling pathway at 
which AnxA1 is implicated. Overall, we here present further results that support 
the idea that AnxA1 is a modulator of inflammation with therapeutic potential in the 
fight against infectious diseases.  
 
Finally, our study was mostly based on the comparison of AnxA1+/+ and AnxA1-/- 
BMDMs and the assumption that the only difference in these two types of cells is 
the expression of AnxA1. Therefore, the inconsistencies in our findings regarding 
cytokine production could be due to the fact that there are other differences in 
these KO macrophages, which alter our observations. Indeed, the study of the 
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AnxA1-/- mouse has revealed that there are such compensatory mechanisms. 
More specifically, knockout of AnxA1 may lead to up-regulation of other annexins 
such as AnxA2 (Hannon et al., 2003). AnxA2 has proven to have a pro-
inflammatory effect in the macrophages such as to increase the IL-6 and TNF- 
content (Swisher et al., 2007). In addition, AnxA2 seems to modulate macrophage 
function through TLR4 (Swisher et al., 2010). Therefore, the comparison of 
AnxA1+/+ to AnxA1-/- BMDMs to study the possible anti-inflammatory role of AnxA1 
could be a problematic set-up to begin with. Alternatively, the treatment of 
macrophages with the human recombinant protein could be a more reliable 
methodology to examine the role of AnxA1 in these cells. Indeed, our very 
preliminary results of comparing the expression of AnxA2 in AnxA1+/+ and AnxA1-/- 
BMDMs has revealed a small increase in the expression of AnxA2 in AnxA1-/- 
cells, supporting this hypothesis (data not shown). It would be interesting to 
examine the use of an AnxA2 neutralising antibody in AnxA1-/- BMDMs before 
treating them with the different TLR ligands. 
 
Summarising, endogenous AnxA1 seems to have a homeostatic role, by 
influencing mainly the MyD88-dependent pathway and to a lesser extent in the 
opposite direction the TRIF-dependent pathway both in vitro and in vivo. 
Conclusively, endogenous AnxA1 has a tonic influence, acting as a molecular 
tuner of the TLR signalling pathways with specificity per different TLR.  
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4.6 Future work 
 
A series of experiments could be added to the work of this Thesis to complement 
our investigation on the exact role of AnxA1 in TLR signalling.  
 
Firstly, AnxA1-/- BMDMs could be treated with hr-AnxA1 followed by measurement 
of IL-6 and TNF- in the supernatant, ERK-phosphorylation and EMSA for NF-B 
DNA-binding activity, in order to investigate whether the phenotype can be 
rescued. 
 
The TLR signalling pathways (MyD88-dependent and MyD88-independent) need 
to be dissected in order to identify the exact molecules in TLR signalling pathway 
at which AnxA1 could exert an effect. These could include all the adaptor proteins 
(MyD88, TRIF, TRAM, TIRAP/MAL, SARM), TRAF3 and TRAF6, IKKs and IBs, 
IRFs, RIP-1, TAB2 and TAB3, TAK1, TBK1, and Pellino-1. This analysis should 
give priority to molecules that are also part of the FPR2 signalling pathway such as 
MAPKs and Akt. Coprecipitation experiments of AnxA1 and the protein(s) of 
interest can take place to investigate possible interactions. Alternatively, we could 
transfect WT and AnxA1-/- BMDMs with plasmids overexpressing the protein of 
interest followed by stimulation with TLR ligands and measurement of IL-6/TNF- 
mRNA synthesis and protein secretion, ERK phoshorylation and NF-B DNA-
binding activity. In addition, WT and AnxA1-/- BMDMs may be transfected with   
NF-B luciferase reporter gene followed with co-transfection with plasmid of the 
protein of interest (e.g. different adaptor proteins). Thereafter, stimulation with the 
different TLR ligands and luciferase reporter assay will show if overexpression of 
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any of these proteins how much will influence NF-B activation in WT and AnxA1-/- 
BMDMs.   
 
Western blotting and Real-time PCR for IB, IB, IB in cell lysates from WT 
and AnxA1-/- BMDMs stimulated with TLR ligands will reveal the possible 
involvement of these molecules in the effect of AnxA1 on TLR signalling. WB and 
Real-time PCR can also be performed for other proteins of interest such as the 
different adaptor proteins. To confirm the involvement of AnxA1 to the TRIF-
pathway, we could measure the levels of IFN- in the supernatant of WT and 
AnxA1-/- BMDMs stimulated with poly (I:C) or LPS. The involvement of IRFs can 
be investigated by performing EMSA for each IRF DNA binding activity with 
depletion analysis using siRNA for IRFs. In order to see if the effect of AnxA1 is 
mediated through ERK activation, we could use an ERK inhibitor and repeat the 
previous experimental procedure. To verify that gene transcription mediates our 
observations, we could use inhibitors such as Actinomycin D followed by Real-time 
PCR for IL-6 and TNF-. 
 
FPR2 null mice could be used as a source for the isolation and generation of 
BMDMs may be used to investigate whether the effect of AnxA1 on TLR signalling 
is mediated through this receptor. After stimulation of these cells with TLR ligands, 
IP/IB for AnxA1 in the supernatant will firstly show if AnxA1 is secreted, and 
repetition of the experimental procedures performed in this thesis will compare WT 
and FPR2-/- BMDMs. Alternatively, Boc2 (a pan antagonist for the FPR-family 
receptors) may be given to WT or AnxA1-/- BMDMs consecutively with the TLR 
ligands. 
 202 
 
All our in vitro observations should be confirmed in vivo after the administration of 
different TLR ligands such as LPS or poly (I:C) to WT and AnxA1-/- mice. For 
example, the concentration of different cytokines such as IL-6, TNF-, IFN- can 
be measured in plasma. Histological samples for analysis may also be taken. 
 
The experiments on BMDMs may be repeated using neutralising antibody against 
Annexin-A2 in order to investigate whether our observations in AnxA1-/- BMDMs 
are indeed findings due to the absence of AnxA1. 
 
Specific viruses and live Gram (+) and Gram (-) bacteria representative of each 
TLR ligand may be used in vivo to infect AnxA1+/+ and AnxA1-/- mice or in vitro to 
AnxA1+/+ and AnxA1-/- BMDMs. Different outcomes, for example viral titers can be 
added to our investigation.  
 
Finally, we could add to our research other measurements such as IL-10 secretion 
in the supernatant or certain protein(s) expression involved in the inflammatory 
process e.g. MIF or HMGB1. 
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